0001144204-16-135413.txt : 20161118 0001144204-16-135413.hdr.sgml : 20161118 20161118170330 ACCESSION NUMBER: 0001144204-16-135413 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161118 DATE AS OF CHANGE: 20161118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 162008445 BUSINESS ADDRESS: STREET 1: 9 INNOVATION WAY, SUITE 100 CITY: NEWARK STATE: DE ZIP: 19711 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 9 INNOVATION WAY, SUITE 100 CITY: NEWARK STATE: DE ZIP: 19711 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 10-Q 1 v452759_10q.htm FORM 10-Q

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2016

 

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission file number 001-35023

 

iBio, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   26-2797813
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
     
600 Madison Avenue, Suite 1601, New York, NY   10022
(Address of principal executive offices)   (Zip Code)

 

(302) 355-0650

(Registrant’s telephone number, including area code)

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  x   No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  x   No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨   Accelerated filer   ¨   Non-accelerated filer  ¨   Smaller reporting company  x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨    No  x  

  

Shares of Common Stock outstanding as of November 18, 2016:           89,109,410

 

 

 

 

iBio, Inc.

 

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION 3
   
Item 1. Financial Statements (Unaudited) 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
Item 4. Controls and Procedures 25
     
PART II. OTHER INFORMATION 26
   
Item 1. Legal Proceedings 26
Item 6. Exhibits 27
   
SIGNATURES 28

 

 2 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1.    Financial Statements (Unaudited)

iBio, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In Thousands, except share and per share amounts)

 

    September 30, 2016     June 30, 2016  
    (Unaudited)     (See Note 2)  
Assets                
Current assets:                
Cash   $ 20,098     $ 23,014  
Accounts receivable - trade     170       484  
Accounts receivable - unbilled     62       122  
Work in process     -       22  
Prepaid expenses and other current assets     132       264  
Total Current Assets     20,462       23,906  
                 
Fixed assets, net of accumulated depreciation     25,580       25,574  
Intangible assets, net of accumulated amortization     2,023       2,092  
Security deposit     26       28  
Total Assets   $ 48,091     $ 51,600  
                 
Liabilities and Stockholders' Equity                
Current liabilities:                
Accounts payable (related party of $239 and $200 as of September 30, 2016 and June 30, 2016, respectively)   $ 979     $ 1,177  
Accrued expenses (related party of $772 and $623 as of September 30, 2016 and June 30, 2016, respectively)     1,022       920  
Capital lease obligation – current portion     173       170  
Deferred revenue     -       24  
Total Current Liabilities     2,174       2,291  
                 
Capital lease obligation - net of current portion     25,220       25,265  
                 
Total Liabilities     27,394       27,556  
                 
Commitments and Contingencies                
                 
Equity                
iBio, Inc. Stockholders’ Equity:                
Preferred stock - no par value; 1,000,000 shares authorized; no shares issued and outstanding     -       -  
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,109,410 shares issued and outstanding as of September 30, 2016 and June 30, 2016     89       89  
Additional paid-in capital     67,733       67,468  
Accumulated other comprehensive loss     (29 )     (29 )
Accumulated deficit     (60,652 )     (57,591 )
Total iBio, Inc. Stockholders’ Equity     7,141       9,937  
Noncontrolling interest     13,556       14,107  
Total Equity     20,697       24,044  
Total Liabilities and Equity   $ 48,091     $ 51,600  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

 

 3 

 

 

iBio, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited; In Thousands, except per share amounts)

 

   Three Months Ended 
   September 30, 
   2016   2015 
Revenues  $135   $160 
           
Operating expenses:          
Research and development (related parties of $239 and $227), net of $36 and $0 in grant income   820    551 
General and administrative (related parties of $175 and $0)   2,469    1,422 
Total operating expenses   3,289    1,973 
           
Operating loss   (3,154)   (1,813)
           
Other income (expense):          
Interest expense (related party of $483 and $0)   (483)   - 
Interest income   13    2 
Royalty income   12    6 
           
Total other income   (458)   8 
           
Consolidated net loss   (3,612)   (1,805)
Net loss attributable to noncontrolling interest   551    - 
Net loss attributable to iBio, Inc.  $(3,061)  $(1,805)
           
Comprehensive loss:          
Net loss  $(3,612)  $(1,805)
Other comprehensive loss - foreign currency translation adjustments   -    (9)
           
Comprehensive loss  $(3,612)  $(1,814)
           
Loss per common share – basic and diluted  $(0.03)  $(0.02)
           
Weighted-average common shares outstanding – basic and diluted   89,109    77,307 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 4 

 

 

iBio, Inc. and Subsidiaries  

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited; In Thousands) 

 

                       Accumulated             
                   Additional   Other             
   Preferred Stock   Common Stock   Paid-In   Comprehensive   Accumulated   Noncontrolling     
   Shares   Amount   Shares   Amount   Capital   Loss   Deficit   Interest   Total 
                                     
Balance as of July 1, 2016   -   $-    89,110   $89   $67,468   $(29)  $(57,591)  $14,107   $24,044 
                                              
Share-based compensation   -    -    -    -    265    -    -    -    265 
                                              
Foreign currency translation adjustment   -    -    -    -    -    -    -    -    - 
                                              
Net loss   -    -    -    -    -    -    (3,061)   (551)   (3,612)
                                              
Balance as of September 30, 2016   -   $-    89,110   $89   $67,733   $(29)  $(60,652)  $13,556   $20,697 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 5 

 

 

iBio, Inc. and Subsidiaries  

Condensed Consolidated Statements of Cash Flows

(Unaudited; In Thousands) 

 

    Three Months Ended  
    September 30,  
    2016     2015  
             
Cash flows from operating activities:                
Net loss   $ (3,612 )   $ (1,805 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Share-based compensation     265       329  
Amortization of intangible assets     88       91  
Depreciation     324       1  
Changes in operating assets and liabilities:                
Accounts receivable - trade     315       (34 )
Accounts receivable - unbilled     61       (126 )
Work in process     22       -  
Prepaid expenses and other current assets     131       90  
Security deposit     2       -  
Accounts payable     53       171  
Accrued expenses     102       136  
Deferred revenue     (24 )     -  
                 
Net cash used in operating activities     (2,273 )     (1,147 )
                 
Cash flows from investing activities:                
Additions to intangible assets     (202 )     (18 )
Purchases of fixed assets     (400 )     -  
                 
Net cash used in investing activities     (602 )     (18 )
                 
Cash flows from financing activities:                
Payment of capital lease obligation     (41 )     -  
Proceeds from exercise of warrants     -       63  
                 
Net cash (used in) provided by financing activities     (41 )     63  
                 
Effect of exchange rate changes     -       (8 )
                 
Net decrease in cash     (2,916 )     (1,110 )
Cash - beginning of period     23,014       9,494  
Cash - end of period   $ 20,098     $ 8,384  
                 
Schedule of non-cash activities:                
Unpaid intangible assets included in accounts payable   $ 184     $ -  
Unpaid fixed assets included in accounts payable   $ 71     $ -  
Unpaid intangible assets included in accrued expenses   $ -     $ (3 )
                 
Supplemental cash flow information:                
Cash paid during the period for interest   $ 484     $ -  

  

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

 

 6 

 

 

iBio, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1.Nature of Business

 

iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods.

 

iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:

 

iBioDefense Biologics LLC (“iBioDefense”) – iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016.

 

iBio Peptide Therapeutics LLC (“iBio Peptide”) – iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016.

 

iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) – iBio Brazil is a subsidiary organized in Brazil in which the Company has a 99% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the current Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.

 

iBio Manufacturing LLC (“iBio Manufacturing”) – iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.

 

iBio CMO LLC (“iBio CMO”) – iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned 100% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $15 million in cash for a 30% interest in iBio CMO. The Company retained a 70% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.

 

iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000 square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Affiliate granted iBio CMO a 34-year sublease for the facility as well as certain equipment (see Note 8). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.

 

2.Basis of Presentation

 

Interim Financial Statements

The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2016, from which the accompanying condensed balance sheet dated June 30, 2016 was derived.

 

 7 

 

 

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.

 

Liquidity

The Company’s primary sources of liquidity are cash on hand and cash available from the sale of common stock of the Company. At this time, cash flows from operating activities represent net outflows for operating expenses and expenses for technology and product development. As of September 30, 2016, the Company had $20.1 million in cash on hand which is expected to support the Company’s activities through September 30, 2017.

 

Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of September 30, 2016, the Company’s accumulated deficit was $60.7 million, and it had cash used in operating activities of $2.3 million for the three months ended September 30, 2016. The Company has historically financed its activities through the sale of common stock and warrants. Through September 30, 2016, the Company has dedicated most of its financial resources to investing in its iBioLaunch™ and iBioModulator™ platforms, its proprietary candidates for treatment of fibrotic diseases, advancing its intellectual property, and general and administrative activities.

 

On May 15, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) pursuant to which the Company has the option to require Aspire Capital, upon and subject to the terms of the agreement, to purchase up to $15 million of its common stock, over a three-year term. No shares have been sold under the 2015 Facility as of the date of the filing of this report. See Note 9 for a further description of the agreement.

 

Coincident with the entry into the iBio CMO joint venture, Eastern agreed to acquire 10 million shares of the Company's common stock at $0.622 per share. The closing for the sale of 3,500,000 of such shares occurred on January 25, 2016 and the sale of the remaining 6,500,000 shares occurred on April 13, 2016. In addition, on January 25, 2016, Eastern exercised warrants it previously acquired to purchase 1,784,000 shares of the Company's common stock at $0.53 per share. As of the date of the filing of this report, the Company has received $15 million for the capitalization of iBio CMO and approximately $7.2 million from Eastern for the acquisition of 10 million shares of common stock and the exercise of the warrants. See Note 9 for a further description of the transactions.

 

The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities, including sales of common stock to Aspire Capital pursuant to the common stock purchase agreement entered into on May 15, 2015, and through proceeds realized in connection with license and collaboration arrangements. The Company cannot be certain that such funding will be available on favorable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution.

 

The Company's financial statements were prepared under the assumption that the Company will continue as a going concern. If the Company is unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and the Company may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations.

 

3.Summary of Significant Accounting Policies

 

The Company’s significant accounting policies are described in Note 3 of the Notes to Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2016.

 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

 

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided.

 

 8 

 

 

The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “Revenue Arrangements with Multiple Deliverables,” and Staff Accounting Bulletin 104, “Revenue Recognition.” Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. In Fiscal 2017 and Fiscal 2016, the Company did not have any revenue arrangements with multiple deliverables.

 

The Company generates (or may generate in the future) contract revenue under the following types of contracts:

 

Fixed-Fee

Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.

 

Time and Materials

Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred.

 

Grant Income

Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In Fiscal 2017, grant income amounted to approximately $36,000. No grant income was recognized in Fiscal 2016.

 

Work in Process

Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. There was no work in process at September 30, 2016.

 

Fixed Assets

Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years.

 

Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5).

 

Intangible Assets

The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges in Fiscal 2017 and Fiscal 2016.

 

Recently Issued Accounting Pronouncements

In May 2014, ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”) was issued. The amendments in ASU 2014-09 affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in ASC 605, “Revenue Recognition,” and most industry-specific guidance, and creates ASC 606, “Revenue from Contracts with Customers.”

 

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:

 

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

 

 9 

 

 

ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” (“ASU 2015-14”) which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual reporting periods after December 15, 2017 (year ended June 30, 2018 for the Company) including interim periods within that reporting period.  Earlier application is permitted only as of annual reporting periods beginning after December 15, 2015, including interim reporting periods within that reporting period. The Company is currently evaluating the effects of adopting ASU 2014-09 on its consolidated financial statements but has not determined the impact as of the filing of this report.

   

Effective January 1, 2016, the Company adopted ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).  ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. An entity should recognize compensation cost in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. ASU 2014-12 became effective for interim and annual periods beginning on or after December 15, 2015. The adoption of ASU 2014-12 did not have a significant impact on the Company’s consolidated financial statements.

 

In June 2014, ASU 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”) was issued.  Before the issuance of ASU 2014-15, there was no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. This guidance is expected to reduce the diversity in the timing and content of footnote disclosures. ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards as specified in the guidance. ASU 2014-15 becomes effective for the annual period ending after December 15, 2016 (year ended June 30, 2017 for the Company) and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the effects of adopting ASU 2014-15 on its consolidated financial statements but the adoption is not expected to have a significant impact.

 

Effective January 1, 2016, the Company adopted ASU 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” (“ASU 2015-01”). ASU 2015-01 eliminates the concept of an extraordinary item from accounting principles generally accepted in the United States of America. As a result, an entity will no longer be required to segregate extraordinary items from the results of ordinary operations, to separately present an extraordinary item on its income statement, net of tax, after income from continuing operations or to disclose income taxes and earnings-per-share data applicable to an extraordinary item. However, ASU 2015-01 will still retain the presentation and disclosure guidance for items that are unusual in nature and occur infrequently. The adoption of ASU 2015-01 did not have a significant impact on the Company’s consolidated financial statements.

 

Effective July 1, 2016, the Company adopted ASU 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”). The amendments in ASU 2015-02 change the analysis that reporting entity must perform to determine whether it should consolidate certain types of legal entities. A reporting entity may apply the amendments in ASU 2015-02 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The adoption of ASU 2015-02 did not have a significant impact on the Company’s consolidated financial statements.

 

In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”).  ASU 2015-17 requires deferred tax assets and liabilities to be classified as noncurrent in the consolidated balance sheet. ASU 2015-17 becomes effective for interim and annual reporting periods beginning after December 15, 2016 (year ended June 30, 2017 for the Company). Early adoption is permitted.  A reporting entity should apply the amendment prospectively or retrospectively. The Company is currently evaluating the effects of adopting ASU 2015-17 on its consolidated financial statements but the adoption is not expected to have a significant impact as the Company continues to provide a full valuation allowance against its net deferred tax assets.

 

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The amendments require all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. This guidance is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company), including interim periods within those fiscal years. The Company will evaluate the effects of adopting ASU 2016-01 if and when it is deemed to be applicable.

 

 10 

 

 

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) which supersedes existing guidance on accounting for leases in “Leases (Topic 840).”  The standard requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet.  A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term.  The new guidance is effective for annual reporting periods beginning after December 15, 2018 (year ended June 30, 2020 for the Company) and interim periods within those fiscal years. The amendments should be applied at the beginning of the earliest period presented using a modified retrospective approach with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the effects of adopting ASU 2016-02 on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.

 

In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 affects entities that issue share-based payment awards to their employees. ASU 2016-09 is designed to simplify several aspects of accounting for share-based payment award transactions which include – the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. This guidance is effective for annual periods beginning after December 15, 2016 (year ended June 30, 2018 for the Company), including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements.

 

In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09, “Revenue from Contracts with Customers.” Specifically, ASU 2016-10 addresses an entity’s identification of its performance obligations in a contract, as well as an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as the new revenue standard, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The Company is currently evaluating the impact of ASU 2016-10 on its consolidated financial statements but has not determined the impact as of the filing of this report.

 

In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients” (“ASU 2016-12”). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. ASU 2016-12 will have the same effective date and transition requirements as the ASU 2014-09. The Company is currently evaluating the impact of ASU 2016-12 on its consolidated financial statements but has not determined the impact as of the filing of this report.

 

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.

 

 11 

 

 

4.Financial Instruments and Fair Value Measurement

 

The carrying values of cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses in the Company’s condensed consolidated balance sheets approximated their fair values as of September 30, 2016 and June 30, 2016 due to their short-term nature. The carrying value of the capital lease obligation approximated its fair value as of September 30, 2016 and June 30, 2016 as the interest rate used to discount the lease payments approximated market.

 

  5. Fixed Assets

 

iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34-year sublease. See Note 8 for more details of the terms of the sublease.

 

The economic substance of the sublease is that the Company is financing the acquisition of the facility and equipment and, accordingly, the facility and equipment are recorded as assets and the lease is recorded as a liability. As the sublease involves real estate and equipment, the Company separated the equipment component and accounted for the facility and equipment as if each was leased separately.

 

The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):

 

   September 30,
2016		   June 30,
2016		 
Facility under capital lease  $20,000   $20,000 
Equipment under capital lease   6,000    6,000 
Facility improvements   57    42 
Medical equipment   305    - 
Office equipment and software   146    137 
    26,508    26,179 
Accumulated depreciation – assets under capital lease   (882)   (571)
Accumulated depreciation – other   (46)   (34)
    (928)   (605)
Net fixed assets  $25,580   $25,574 

 

Depreciation expense was approximately $324,000 and $1,300 in Fiscal 2017 and Fiscal 2016, respectively. Depreciation of the assets under the capital lease amounted to approximately $311,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively.

 

6.Intangible Assets

 

The Company has two categories of intangible assets – intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (“Fraunhofer”), pursuant to a Technology Transfer Agreement, as amended (the “TTA”). The Company designates such technology acquired from Fraunhofer as iBioLaunch technology or as iBioModulator technology. The value attributed to Patents owned or controlled by the Company is based on payments for services and fees related to the further development and protection of the Company’s patent portfolio.

 

In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the “Licensed Technology”). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing a New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (“IND”) – became due on December 1, 2015. A six-month extension was automatically granted until June 1, 2016 under the license agreement. On August 11, 2016, the agreement was amended and replaced the original milestone schedule to provide that the IND filing be accomplished by June 30, 2017.

 

 12 

 

 

The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges during Fiscal 2017 and Fiscal 2016.

 

The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):

 

   September 30,
2016		   June 30,
2016		 
Intellectual property – gross carrying value  $3,100   $3,100 
Patents – gross carrying value   2,284    2,265 
    5,384    5,365 
Intellectual property – accumulated amortization   (1,971)   (1,932)
Patents – accumulated amortization   (1,390)   (1,341)
    (3,361)   (3,273)
Net intangible assets  $2,023   $2,092 

 

Amortization expense was approximately $88,000 and $91,000 for Fiscal 2017 and Fiscal 2016, respectively.

 

7.Significant Vendors

 

Fraunhofer

Fraunhofer was the Company’s most significant vendor solely on the basis of the three-party Yellow Fever vaccine development program among Fiocruz/Bio-Manguinhos, the Company, and Fraunhofer (described in greater detail below). The accounts payable balance under this three-party agreement includes amounts due Fraunhofer of approximately $122,000 and $341,000 as of September 30, 2016 and June 30, 2016, respectively, and accrued expenses of $62,000 and $122,000 as of September 30, 2016 and June 30, 2016, respectively. See Note 14 – Commitments and Contingencies.

 

On January 4, 2011, the Company entered into the Collaboration and License Agreement (the “CLA”) which is a three-party agreement involving the Company, Fraunhofer and Fiocruz, a public entity, member of the Indirect Federal Public Administration and linked to the Health Ministry of Brazil, acting through its unit Bio-Manguinhos. The CLA provides for the development of a Yellow Fever vaccine to be manufactured and distributed within Latin America and Africa by Fiocruz. The CLA was supplemented by a bilateral agreement between iBio and Fraunhofer dated December 27, 2010 in which the Company engaged Fraunhofer as a contractor to provide the research and development services (both, together, the “Agreement”). The services are billed to Fiocruz at Fraunhofer’s cost, so the Company’s revenue is equivalent to expense and there is no profit.

 

On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) which provides for revised research and development, work plans, reporting, objectives, estimated budget, and project billing process. In Fiscal 2017 and Fiscal 2016, under the Amended Agreement, the Company recognized revenue of $62,000 and $160,000, respectively, for work performed for Fiocruz pursuant to the Amended Agreement by the Company’s subcontractor, Fraunhofer, and recognized research and development expenses of the same amount due Fraunhofer for that work.

 

In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. See Note 14 - Commitments and Contingencies for significant modifications.

 

On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov, Fraunhofer's Executive Director. See Note 14 - Lawsuits for additional information.

  

Novici Biotech, LLC

In January 2012, the Company entered into an agreement with Novici Biotech, LLC (“Novici”) in which iBio’s President is a minority stockholder. Novici performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. In addition, the Company and Novici collaborate on the development of new technologies and product candidates for exclusive worldwide commercial use by the Company. The accounts payable balance includes amounts due to Novici of approximately $239,000 and $200,000 at September 30, 2016 and June 30, 2016, respectively. Research and development expenses related to Novici were approximately $239,000 and $227,000 in Fiscal 2017 and Fiscal 2016, respectively.

 

 13 

 

 

  8. Capital Lease Obligation

 

As discussed above, iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34-year sublease. iBio CMO began operations at the facility on December 22, 2015 pursuant to agreements between iBio CMO and the Second Affiliate granting iBio CMO temporary rights to access the facility. These temporary agreements were superseded by the Sublease Agreement, dated January 13, 2016, between iBio CMO and the Second Affiliate (the “sublease”). The 34-year term of the sublease may be extended by iBio CMO for a ten-year period, so long as iBio CMO is not in default under the sublease. Under the sublease, iBio CMO is required to pay base rent at an annual rate of $2,100,000, paid in equal quarterly installments on the first day of each February, May, August and November. The base rent is subject to increase annually in accordance with increases in the Consumer Price Index. The base rent under the Second Affiliate’s ground lease for the property is subject to adjustment, based on an appraisal of the property, in 2030 and upon any extension of the ground lease. The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. iBio CMO is also responsible for all costs and expenses in connection with the ownership, management, operation, replacement, maintenance and repair of the property under the sublease.

 

In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively.

 

Interest expense incurred under the capital lease obligation amounted to approximately $484,000 and $0 for Fiscal 2017 and Fiscal 2016, respectively.

 

Future minimum payments under the capitalized lease obligations are due as follows:

 

Fiscal period ending on September 30,:  Principal   Interest   Total 
2017  $173,048   $1,926,952   $2,100,000 
2018   186,593    1,913,407    2,100,000 
2019   201,198    1,898,802    2,100,000 
2020   216,947    1,883,053    2,100,000 
2021   233,928    1,866,072    2,100,000 
Thereafter   24,381,531    35,468,469    59,850,000 
                
Total minimum lease payments   25,393,245   $44,956,755   $70,350,000 
Less: current portion   (173,048)          
Long-term portion of minimum lease obligations  $25,220,197           

 

9.Stockholders’ Equity

 

Preferred Stock

The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. As of September 30, 2016 and June 30, 2016, there were no shares of preferred stock issued and outstanding.

 

Common Stock

As of September 30, 2016 and 2015, the Company was authorized to issue up to 175 million shares of common stock.   As of September 30, 2016, the Company had reserved up to 15 million shares of common stock for incentive compensation (stock options and restricted stock). No shares are reserved for the exercise of warrants.

 

No shares of common stock were issued for the period July 1, 2016 through the date of the filing of this report. Recent issuances of common stock include the following:

 

 14 

 

 

Aspire Capital – 2015 Facility

 

On May 15, 2015, the Company entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire Capital, pursuant to which the Company has the option to require Aspire Capital to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock (the “Purchase Shares”) upon and subject to the terms of the 2015 Aspire Purchase Agreement.  In consideration for entering into the purchase agreement, Aspire Capital received a commitment fee of 450,000 shares (the “Commitment Shares”).

 

On any business day after the Commencement Date (as defined below) and over the 36-month term of the 2015 Aspire Purchase Agreement, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase up to 200,000 Purchase Shares per business day; however, no sale pursuant to such a Purchase Notice may exceed five hundred thousand dollars ($500,000) per business day, unless the Company and Aspire Capital mutually agree. The Company and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional 2,000,000 Purchase Shares per business day. The purchase price per Purchase Share pursuant to such Purchase Notice (the “Purchase Price”) is the lower of (i) the lowest sale price for the Company’s common stock on the date of sale or (ii) the average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The applicable Purchase Price will be determined prior to delivery of any Purchase Notice.

 

In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital for at least 150,000 Purchase Shares and the closing sale price of the Company’s common stock is higher than $0.40, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of the Company’s common stock equal to up to 35% of the aggregate shares of common stock traded on the next business day (the “VWAP Purchase Date”), subject to a maximum number of shares determined by the Company (the “VWAP Purchase Share Volume Maximum”). The purchase price per Purchase Share pursuant to such VWAP Purchase Notice (the “VWAP Purchase Price”) shall be the lesser of the closing sale price of the Company’s common stock on the VWAP Purchase Date or 97% of the volume weighted average price for the Company’s common stock traded on the VWAP Purchase Date if the aggregate shares to be purchased on that date does not exceed the VWAP Purchase Share Volume Maximum, or the portion of such business day until such time as the sooner to occur of (1) the time at which the aggregate shares traded has exceeded the VWAP Purchase Share Volume Maximum, or (2) the time at which the sale price of the Company’s common stock falls below the VWAP Minimum Price Threshold (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). The VWAP Minimum Price Threshold is the greater of (i) 80% of the closing sale price of the Company’s common stock on the business day immediately preceding the VWAP Purchase Date or (ii) such higher price as set forth by the Company in the VWAP Purchase Notice.

 

The number of Purchase Shares covered by and timing of each Purchase Notice or VWAP Purchase Notice are determined at the Company’s discretion. The aggregate number of shares that the Company can sell to Aspire Capital under the 2015 Aspire Purchase Agreement may in no case exceed 15,343,406 shares of our common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the 2015 Aspire Purchase Agreement, including the 450,000 Commitment Shares issued to Aspire Capital in consideration for entering into the 2015 Aspire Purchase Agreement) (the “Exchange Cap”), unless (i) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company’s common stock.

 

The 2015 Aspire Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. Sales under the 2015 Aspire Purchase Agreement could commence only after certain conditions were satisfied (the date on which all requisite conditions have been satisfied being referred to as the “Commencement Date”), which conditions included the delivery to Aspire Capital of a prospectus supplement covering the Commitment Shares and the Purchase Shares, approval for listing on NYSE MKT of the Purchase Shares and the Commitment Shares, the issuance of the Commitment Shares to Aspire Capital, and the receipt by Aspire Capital of a customary opinion of counsel and other certificates and closing documents. Either party had the option to terminate the 2015 Aspire Purchase Agreement in the event the Commencement Date had not occurred by July 1, 2015. The 2015 Aspire Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost or penalty.

 

The Company’s net proceeds will depend on the Purchase Price, the VWAP Purchase Price and the frequency of the Company’s sales of Purchase Shares to Aspire Capital; subject to the maximum $15.0 million available amount. The Company’s delivery of Purchase Notices and VWAP Purchase Notices will be made subject to market conditions, in light of the Company’s capital needs from time to time. The Company expects to use proceeds from sales of Purchase Shares for general corporate purposes and working capital requirements.

 

In connection with the 2015 Aspire Purchase Agreement, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Aspire Capital, dated May 15, 2015. The Registration Rights Agreement provides, among other things, a requirement to register the sale of the Commitment Shares and the Purchase Shares to Aspire Capital pursuant to the Company’s existing shelf registration statement (the “Registration Statement”). The Company further agreed to keep the Registration Statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement. On May 29, 2015, the Company filed a prospectus supplement to the Company’s existing Registration Statement on Form S-3, registering $15.0 million of the Company’s common stock that it may issue and sell to Aspire Capital from time to time pursuant to the 2015 Aspire Purchase Agreement, together with the 450,000 Commitment Shares issued to Aspire Capital in consideration for entering into the 2015 Aspire Purchase Agreement.

 

 15 

 

 

No shares have been sold under the 2015 Facility as of the date of the filing of this report.

 

Eastern – Share Purchase Agreements

 

On January 13, 2016, the Company entered into a share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 3,500,000 shares of the Company’s common stock at a price of $0.622 per share. The Company received proceeds of $2,177,000 and the shares were issued on January 25, 2016. In addition, Eastern agreed to exercise warrants it had previously acquired to purchase 1,784,000 shares of the Company’s common stock at an exercise price of $0.53 per share. The Company received proceeds of approximately $945,000 from the exercise of the warrants and the shares were issued on January 25, 2016.

 

On January 13, 2016, the Company entered into a separate share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 6,500,000 shares of the Company’s common stock at a price of $0.622 per share, subject to the approval of the Company’s stockholders. The Company’s stockholders approved the issuance of the 6,500,000 shares to Eastern at the Company’s annual meeting on April 7, 2016. On April 13, 2016, the Company issued the 6,500,000 shares and received proceeds of $4,043,000. These shares are subject to a three-year standstill agreement which will restrict additional acquisitions of the Company’s common stock by Eastern and its controlled affiliates to limit its beneficial ownership of the Company’s outstanding shares of common stock to a maximum of 38%, absent the approval by a majority of the Company’s board of directors.

  

Warrants

The Company has historically financed its operations through the sale of common stock and warrants, sold together as units. No warrants were outstanding as of September 30, 2016 and June 30, 2016.

  

10.Earnings (Loss) Per Common Share

 

Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

 

   Three Months ended
September 30,		 
   2016   2015 
Basic and diluted numerator:          
           
Net loss available to iBio, Inc. stockholders  $(3,061)  $(1,805)
           
Basic and diluted denominator:          
           
Weighted-average common shares outstanding   89,109    77,307 
           
Per Share Amount  $(0.03)  $(0.02)

  

In Fiscal 2017 and Fiscal 2016, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September 30, 2016, shares issuable which could potentially dilute future earnings included approximately 12.3 million stock options.   As of September 30, 2015, shares issuable which could potentially dilute future earnings included approximately 12.1 million stock options and 6.0 million warrants.

 

11.Share-Based Compensation

 

The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):

 

   Three Months Ended
September 30,		 
   2016   2015 
Research and development  $6   $5 
General and administrative   259    324 
Total  $265   $329 

 

 16 

 

 

Stock Options

On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors and external service providers. The Plan, as amended on December 18, 2013, provided that the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 15 million shares. As of September 30, 2016, there were approximately 2.7 million shares of common stock reserved for future issuance under the Plan. Stock options granted under the Plan may be either incentive stock options (as defined by Section 422 of the Internal Revenue Code of 1986, as amended) or non-qualified stock options at the discretion of the Board of Directors. Vesting of service awards occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria have been satisfied. The Company uses historical data to estimate forfeiture rates.

 

No stock options were issued during Fiscal 2017.

  

The following table summarizes all stock option activity during Fiscal 2017:

 

   Stock
Options		   Weighted-
average
Exercise
Price		   Weighted-
average
Remaining
Contractual
Term (in years)		   Aggregate
Intrinsic Value
(in thousands)		 
Outstanding as of July 1, 2016   12,273,334   $1.31    6.4   $993 
Granted   -                
Outstanding as of September 30, 2016   12,273,334   $1.31    6.1   $433 
Vested and, as of September 30, 2016, expected to vest   12,233,897   $1.31    6.1   $433 
                     
Exercisable as of September 30, 2016   9,361,697   $1.31    5.5   $405 

 

As of September 30, 2016, there was approximately $1.4 million of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of 1.68 years.

 

12.Related Party Transactions

 

Novici Biotech, LLC 

In January 2012, the Company entered into an agreement with Novici in which iBio’s President is a minority stockholder. See Note 7.

 

Agreements with Eastern Capital Limited and its Affiliates.

As more fully discussed in Note 9, the Company entered into two share purchase agreements with Eastern and sold 10 million shares of common stock at a price of $0.622 per share. The Company received proceeds of $6,220,000. In addition, Eastern agreed to exercise warrants it had previously acquired to purchase 1,784,000 shares of the Company’s common stock at an exercise price of $0.53 per share. The Company received proceeds of approximately $945,000 from the exercise of the warrants.

 

Concurrently with the execution of the Purchase Agreements, iBio entered into a contract manufacturing joint venture with an affiliate of Eastern to develop and manufacture plant-made pharmaceuticals through iBio’s recently formed subsidiary, iBio CMO. The Eastern Affiliate contributed $15.0 million in cash to iBio CMO, for a 30% interest in iBio CMO. iBio retained a 70% equity interest in iBio CMO. As the majority equity holder, iBio has the right to appoint a majority of the members of the Board of Managers that manages the iBio CMO joint venture. Specified material actions by the joint venture require the consent of iBio and the Eastern Affiliate. iBio contributed to the capital of iBio CMO a royalty bearing license, which grants iBio CMO a non-exclusive license to use the iBio’s proprietary technologies, including the iBioLaunch technology and additional iBio technologies, for research purposes and an exclusive U.S. license for manufacturing purposes. iBio retains all other rights in its intellectual property, including the right for itself to commercialize products based on its proprietary technologies or to grant licenses to others to do so.

 

In connection with the joint venture, the Second Eastern Affiliate, which controls the subject property as sublandlord, granted iBio CMO a 34-year sublease of a Class A life sciences building in Bryan, Texas, on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. Accrued expenses at September 30, 2016 and June 30, 2016 due to the Second Eastern Affiliate amounted to $772,000 and $623,000, respectively. General and administrative expenses related to Second Eastern Affiliate were approximately $167,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively. Interest expense related to the Second Eastern Affiliate was approximately $483,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively. The terms of the sublease are described in Note 8.

 

 17 

 

 

A three-year standstill agreement (the “Standstill Agreement”) that took effect upon the issuance of the Eastern Shares pursuant to the 6,500,000 Purchase Agreement restricts additional acquisitions of iBio common stock by Eastern and its controlled affiliates to limit its beneficial ownership of the Company’s outstanding shares of common stock to a maximum of 38%, absent approval by a majority of the Company’s Board of Directors.

 

Operating Lease with Minority Stockholder

Effective January 1, 2015, the Company is leasing office space on a month-to-month basis from an entity owned by a minority stockholder of the Company. Rent was $2,200 per month through November 2015 and increased to $2,500 per month effective December 2015. Rent expense totaled $7,500 and $6,600 in Fiscal 2017 and Fiscal 2016, respectively.

 

13. Income Taxes

 

The Company recorded no income tax expense for the three months ended September 30, 2016 and 2015 because the estimated annual effective tax rate was zero. As of September 30, 2016, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

 

14. Commitments and Contingencies  

 

Agreements

In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. The significant modifications post June 30, 2013 are of follows:

 

The Company’s obligation under the TTA, prior to the Settlement Agreement, to make three $1 million payments to Fraunhofer in April 2013, November 2013, and April 2014 (the “Guaranteed Annual Payments”) was terminated and replaced with an undertaking to engage Fraunhofer to perform at least $3 million in work requested and as directed by iBio before December 31, 2015. For the year ended June 30, 2015, $2.7 million in research and development services were performed by Fraunhofer. As of December 31, 2015, the total engagement of Fraunhofer for work requested by iBio is $3.0 million. In addition to the foregoing, the Company sought to engage Fraunhofer for substantial additional other work, but Fraunhofer did not respond to the Company’s requests for proposals for such work.

 

The Company’s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $200,000 was terminated. Instead under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties. The Company will be obligated to remit royalties to Fraunhofer only on technology license revenues that iBio actually receives and on revenues from actual sales by iBio of products derived from the technology developed under the TTA until the later of November 2023 or until such time as the aggregate royalty payments total at least $4 million. All new intellectual property invented by Fraunhofer during the period of the TTA is owned by and is required to be transferred to iBio. The Company has no financial obligations to Fraunhofer with respect to the Company’s use of technologies developed independently of Fraunhofer.

 

On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) to create a new research and development plan for the development of a recombinant Yellow Fever vaccine providing revised reporting, objectives, estimated budget, and project billing process. Under the CLA and bilateral agreement between iBio and Fraunhofer dated December 27, 2010, Fraunhofer, which has been engaged to act as the Company’s subcontractor for performance of research and development services for the new research and development plan, will bill Fiocruz directly on behalf of the Company at the rates, amounts and times provided in the Amended Agreement, and the proceeds of such billings and only the proceeds will be paid to Fraunhofer for its services so the Company’s expense is equal to its revenue and no profit is recognized for these activities under the Amended Agreement. For the year ended June 30, 2015, $2.1 million in research and development services were performed by Fraunhofer for the Company pursuant to the amended CLA. As of December 31, 2015, the total engagement of Fraunhofer for work requested by iBio is $3.0 million. See Note 7 - Significant Vendors for additional information. In addition to the foregoing, the Company sought to engage Fraunhofer for substantial additional other work, but Fraunhofer did not respond to the Company’s requests for proposals for such work 

 

On January 14, 2014 (the “Effective Date”), the Company entered into an exclusive worldwide License Agreement (“LA”) with the University of Pittsburgh (“UP”) covering all of the U.S. and foreign patents and patent applications and related intellectual property owned by UP pertinent to the use of endostatin peptides for the treatment of fibrosis. The Company paid an initial license fee of $20,000 and is required to pay all of UP’s patent prosecution costs that were incurred prior to, totaling $30,627, and subsequent to the Effective Date. On each anniversary date the Company is to pay license fees ranging from $25,000 to $150,000 for the first five years and $150,000 on each subsequent anniversary date until the first commercial sale of the licensed technology. Beginning with commercial sales of the technology or approval by the FDA or foreign equivalent, the Company will be required to pay milestone payments, royalties and a percentage of any non-royalty sublicense income to UP.

 

 18 

 

 

On December 30, 2013, the Company entered into a Project Agreement with the Medical University of South Carolina (“MUSC”) providing for the performance of research and development services by MUSC related to peptides for the treatment of fibrosis. The agreement requires the Company to make payments totaling $78,000 through December 1, 2014 and provides the Company with certain intellectual property rights. Effective September 1, 2014, the Company and MUSC executed an Amendment to the agreement. The Amendment extended the term of the agreement to December 31, 2015 and increased the total payments due MUSC from the Company by $161,754.

 

Lawsuits

 

On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (“Yusibov”), Fraunhofer’s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer’s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. Briefing was completed on a motion to dismiss filed by Fraunhofer in lieu of filing an answer to the complaint. Fraunhofer also moved for a protective order in connection with certain discovery served by iBio. The Court bifurcated the action to first resolve the threshold question in the case – the scope of iBio’s ownership of the technology developed or held by Fraunhofer — before proceeding with the rest of the case and the parties stipulated their agreement to that approach. After considering the parties’ written submissions and oral argument on this threshold issue on April 29, 2016, the Court resolved the threshold issue in favor of iBio on July 29, 2016, holding that iBio owns all proprietary rights of any kind to all plant-based technology of Fraunhofer developed or held as of December 31, 2014, including know-how, and is entitled to receive a transfer of the technology from Fraunhofer. On September 19, 2016, Fraunhofer informed the Court that it does not intend to pursue its motion for protective order at this time. iBio has sought leave of Court to supplement and amend its current complaint to add additional state law claims against Fraunhofer. Fraunhofer opposes this motion. The Company is unable to predict the further outcome of this action at this time.

 

On December 4, 2015, a putative derivative action captioned Savage, Derivatively on Behalf of iBio, Inc., Plaintiff, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant was filed in the Supreme Court of the State of New York, County of New York. The action alleged that the Company and its management made misstatements about the Company’s business resulting either from (i) a failure by iBio’s directors to establish a system of controls over the Company’s disclosures, or (ii) the directors’ consciously ignoring “red flags” relating to disclosures, and sought to recover an unspecified amount of damages. On January 15, 2016, the defendants filed a motion to dismiss all claims against them. On March 16, 2016, the plaintiff filed a Verified Amended Complaint that added an additional named plaintiff and alleged derivative claims generally along the same lines as the original complaint, together with purported direct breach of fiduciary duty and unjust enrichment claims based on the same conduct. The Verified Amended Complaint sought to recover an unspecified amount of damages. On April 29, 2016, the defendants filed a motion to dismiss all claims against them. Plaintiffs’ opposition to the motion was filed on June 6, 2016. On June 22, 2016, the plaintiffs advised the Court that the parties had reached a settlement in principle, and on July 1, 2016, the Court ordered that the defendants’ pending motion to dismiss be withdrawn without prejudice. The parties entered a Stipulation of Settlement dated as of September 20, 2016. On October 11, 2016, the plaintiffs filed a motion with the Court seeking preliminary approval of the settlement. The terms of the settlement are subject to preliminary and final approval by the Court. The Company expects that the settlement will be funded by the Company’s insurance carrier.

 

15. Segment Reporting

 

In accordance with FASB ASC 280, “Segment Reporting,” the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, iBio, Inc. and iBio CMO. Commencing July 1, 2016, management determined that the activity of iBio CMO should be segregated as a separate segment. In addition, management determined that the activity of iBio Brazil was no longer material and will be included in the activity of iBio, Inc. As such, the segment information for the three months ended September 30, 2015 was conformed to the current presentation. These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.

 

 19 

 

 

Three Months Ended September 30, 2016 (in thousands)  iBio, Inc.   iBio CMO   Eliminations   Total 
                 
Revenues - external customers  $86   $49   $-   $135 
Revenues – intersegment   152    182    (334)   - 
Research and development   684    321    (185)   820 
General and administrative   1,347    1,271    (149)   2,469 
Operating loss   (1,793)   (1,361)   -    (3,154)
Interest expense   -    (483)   -    (483)
Interest and other income   18    7    -    25 
Consolidated net loss   (1,775)   (1,837)   -    (3,612)
Total assets   11,810    36,330    (49)   48,091 
Fixed assets, net   8    25,572    -    25,580 
Intangible assets, net   2,023    -    -    2,023 
Depreciation expense   1    323    -    324 
Amortization of intangible assets   88    -    -    88 

 

Three Months Ended September 30, 2015 (in thousands)  iBio, Inc.   iBio CMO *   Eliminations   Total 
                 
Revenues - external customers  $160   $-   $-   $160 
Revenues – intersegment   -    -    -    - 
Research and development   551    -    -    551 
General and administrative   1,422    -    -    1,422 
Operating loss   (1,813)   -    -    (1,813)
Interest expense   -    -    -    - 
Interest and other income   8    -    -    8 
Consolidated net loss   (1,805)   -    -    (1,805)
Total assets   11,374    -    -    11,374 
Fixed assets, net   10    -    -    10 
Intangible assets, net   2,284    -    -    2,284 
Depreciation expense   1    -    -    1 
Amortization of intangible assets   91    -    -    91 

 

* iBio CMO commenced operations in December 2015

 

 20 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following information should be read together with the financial statements and the notes thereto and other information included elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended June 30, 2016. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “iBio,” the “Company,” “we,” “us,” or “our” and similar terms mean iBio, Inc.

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. For this purpose, any statements contained herein regarding our strategy, future operations, financial position, future revenues, projected costs and expenses, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words “anticipate”, “believe”, “estimate”, “may”, “plan”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements reflect our current views with respect to future events. Because these forward-looking statements involve known and unknown risks and uncertainties, actual results, performance or achievements could differ materially from those expressed or implied by these forward-looking statements for a number of important reasons, including those discussed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q, as well as in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended June 30, 2016. We cannot guarantee any future results, levels of activity, performance or achievements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Quarterly Report on Form 10-Q as anticipated, believed, estimated or expected. The forward-looking statements contained in this Quarterly Report on Form 10-Q represent our estimates as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated) and should not be relied upon as representing our expectations as of any other date. While we may elect to update these forward-looking statements, we specifically disclaim any obligation to do so.

 

Overview

 

We are a biotechnology company focused on commercializing our proprietary technologies and product candidates and providing product development and manufacturing services to clients and collaborators. The Company’s technologies constitute a proprietary, transformative platform for development and production of biologics in hydroponically grown green plants.

 

Stated simply, iBio’s technologies harness the natural protein production capability that plants use to sustain their own growth, and direct it instead to produce proteins for a range of applications including for vaccines and biopharmaceuticals. The Company’s technologies can be used to produce a wide array of biologics and also to create and produce proprietary derivatives of preexisting products with improved properties. The Company has used its technologies and its collaborative relationships to demonstrate the applicability of its technologies to a diverse range of product candidates including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are currently derived from human blood plasma.

 

In addition to the broad array of biological products that can be produced with the Company’s technologies we believe our technologies offer other advantages that are not available with conventional manufacturing systems. These anticipated advantages may include reduced production time and lower operating costs. Further, we believe that the capital investment required to create facilities that will manufacture proteins using the Company’s technologies will be substantially less than the capital investment which would be required for the creation of similar capacity facilities utilizing conventional manufacturing methods dependent upon animal cells, bacterial fermenters and chicken eggs. Additionally, operating costs in a manufacturing facility using iBio’s platform are expected to be reduced significantly in comparison to conventional manufacturing processes due to the rapid nature of our production cycle and the elimination of the expenses associated with the operation and maintenance of bioreactors, fermenters, sterile liquid handling systems and other expensive equipment which is not required in connection with the use of the Company’s technologies.

 

Among the Company’s proprietary technologies are the patented iBioLaunch technology, the patented iBioModulator technology, and additional newer and more advanced technologies. Bio-Manguinhos/Fiocruz, or Fiocruz, a unit of the Oswaldo Cruz Foundation, a central agency of the Ministry of Health of Brazil, is sponsoring the development an iBioLaunch-produced yellow fever vaccine to replace the vaccine it currently makes in chicken eggs for the populations of Brazil and more than 20 other nations. These advances are occurring subsequent to the demonstration of safety of iBioLaunch-produced vaccine candidates against each of the H1N1 “Swine” flu virus and the H5N1 avian flu virus in successfully completed Phase 1 clinical trials.

 

We developed our iBioModulator technology based on the use of a modified form of the cellulose degrading enzyme lichenase from Clostridium thermocellum, a thermophilic and anaerobic bacterium. iBioModulator enables an adjuvant component to be fused directly to preferred recombinant antigens to create a single protein for use in vaccine applications.

 

 21 

 

 

The iBioModulator platform has been shown to be applicable to a range of vaccine proteins and can significantly modify the immune response to a vaccine in two important ways. Animal efficacy studies have demonstrated that it can increase the strength of the initial immune response to a vaccine antigen (as measured by antibody titer) and also extend the duration of the immune response. These results suggest the possibility that use of the iBioModulator platform may lower vaccine antigen requirements and enable fewer doses to establish prolonged protective immunity.

 

In addition to technology developed for iBio pursuant to agreements with Fraunhofer U.S.A., Inc., iBio’s more recently developed technologies provide us with higher expression yields of certain proteins and increased efficiency in adapting gene sequences to achieve specific product objectives. In addition, we are developing improved, proprietary manufacturing processes that we expect to protect as trade secrets.

 

Our near-term focus is to realize two key objectives: (1) the establishment of additional business arrangements pursuant to which commercial, government and not-for-profit licensees will utilize the Company’s technologies in connection with the development and manufacturing of therapeutic proteins and vaccine products; and (2) the further development of select product candidates based upon or enhanced by our technology platforms. These objectives are the core components of our strategy to commercialize the proprietary technologies we have developed and validated.

 

Our strategy to engage in partnering and out-licensing of our technologies seeks to preserve the opportunity for iBio to share in the successful development and commercialization of product candidates by our licensees while enhancing our own capital and financial resources for development, alone or through commercial alliances with others, of high-potential product candidates based upon our technologies. In addition to financial resources we may receive in connection with the license of our technologies, we believe that successful development by third party licensees of iBio technology-enhanced product candidates will further validate our technologies, increase awareness of the advantages that may be realized by the use of such platforms and promote broader adoption of our technologies by additional third parties.

 

The advancement of iBio technology-enhanced product candidates is a key element of our strategy. We believe that selecting and developing products which individually have substantial commercial value and are representative of classes of pharmaceuticals that can be successfully produced using our technology platforms will allow us to maximize the near and longer term value of our technologies while exploiting individual product opportunities. To realize this result, we are currently internally advancing through preclinical IND enabling studies a proprietary recombinant protein we call IBIO-CFB03 for treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and potentially other fibrotic diseases. To the extent that we anticipate the opportunity to realize additional value, we may elect to further the development of this or other product candidates through the early stages of clinical development before seeking to license the product candidate to other industry participants for late stage clinical development and if successful, commercialization.

 

On December 16, 2015, we formed iBio CMO LLC (“iBio CMO”), a Delaware limited liability corporation, to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, we owned 100% of iBio CMO. On January 13, 2016, we entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $15 million in cash for a 30% interest in iBio CMO. We retained a 70% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use our proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. We retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using our technology.

 

iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Affiliate granted iBio CMO a 34-year sublease for the facility. Commercial operations commenced in January 2016. iBio CMO operates on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.

 

Proprietary iBio technologies have been used to advance development of certain products that have been commercially infeasible to develop with conventional technologies such as Chinese hamster ovary cell systems and microbial fermentation methods. They can be used to create and operate manufacturing facilities at substantially lower capital and operating costs. These include development and manufacture of both vaccine and therapeutic product candidates. iBio CMO plans to promote commercial collaborations with third parties on the basis of these technology advantages and to work with customers to achieve laboratory scale technical milestones that can form the basis of longer-term manufacturing business arrangements. iBio itself will be a client of iBio CMO for further IND advancement of its proprietary products beginning with IBIO-CFB03 for the treatment of a range of fibrotic diseases. iBio will work with iBio CMO on the production of IBIO-CFB03 for clinical trials and, with clinical success, for commercial launch.

 

Due to the lower capital and operating cost requirements for pharmaceutical production via iBio technology versus legacy methods, certain corporations and governments that have not already established manufacturing capacity for biologic products are client prospects for both development and for commercial technology transfer services to enable autonomous manufacturing in the market being served. For example, in Brazil, iBio has been collaborating with the Oswaldo Cruz Foundation (Fiocruz) to develop a recombinant yellow fever vaccine based on iBio technology. iBio’s contract with Fiocruz provides for commercial technology transfer services as the product candidates enters human clinical trials. Over time, iBio expects to work closely with iBio CMO to provide such technology transfer services for a variety of both commercial and government clients.

 

 22 

 

 

Results of Operations - Comparison of Three Months ended September 30, 2016 (“Fiscal 2017”) versus September 30, 2015 (“Fiscal 2016”)

 

Revenue

Gross revenue for Fiscal 2017 and 2016 was approximately $135,000 and $160,000, respectively, a decrease of approximately $25,000.

 

Revenue has been attributable to technology services provided to Bio-Manguinhos/FioCruz (“FioCruz”) in connection with the development by FioCruz of a yellow fever vaccine using our iBioLaunch™ technology. To fulfill our obligations, we engaged Fraunhofer USA Inc. ("Fraunhofer") as a subcontractor to perform the services required. During 2013, the Company, FioCruz and Fraunhofer were awaiting approval by the Brazilian government of a contract amendment reflecting the agreed modifications to the work plan. During this waiting period, no revenues were recognized by the Company in connection with services provided to FioCruz through the subcontract arrangement with Fraunhofer. In June 2014, the Company, FioCruz and Fraunhofer amended their Collaboration and License Agreement reflecting the agreed modifications to the work plan and work was resumed by Fraunhofer for the Company to continue development of a yellow fever vaccine using the Company’s iBioLaunch ™ technology. In Fiscal 2017, revenue was lower due to changes in technology services performed pursuant to the agreement with FioCruz.

 

Research and development expenses

Research and development expenses for Fiscal 2017 and Fiscal 2016 were $820,000 and $551,000, respectively, a decrease of approximately $269,000. The increase was primarily related to the addition of iBio CMO operations net of the decrease in contracted research expenses with Fiocruz.

 

General and administrative expenses

General and administrative expenses for Fiscal 2017 and Fiscal 2016 were approximately $2.5 million and $1.4 million, respectively, an increase of approximately $1.1 million. General and administrative expenses principally include officer and employee salaries and benefits, legal and accounting fees, insurance, consulting services, investor and public relations services, and other costs associated with being a publicly traded company. The increase was primarily due to the expenses related to iBio CMO operations which commenced in December 2015 of approximately $830,000.

 

Other Income (Expense)

 

Other income (expense) for Fiscal 2017 and Fiscal 2016 was approximately ($458,000) and $8,000, respectively.

 

As discussed above, iBio CMO’s operations take place in a facility in Bryan, Texas under a 34-year sublease. Such sublease is accounted for as a capital lease. In Fiscal 2017, other income (expense) included interest expense of $483,000 incurred under the capital lease and interest and royalty income of $25,000. Other income in Fiscal 2016 consisted of interest and royalty income.

 

Net loss attributable to noncontrolling interest

 

This represents the share of the loss in iBio CMO for the Eastern Affiliate in Fiscal 2017.

 

Liquidity and Capital Resources

 

As of September 30, 2016, we had cash of $20.1 million as compared to $23.0 million as of June 30, 2016. Cash at June 30, 2016 included the remaining proceeds received from stock purchase agreements from Eastern and the contribution for the formation of iBio CMO of $15 million.

 

Net Cash Used in Operating Activities

Operating activities used $2.3 million in cash for Fiscal 2017. The decrease in cash was primarily attributable to funding the loss for the period.

 

Net Cash Used in Investing Activities

In Fiscal 2017, net cash used in investing activities was approximately $602,000. Cash used in investing activities was attributable to additions to intangible assets of $202,000 and fixed assets primarily for iBio CMO of $400,000.

 

Net Cash Provided by Financing Activities

In fiscal 2017, net cash used in financing activities was $41,000, which represented payments of the capital lease obligation.  

 

Funding Requirements

We have incurred significant losses and negative cash flows from operations since our spinoff from Integrated BioPharma, Inc. in August 2008. As of September 30, 2016, our accumulated deficit was approximately $60.7 million, and we used approximately $2.3 million of cash for operating activities for Fiscal 2017. As of September 30, 2016, cash on hand of approximately $20.1 million is expected to support the Company’s activities through September 30, 2017.

 

 23 

 

 

We have historically financed our activities through the sale of common stock and warrants. We plan to fund our future business operations using cash on hand, through proceeds from the sale of additional equity and other securities and through proceeds realized in connection with license and collaboration arrangements and operation of the Company’s new subsidiary, iBio CMO.

 

 

On May 15, 2015, we entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (referred to below as “Aspire Capital”) pursuant to which we have the option to require Aspire Capital to purchase up to an aggregate of $15.0 million of shares of our common stock (the “Purchase Shares”) upon and subject to the terms of the 2015 Aspire Purchase Agreement. The description of the 2015 Aspire Purchase Agreement and other information included under the heading “Aspire Capital – 2015 Facility” set forth in Note 9 of the consolidated financial statements included in this report.

 

No shares have been sold under the 2015 Aspire Purchase Agreement as of the date of the filing of this report. Despite the proceeds that we may receive pursuant to the 2015 Aspire Purchase Agreement, we may still need additional capital to fully implement our business, operating and development plans for periods beyond June 30, 2017.

 

On November 20, 2014, we filed with the Securities and Exchange Commission a Registration Statement on Form S-3 under the Securities Act, which was declared effective by the Securities and Exchange Commission on December 2, 2014. This registration statement allows us, from time to time, to offer and sell shares of common stock, shares of preferred stock, debt securities, units comprised of shares of common stock, preferred stock, debt securities and warrants in any combination, and warrants to purchase common stock, preferred stock, debt securities and/or units, up to a maximum aggregate amount of $100 million of such securities. On May 29, 2016, we filed a prospectus supplement to the Registration Statement registering $15.0 million of our common stock that we may issue and sell to Aspire Capital from time to time pursuant to the 2015 Aspire Purchase Agreement, together with the 450,000 Commitment Shares issued to Aspire Capital in consideration for entering into the 2015 Aspire Purchase Agreement. We currently have no other firm agreements with any third parties for the sale of our securities pursuant to this registration statement. We cannot be certain that funding will be available on favorable terms or available at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. If we are unable to raise funds when required or on favorable terms, we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations.

 

On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate (the “Eastern Affiliate”) of Eastern Capital Limited (“Eastern”), a stockholder of the Company. The Eastern Affiliate contributed $15 million in cash for a 30% interest in the Company’s subsidiary iBio CMO LLC (“iBio CMO”). The Company retained a 70% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. On January 13, 2016, the Company also entered into share purchase agreements with Eastern pursuant to which Eastern agreed to purchase 10 million shares of the Company’s common stock at $0.622 per share. The closing for the sale of 3,500,000 of such shares occurred on January 25, 2016. The closing for the remaining 6,500,000 shares occurred in April 2016. In addition, Eastern agreed to exercise warrants it previously acquired to purchase 1,784,000 shares of the Company’s common stock at $0.53 per share. As of the date of the filing of this report, iBio CMO has received $15 million for the capitalization of iBio CMO and the Company has received approximately $7.2 million from Eastern for the acquisition of 10 million shares of common stock and the exercise of the warrants. Prior to the issuance of the shares of common stock pursuant to the purchase agreements with Eastern, Eastern beneficially owned approximately 30% of the Company’s common stock, as reported in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015, filed with the SEC on October 13, 2015, calculated in accordance with the SEC’s beneficial ownership rules. As of the closing of the purchase agreements with Eastern and the simultaneous exercise by Eastern of its warrants to purchase iBio common stock, Eastern beneficially owned approximately 38% of the Company’s outstanding shares of common stock. See Note 9 in the consolidated financial statements for a further description of the transactions.

 

Off-Balance Sheet Arrangements

 

As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPEs), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of September 30, 2016, we were not involved in any SPE transactions.

 

Critical Accounting Policies and Estimates

 

A critical accounting policy is one that is both important to the portrayal of a company’s financial condition and results of operations and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

 

 24 

 

 

Our condensed consolidated financial statements are presented in accordance with U.S. GAAP, and all applicable U.S. GAAP accounting standards effective as of September 30, 2016 have been taken into consideration in preparing the condensed consolidated financial statements. The preparation of condensed consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. The following accounting policies and estimates have been highlighted as significant because changes to certain judgments and assumptions inherent in these policies could affect our condensed consolidated financial statements:

 

  · Valuation of intellectual property;

 

  · Legal and contractual contingencies;

  

  · Research and development expenses; and

 

  · Share-based compensation expenses.

 

We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an on-going basis and make changes when necessary. Actual results could differ from our estimates.

  

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, under the direction of our Executive Chairman and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of September 30, 2016. Based upon that evaluation, our Executive Chairman and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2016.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 25 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Lawsuits

On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (“Yusibov”), Fraunhofer’s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer’s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. Briefing was completed on a motion to dismiss filed by Fraunhofer in lieu of filing an answer to the complaint. Fraunhofer also moved for a protective order in connection with certain discovery served by iBio. The Court bifurcated the action to first resolve the threshold question in the case – the scope of iBio’s ownership of the technology developed or held by Fraunhofer — before proceeding with the rest of the case and the parties stipulated their agreement to that approach. After considering the parties’ written submissions and oral argument on this threshold issue on April 29, 2016, the Court resolved the threshold issue in favor of iBio on July 29, 2016, holding that iBio owns all proprietary rights of any kind to all plant-based technology of Fraunhofer developed or held as of December 31, 2014, including know-how, and is entitled to receive a transfer of the technology from Fraunhofer. On September 19, 2016, Fraunhofer informed the Court that it does not intend to pursue its motion for protective order at this time. iBio has sought leave of Court to supplement and amend its current complaint to add additional state law claims against Fraunhofer. Fraunhofer opposes this motion. The Company is unable to predict the further outcome of this action at this time.

 

On December 4, 2015, a putative derivative action captioned Savage, Derivatively on Behalf of iBio, Inc., Plaintiff, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant was filed in the Supreme Court of the State of New York, County of New York. The action alleged that the Company and its management made misstatements about the Company’s business resulting either from (i) a failure by iBio’s directors to establish a system of controls over the Company’s disclosures, or (ii) the directors’ consciously ignoring “red flags” relating to disclosures, and sought to recover an unspecified amount of damages. On January 15, 2016, the defendants filed a motion to dismiss all claims against them. On March 16, 2016, the plaintiff filed a Verified Amended Complaint that added an additional named plaintiff and alleged derivative claims generally along the same lines as the original complaint, together with purported direct breach of fiduciary duty and unjust enrichment claims based on the same conduct. The Verified Amended Complaint sought to recover an unspecified amount of damages. On April 29, 2016, the defendants filed a motion to dismiss all claims against them. Plaintiffs’ opposition to the motion was filed on June 6, 2016. On June 22, 2016, the plaintiffs advised the Court that the parties had reached a settlement in principle, and on July 1, 2016, the Court ordered that the defendants’ pending motion to dismiss be withdrawn without prejudice. The parties entered a Stipulation of Settlement dated as of September 20, 2016. On October 11, 2016, the plaintiffs filed a motion with the Court seeking preliminary approval of the settlement. The terms of the settlement are subject to preliminary and final approval by the Court. The Company expects that the settlement will be funded by the Company’s insurance carrier.

 

 26 

 

 

Item 6. Exhibits.

 

Exhibit Number    
     
3.1   Certificate of Incorporation of the Company (1)
3.2   First Amended and Restated Bylaws of the Company (2)
4.1   Registration Rights Agreement, dated May 15, 2016, between the Company and Aspire Capital Fund, LLC (3)
31.1   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
32.1   Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
32.2   Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS   XBRL Instance*
101.SCH   XBRL Taxonomy Extension Schema*
101.CAL   XBRL Taxonomy Extension Calculation*
101.DEF   XBRL Taxonomy Extension Definition*
101.LAB   XBRL Taxonomy Extension Labeled*
101.PRE   XBRL Taxonomy Extension Presentation*

 

  (1) Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2014 (Commission File No. 001-35023).
  (2) Incorporated herein by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 14, 2009 (Commission File No. 000-53125).
  (3) Incorporated herein by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 15, 2016 (Commission File No. 001-35023).
   * Filed herewith.

 

 27 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  iBio, Inc.
  (Registrant)
   
Date:          November 18, 2016 /s/ Robert B. Kay
  Robert B. Kay
  Executive Chairman
   
Date:          November 18, 2016 /s/ Mark Giannone
  Mark Giannone
  Chief Financial Officer

 

 28 

 EX-31.1 2 v452759_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Robert B. Kay, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 of iBio, Inc. (the registrant);
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
  4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within these entities, particularly during the period in which this report is being prepared;
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

  5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 18, 2016 /s/ Robert B. Kay
  Robert B. Kay
  Executive Chairman
  (Principal Executive Officer)

 

 

 

 EX-31.2 3 v452759_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Mark Giannone, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 of iBio, Inc. (the registrant);
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
  4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within these entities, particularly during the period in which this report is being prepared;
  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

  5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 18, 2016 /s/ Mark Giannone
  Mark Giannone
 

Chief Financial Officer

(Principal Financial Officer and

Principal Accounting Officer)

 

 

 

 EX-32.1 4 v452759_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the Company) for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert B. Kay, Executive Chairman of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 18, 2016 /s/ Robert B. Kay
    Robert B. Kay
    Executive Chairman
    (Principal Executive Officer)

 

 

 

 EX-32.2 5 v452759_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the Company) for the quarterly period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Mark Giannone, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 18, 2016 /s/ Mark Giannone
    Mark Giannone
    Chief Financial Officer
    (Principal Financial Officer and
    Principal Accounting Officer)

 

 

 

 EX-101.INS 6 ibio-20160930.xml XBRL INSTANCE DOCUMENT 0001420720 2016-03-15 2016-04-13 0001420720 2015-05-29 0001420720 2016-06-30 0001420720 2015-07-01 2016-06-30 0001420720 2015-07-01 2015-09-30 0001420720 2016-07-01 2016-09-30 0001420720 2015-09-30 0001420720 2016-09-30 0001420720 2016-11-18 0001420720 2015-06-30 0001420720 us-gaap:PreferredStockMember 2016-06-30 0001420720 us-gaap:CommonStockMember 2016-06-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001420720 us-gaap:RetainedEarningsMember 2016-06-30 0001420720 us-gaap:NoncontrollingInterestMember 2016-06-30 0001420720 us-gaap:PreferredStockMember 2016-07-01 2016-09-30 0001420720 us-gaap:CommonStockMember 2016-07-01 2016-09-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2016-09-30 0001420720 us-gaap:RetainedEarningsMember 2016-07-01 2016-09-30 0001420720 us-gaap:NoncontrollingInterestMember 2016-07-01 2016-09-30 0001420720 us-gaap:PreferredStockMember 2016-09-30 0001420720 us-gaap:CommonStockMember 2016-09-30 0001420720 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001420720 us-gaap:RetainedEarningsMember 2016-09-30 0001420720 us-gaap:NoncontrollingInterestMember 2016-09-30 0001420720 us-gaap:OtherComprehensiveIncomeMember 2016-06-30 0001420720 us-gaap:OtherComprehensiveIncomeMember 2016-07-01 2016-09-30 0001420720 us-gaap:OtherComprehensiveIncomeMember 2016-09-30 0001420720 country:BR 2016-09-30 0001420720 ibio:IbioCmoMember 2015-12-31 0001420720 ibio:IbioCmoMember ibio:SecondEasternAffilateMember 2016-01-13 0001420720 ibio:IbioCmoMember 2016-01-13 0001420720 ibio:SecondEasternAffilateMember 2016-09-30 0001420720 ibio:SecondEasternAffilateMember ibio:IbioCmoLlcMember 2016-07-01 2016-09-30 0001420720 ibio:AspireCapitalFundLlcMember us-gaap:MaximumMember 2015-05-01 2015-05-15 0001420720 ibio:EasternMember ibio:IbioCmoMember 2016-07-01 2016-09-30 0001420720 ibio:EasternMember ibio:IbioCmoMember 2016-01-01 2016-01-25 0001420720 ibio:IbioCmoMember ibio:EasternMember 2016-01-25 0001420720 ibio:IbioCmoMember ibio:EasternMember 2016-09-30 0001420720 ibio:FacilityUnderCapitalLeaseMember 2016-09-30 0001420720 ibio:FacilityUnderCapitalLeaseMember 2016-06-30 0001420720 ibio:EquipmentUnderCapitalLeaseMember 2016-09-30 0001420720 ibio:FacilityImprovementsMember 2016-09-30 0001420720 us-gaap:OfficeEquipmentMember 2016-09-30 0001420720 us-gaap:OfficeEquipmentMember 2016-06-30 0001420720 ibio:FacilityImprovementsMember 2016-06-30 0001420720 ibio:EquipmentUnderCapitalLeaseMember 2016-06-30 0001420720 ibio:CapitalLeasedAssetsMember 2016-07-01 2016-09-30 0001420720 us-gaap:IntellectualPropertyMember 2016-09-30 0001420720 us-gaap:PatentsMember 2016-09-30 0001420720 us-gaap:IntellectualPropertyMember 2016-06-30 0001420720 us-gaap:PatentsMember 2016-06-30 0001420720 ibio:FraunhoferMember 2016-06-30 0001420720 ibio:AmendedAgreementMember 2015-07-01 2015-09-30 0001420720 ibio:PrincipalMember 2016-09-30 0001420720 ibio:InterestMember 2016-09-30 0001420720 us-gaap:CommitmentsMember 2015-12-01 2015-12-31 0001420720 ibio:AmendedAgreementMember 2014-07-01 2015-06-30 0001420720 us-gaap:CommitmentsMember 2014-01-01 2014-01-14 0001420720 us-gaap:CommitmentsMember us-gaap:MinimumMember 2014-01-01 2014-01-14 0001420720 us-gaap:CommitmentsMember us-gaap:MaximumMember 2014-01-01 2014-01-14 0001420720 us-gaap:CommitmentsMember 2013-12-30 0001420720 us-gaap:CommitmentsMember 2014-09-01 0001420720 ibio:FraunhoferMember 2015-12-31 0001420720 ibio:FraunhoferMember 2016-09-30 0001420720 ibio:SettlementAgreementMember 2013-04-30 0001420720 ibio:EasternCapitalLimitedAndItsAffiliatesMember ibio:IbioCmoLlcMember 2016-09-30 0001420720 ibio:EasternCapitalLimitedAndItsAffiliatesMember us-gaap:RetainedInterestMember 2016-09-30 0001420720 us-gaap:StandstillAgreementsMember ibio:StockholdersMember 2016-07-01 2016-09-30 0001420720 us-gaap:StandstillAgreementsMember us-gaap:DirectorMember us-gaap:MaximumMember 2016-09-30 0001420720 ibio:EasternTwoSharePurchaseAgreementsMember 2016-07-01 2016-09-30 0001420720 ibio:EasternTwoSharePurchaseAgreementsMember 2016-09-30 0001420720 ibio:SecondEasternAffilateMember 2016-07-01 2016-09-30 0001420720 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001420720 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001420720 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001420720 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001420720 us-gaap:EmployeeStockOptionMember 2016-09-30 0001420720 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001420720 us-gaap:WarrantMember 2015-07-01 2015-09-30 0001420720 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001420720 ibio:AspireCapitalFundLlc2014Member 2016-09-30 0001420720 ibio:EasternSharePurchaseAgreementsMember 2016-01-01 2016-01-13 0001420720 ibio:EasternSharePurchaseAgreementsMember 2016-01-13 0001420720 ibio:EasternSharePurchaseAgreementsMember 2016-01-01 2016-01-25 0001420720 ibio:EasternSharePurchaseAgreementsMember 2016-01-25 0001420720 ibio:EasternSharePurchaseAgreementsMember ibio:StockholdersMember 2016-01-13 0001420720 ibio:AspireCapitalFundLlc2014Member 2015-05-15 0001420720 ibio:AspireCapitalFundLlc2015Member 2015-05-01 2015-05-15 0001420720 ibio:AspireCapitalFundLlcMember 2015-05-01 2015-05-15 0001420720 ibio:AspireCapitalFundLlc2014Member 2016-07-01 2016-09-30 0001420720 ibio:AspireCapitalFundLlc2015Member ibio:AspirrePurchaseAgreement2015Member 2016-09-30 0001420720 ibio:AspireCapitalFundLlc2015Member ibio:AspirrePurchaseAgreement2015Member 2016-07-01 2016-09-30 0001420720 ibio:AspireCapitalFundLlc2015Member 2016-09-30 0001420720 us-gaap:MinimumMember 2016-07-01 2016-09-30 0001420720 us-gaap:MaximumMember 2016-07-01 2016-09-30 0001420720 us-gaap:PatentsMember 2016-07-01 2016-09-30 0001420720 us-gaap:IntellectualPropertyMember us-gaap:MinimumMember 2016-07-01 2016-09-30 0001420720 us-gaap:IntellectualPropertyMember us-gaap:MaximumMember 2016-07-01 2016-09-30 0001420720 ibio:MedicalEquipmentMember 2016-09-30 0001420720 ibio:MedicalEquipmentMember 2016-06-30 0001420720 ibio:IbioIncMember us-gaap:OperatingSegmentsMember 2016-07-01 2016-09-30 0001420720 us-gaap:OperatingSegmentsMember 2016-07-01 2016-09-30 0001420720 us-gaap:IntersegmentEliminationMember 2016-07-01 2016-09-30 0001420720 ibio:IbioIncMember us-gaap:OperatingSegmentsMember 2016-09-30 0001420720 us-gaap:OperatingSegmentsMember 2016-09-30 0001420720 us-gaap:IntersegmentEliminationMember 2016-09-30 0001420720 ibio:CapitalLeasedAssetsMember 2015-07-01 2015-09-30 0001420720 ibio:IbioIncMember us-gaap:OperatingSegmentsMember 2015-07-01 2015-09-30 0001420720 ibio:IbioCmoMember us-gaap:OperatingSegmentsMember 2015-07-01 2015-09-30 0001420720 us-gaap:IntersegmentEliminationMember 2015-07-01 2015-09-30 0001420720 ibio:IbioIncMember us-gaap:OperatingSegmentsMember 2015-09-30 0001420720 ibio:IbioCmoMember us-gaap:OperatingSegmentsMember 2015-09-30 0001420720 us-gaap:IntersegmentEliminationMember 2015-09-30 0001420720 us-gaap:CommitmentsMember 2016-07-01 2016-09-30 0001420720 ibio:FraunhoferMember 2016-07-01 2016-09-30 0001420720 ibio:AmendedAgreementMember 2016-07-01 2016-09-30 0001420720 ibio:NoviciMember 2016-09-30 0001420720 ibio:NoviciMember 2016-06-30 0001420720 ibio:NoviciMember 2016-07-01 2016-09-30 0001420720 ibio:NoviciMember 2015-07-01 2015-09-30 0001420720 ibio:SecondEasternAffilateMember 2016-06-30 0001420720 ibio:SecondEasternAffilateMember 2015-07-01 2015-09-30 0001420720 ibio:RelatedPartyMember 2015-11-01 2015-11-30 0001420720 ibio:RelatedPartyMember 2015-12-01 2015-12-31 0001420720 ibio:RelatedPartyMember 2016-07-01 2016-09-30 0001420720 ibio:RelatedPartyMember 2015-07-01 2015-09-30 0001420720 ibio:StockholdersMember 2016-04-01 2016-04-07 0001420720 ibio:SettlementAgreementMember 2013-11-30 0001420720 ibio:SettlementAgreementMember 2014-04-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:sqft xbrli:pure 23014000 20098000 484000 170000 264000 132000 23906000 20462000 25574000 25580000 2092000 2023000 51600000 48091000 920000 1022000 1177000 979000 67468000 67733000 -29000 -29000 -57591000 -60652000 9937000 7141000 51600000 48091000 27394000 27556000 0 24000 0 22000 26000 28000 13556000 14107000 20697000 24044000 89000 89000 0 0 173000 170000 2174000 2291000 25220000 25265000 62000 122000 135000 160000 820000 551000 2469000 1422000 3289000 1973000 -3154000 -1813000 13000 2000 12000 6000 -458000 8000 -3612000 -1814000 -0.03 -0.02 89109000 77307000 -551000 0 0 -9000 483000 0 -3612000 -1805000 -1805000 -3061000 0 89000 67468000 -57591000 14107000 0 89110000 265000 0 0 265000 0 0 0 0 0 0 0 0 0 0 -3061000 -551000 0 89000 67733000 -60652000 13556000 0 89110000 -29000 0 0 0 -29000 265000 329000 88000 91000 324000 1000 -315000 34000 -131000 -90000 53000 171000 102000 136000 -2273000 -1147000 202000 18000 400000 0 -602000 -18000 0 63000 -41000 63000 0 -8000 -2916000 -1110000 9494000 8384000 184000 0 0 -3000 -61000 126000 -24000 0 484000 0 2000 0 -22000 0 41000 0 0.99 1 15000000 0.3 0.7 139000 P34Y 15000000 10000000 3500000 1784000 0.53 15000000 7200000 10000000 0.622 20000000 20000000 6000000 57000 146000 137000 42000 6000000 46000 34000 882000 571000 311000 3100000 2284000 3100000 2265000 1971000 1390000 1932000 1341000 2023000 2092000 341000 160000 122000 173048 2100000 1926952 2100000 186593 1913407 2100000 201198 1898802 2100000 216947 1883053 2100000 233928 1866072 59850000 24381531 35468469 70350000 25393245 44956755 25220197 173048 484000 0 P34Y 2100000 25000 11374000 10000 2284000 8000 3000000 2100000 20000 30627 25000 150000 78000 161754 2015-12-31 3000000 4000000 200000 1000000 15000000 0.3 0.7 6500000 0.38 10000000 6220000 1784000 0.53 945000 0.622 772000 167000 483000 265000 329000 6000 259000 5000 324000 433000 405000 2700000 15000000 -3061000 -1805000 12300000 6000000 12100000 15000000 3500000 0.622 1784000 0.53 945000 6500000 0.622 0.38 4043000 2177000 15000000 450000 200000 500000 2000000 0.35 0.8 0.97 150000 0.40 0.1999 450000 15343406 15000000 15000000 10-Q false 2016-09-30 2017 Q1 iBio, Inc. 0001420720 --06-30 Smaller Reporting Company IBIO 89109410 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Nature of Business</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio, Inc. and Subsidiaries (&#8220;iBio&#8221; or the &#8220;Company&#8221;) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio&#8217;s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company&#8217;s wholly-owned and majority-owned subsidiaries are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBioDefense Biologics LLC (&#8220;iBioDefense&#8221;) &#150; iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company&#8217;s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Peptide Therapeutics LLC (&#8220;iBio Peptide&#8221;) &#150; iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016.</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBIO DO BRASIL BIOFARMAC&#202;UTICA LTDA. (&#8220;iBio Brazil&#8221;) &#150; iBio Brazil is a subsidiary organized in Brazil in which the Company has a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99</font>% interest. iBio Brazil was formed to manage and expand the Company&#8217;s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company&#8217;s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (&#8220;Fiocruz&#8221;) beyond the current Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio Manufacturing LLC (&#8220;iBio Manufacturing&#8221;) &#150; iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO LLC (&#8220;iBio CMO&#8221;) &#150; iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100</font>% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (&#8220;Eastern&#8221;), a stockholder of the Company (the &#8220;Eastern Affiliate&#8221;). The Eastern Affiliate contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million in cash for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% interest in iBio CMO. The Company retained a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company&#8217;s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company&#8217;s technologies.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO&#8217;s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the &#8220;Second Eastern Affiliate&#8221;) as sublandlord. The facility is a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 139,000</font> square foot Class A life sciences building on the campus of Texas A&amp;M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Affiliate granted iBio CMO a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease for the facility as well as certain equipment (see Note 8). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio&#8217;s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">2.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Basis of Presentation</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Interim Financial Statements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2016, from which the accompanying condensed balance sheet dated June 30, 2016 was derived.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Principles of Consolidation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Liquidity</font></i></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s primary sources of liquidity are cash on hand and cash available from the sale of common stock of the Company. At this time, cash flows from operating activities represent net outflows for operating expenses and expenses for technology and product development. As of September 30, 2016, the Company had $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20.1</font> million in cash on hand which is expected to support the Company&#8217;s activities through September 30, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of September 30, 2016, the Company&#8217;s accumulated deficit was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60.7</font> million, and it had cash used in operating activities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.3</font> million for the three months ended September 30, 2016. The Company has historically financed its activities through the sale of common stock and warrants. Through September 30, 2016, the Company has dedicated most of its financial resources to investing in its iBioLaunch&#153; and iBioModulator&#153; platforms, its proprietary candidates for treatment of fibrotic diseases, advancing its intellectual property, and general and administrative activities<font style="COLOR: #211f1f">.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #211f1f; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 15, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (&#8220;Aspire Capital&#8221;) pursuant to which the Company has the option to require Aspire Capital, upon and subject to the terms of the agreement, to purchase up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million of its common stock, over a three-year term. <font style="COLOR: #211f1f">No shares have been sold under the 2015 Facility as of the date of the filing of this report. See Note 9 for a further description of the agreement.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Coincident with the entry into the iBio CMO joint venture, Eastern agreed to acquire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million shares of the Company's common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.622</font> per share. The closing for the sale of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,500,000</font> of such shares occurred on January 25, 2016 and the sale of the remaining <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,500,000</font> shares occurred on April 13, 2016. In addition, on January 25, 2016, Eastern exercised warrants it previously acquired to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,784,000</font> shares of the Company's common stock at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.53</font> per share. As of the date of the filing of this report, the Company has received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million for the capitalization of iBio CMO and approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.2</font> million from Eastern for the acquisition of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million shares of common stock and the exercise of the warrants. See Note 9 for a further description of the transactions.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities, including sales of common stock to Aspire Capital pursuant to the common stock purchase agreement entered into on May 15, 2015, and through proceeds realized in connection with license and collaboration arrangements. The Company cannot be certain that such funding will be available on favorable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company's financial statements were prepared under the assumption that the Company will continue as a going concern. If the Company is unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and the Company may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 239000 200000 772000 623000 0 0 175000000 175000000 1000000 1000000 0 0 0 0 0.001 0.001 89109410 89109410 89109410 89109410 6500000 239000 227000 36000 0 175000 0 483000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">3.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Summary of Significant Accounting Policies</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s significant accounting policies are described in Note 3 of the Notes to Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 605-25, &#8220;<i>Revenue Arrangements with Multiple Deliverables</i>,&#8221; and Staff Accounting Bulletin 104, &#8220;<i>Revenue Recognition</i>.&#8221; Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. In Fiscal 2017 and Fiscal 2016, the Company did not have any revenue arrangements with multiple deliverables.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt"> Fixed-Fee</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Time and Materials</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Grant Income</font></u></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In Fiscal 2017, grant income amounted to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36,000</font>. No grant income was recognized in Fiscal 2016.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Work in Process</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. There was no work in process at September 30, 2016.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fixed Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5).<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Intangible Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23</font> years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges in Fiscal 2017 and Fiscal 2016.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recently Issued Accounting Pronouncements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, ASU No. 2014-09, &#8220;<i>Revenue from Contracts with Customers</i>&#8221; (&#8220;ASU 2014-09&#8221;) was issued. The amendments in ASU 2014-09 affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in ASC 605, &#8220;<i>Revenue Recognition</i>,&#8221; and most industry-specific guidance, and creates&#160;ASC 606, &#8220;<i>Revenue from Contracts with Customers</i>.&#8221;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 1: Identify the contract(s) with a customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 2: Identify the performance obligations in the contract.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 3: Determine the transaction price.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 4: Allocate the transaction price to the performance obligations in the contract.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, <i>&#8220;Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date&#8221;</i> (&#8220;ASU 2015-14&#8221;) which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual reporting periods after December 15, 2017 (year ended June 30, 2018 for the Company) including interim periods within that reporting period.&#160; Earlier application is permitted only as of annual reporting periods beginning after December 15, 2015, including interim reporting periods within that reporting period. The Company is currently evaluating the effects of adopting ASU 2014-09 on its consolidated financial statements but has not determined the impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Effective January 1, 2016, the Company adopted ASU 2014-12, &#8220;<i>Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i>&#8221; (&#8220;ASU 2014-12&#8221;).&#160;&#160;ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. An entity should recognize compensation cost in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. ASU 2014-12 became effective for interim and annual periods beginning on or after December 15, 2015. The adoption of ASU 2014-12 did not have a significant impact on the Company&#8217;s consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In June 2014, ASU 2014-15, &#8220;<i>Presentation of Financial Statements &#150; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>&#8221; (&#8220;ASU 2014-15&#8221;) was issued.&#160; Before the issuance of ASU 2014-15, there was no guidance in U.S. GAAP about management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern or to provide related footnote disclosures. This guidance is expected to reduce the diversity in the timing and content of footnote disclosures. ASU 2014-15 requires management to assess an entity&#8217;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards as specified in the guidance. ASU 2014-15 becomes effective for the annual period ending after December 15, 2016 (year ended June 30, 2017 for the Company) and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the effects of adopting ASU 2014-15 on its consolidated financial statements but the adoption is not expected to have a significant impact.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Effective January 1, 2016, the Company adopted ASU 2015-01, &#8220;<i>Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items&#8221;</i> (&#8220;ASU 2015-01&#8221;). ASU 2015-01 eliminates the concept of an extraordinary item from accounting principles generally accepted in the United States of America. As a result, an entity will no longer be required to segregate extraordinary items from the results of ordinary operations, to separately present an extraordinary item on its income statement, net of tax, after income from continuing operations or to disclose income taxes and earnings-per-share data applicable to an extraordinary item. However, ASU 2015-01 will still retain the presentation and disclosure guidance for items that are unusual in nature and occur infrequently. The adoption of ASU 2015-01 did not have a significant impact on the Company&#8217;s consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Effective July 1, 2016, the Company adopted ASU 2015-02, &#8220;<i>Consolidation (Topic 810): Amendments to the Consolidation Analysis</i>&#8221; (&#8220;ASU 2015-02&#8221;). The amendments in ASU 2015-02 change the analysis that reporting entity must perform to determine whether it should consolidate certain types of legal entities. A reporting entity may apply the amendments in ASU 2015-02 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The adoption of ASU 2015-02 did not have a significant impact on the Company&#8217;s consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In November 2015, the FASB issued ASU 2015-17, &#8220;<i>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</i>&#8221; (&#8220;ASU 2015-17&#8221;).&#160;&#160;ASU 2015-17 requires deferred tax assets and liabilities to be classified as noncurrent in the consolidated balance sheet. ASU 2015-17 becomes effective for interim and annual reporting periods beginning after December 15, 2016 (year ended June 30, 2017 for the Company). Early adoption is permitted.&#160; A reporting entity should apply the amendment prospectively or retrospectively. The Company is currently evaluating the effects of adopting ASU 2015-17 on its consolidated financial statements but the adoption is not expected to have a significant impact as the Company continues to provide a full valuation allowance against its net deferred tax assets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2016, the FASB issued ASU 2016-01, &#8220;<i>Financial Instruments &#150; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>&#8221; (&#8220;ASU 2016-01&#8221;). The amendments require all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. This guidance is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company), including interim periods within those fiscal years. The Company will evaluate the effects of adopting ASU 2016-01 if and when it is deemed to be applicable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, &#8220;<i>Leases (Topic 842)</i>&#8221; (&#8220;ASU 2016-02&#8221;) which supersedes existing guidance on accounting for leases in &#8220;<i>Leases (Topic 840)</i>.&#8221;&#160; The standard requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet.&#160; A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term.&#160; The new guidance is effective for annual reporting periods beginning after December 15, 2018 (year ended June 30, 2020 for the Company) and interim periods within those fiscal years. The amendments should be applied at the beginning of the earliest period presented using a modified retrospective approach with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the effects of adopting ASU 2016-02 on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09,&#160;&#8220;<i>Improvements to Employee Share-Based Payment Accounting</i>&#8221; (&#8220;ASU 2016-09&#8221;). ASU 2016-09 affects entities that issue share-based payment awards to their employees. ASU 2016-09 is designed to simplify several aspects of accounting for share-based payment award transactions which include &#150; the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. This guidance is effective for annual periods beginning after December 15, 2016 (year ended June 30, 2018 for the Company), including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2016, the FASB issued ASU 2016-10, &#8220;<i>Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</i>&#8221; (&#8220;ASU 2016-10&#8221;) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09, &#8220;<i>Revenue from Contracts with Customers</i>.&#8221; Specifically, ASU 2016-10 addresses an entity&#8217;s identification of its performance obligations in a contract, as well as an entity&#8217;s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as the new revenue standard, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The Company is currently evaluating the impact of ASU 2016-10 on its consolidated financial statements but has not determined the impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2016, the FASB issued ASU 2016-12, &#8220;<i>Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients</i>&#8221; (&#8220;ASU 2016-12&#8221;). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. ASU 2016-12 will have the same effective date and transition requirements as the ASU 2014-09. The Company is currently evaluating the impact of ASU 2016-12 on its consolidated financial statements but has not determined the impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In August 2016, the FASB issued ASU 2016-15, &#8220;<i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</i>&#8221; (&#8220;ASU 2016-15&#8221;). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 605-25, &#8220;<i>Revenue Arrangements with Multiple Deliverables</i>,&#8221; and Staff Accounting Bulletin 104, &#8220;<i>Revenue Recognition</i>.&#8221; Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. In Fiscal 2017 and Fiscal 2016, the Company did not have any revenue arrangements with multiple deliverables.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt"> Fixed-Fee</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Time and Materials</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><u><font style="FONT-SIZE: 10pt">Grant Income</font></u></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In Fiscal 2017, grant income amounted to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36,000</font>. No grant income was recognized in Fiscal 2016.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Work in Process</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. There was no work in process at September 30, 2016.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Fixed Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Intangible Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">23</font> years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges in Fiscal 2017 and Fiscal 2016.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Recently Issued Accounting Pronouncements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, ASU No. 2014-09, &#8220;<i>Revenue from Contracts with Customers</i>&#8221; (&#8220;ASU 2014-09&#8221;) was issued. The amendments in ASU 2014-09 affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in ASC 605, &#8220;<i>Revenue Recognition</i>,&#8221; and most industry-specific guidance, and creates&#160;ASC 606, &#8220;<i>Revenue from Contracts with Customers</i>.&#8221;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 1: Identify the contract(s) with a customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 2: Identify the performance obligations in the contract.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 3: Determine the transaction price.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 4: Allocate the transaction price to the performance obligations in the contract.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, <i>&#8220;Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date&#8221;</i> (&#8220;ASU 2015-14&#8221;) which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual reporting periods after December 15, 2017 (year ended June 30, 2018 for the Company) including interim periods within that reporting period.&#160; Earlier application is permitted only as of annual reporting periods beginning after December 15, 2015, including interim reporting periods within that reporting period. The Company is currently evaluating the effects of adopting ASU 2014-09 on its consolidated financial statements but has not determined the impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Effective January 1, 2016, the Company adopted ASU 2014-12, &#8220;<i>Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period</i>&#8221; (&#8220;ASU 2014-12&#8221;).&#160;&#160;ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. An entity should recognize compensation cost in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. ASU 2014-12 became effective for interim and annual periods beginning on or after December 15, 2015. The adoption of ASU 2014-12 did not have a significant impact on the Company&#8217;s consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In June 2014, ASU 2014-15, &#8220;<i>Presentation of Financial Statements &#150; Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>&#8221; (&#8220;ASU 2014-15&#8221;) was issued.&#160; Before the issuance of ASU 2014-15, there was no guidance in U.S. GAAP about management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern or to provide related footnote disclosures. This guidance is expected to reduce the diversity in the timing and content of footnote disclosures. ASU 2014-15 requires management to assess an entity&#8217;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards as specified in the guidance. ASU 2014-15 becomes effective for the annual period ending after December 15, 2016 (year ended June 30, 2017 for the Company) and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the effects of adopting ASU 2014-15 on its consolidated financial statements but the adoption is not expected to have a significant impact.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Effective January 1, 2016, the Company adopted ASU 2015-01, &#8220;<i>Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items&#8221;</i> (&#8220;ASU 2015-01&#8221;). ASU 2015-01 eliminates the concept of an extraordinary item from accounting principles generally accepted in the United States of America. As a result, an entity will no longer be required to segregate extraordinary items from the results of ordinary operations, to separately present an extraordinary item on its income statement, net of tax, after income from continuing operations or to disclose income taxes and earnings-per-share data applicable to an extraordinary item. However, ASU 2015-01 will still retain the presentation and disclosure guidance for items that are unusual in nature and occur infrequently. The adoption of ASU 2015-01 did not have a significant impact on the Company&#8217;s consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Effective July 1, 2016, the Company adopted ASU 2015-02, &#8220;<i>Consolidation (Topic 810): Amendments to the Consolidation Analysis</i>&#8221; (&#8220;ASU 2015-02&#8221;). The amendments in ASU 2015-02 change the analysis that reporting entity must perform to determine whether it should consolidate certain types of legal entities. A reporting entity may apply the amendments in ASU 2015-02 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The adoption of ASU 2015-02 did not have a significant impact on the Company&#8217;s consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In November 2015, the FASB issued ASU 2015-17, &#8220;<i>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</i>&#8221; (&#8220;ASU 2015-17&#8221;).&#160;&#160;ASU 2015-17 requires deferred tax assets and liabilities to be classified as noncurrent in the consolidated balance sheet. ASU 2015-17 becomes effective for interim and annual reporting periods beginning after December 15, 2016 (year ended June 30, 2017 for the Company). Early adoption is permitted.&#160; A reporting entity should apply the amendment prospectively or retrospectively. The Company is currently evaluating the effects of adopting ASU 2015-17 on its consolidated financial statements but the adoption is not expected to have a significant impact as the Company continues to provide a full valuation allowance against its net deferred tax assets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2016, the FASB issued ASU 2016-01, &#8220;<i>Financial Instruments &#150; Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</i>&#8221; (&#8220;ASU 2016-01&#8221;). The amendments require all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. This guidance is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company), including interim periods within those fiscal years. The Company will evaluate the effects of adopting ASU 2016-01 if and when it is deemed to be applicable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, &#8220;<i>Leases (Topic 842)</i>&#8221; (&#8220;ASU 2016-02&#8221;) which supersedes existing guidance on accounting for leases in &#8220;<i>Leases (Topic 840)</i>.&#8221;&#160; The standard requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet.&#160; A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term.&#160; The new guidance is effective for annual reporting periods beginning after December 15, 2018 (year ended June 30, 2020 for the Company) and interim periods within those fiscal years. The amendments should be applied at the beginning of the earliest period presented using a modified retrospective approach with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the effects of adopting ASU 2016-02 on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09,&#160;&#8220;<i>Improvements to Employee Share-Based Payment Accounting</i>&#8221; (&#8220;ASU 2016-09&#8221;). ASU 2016-09 affects entities that issue share-based payment awards to their employees. ASU 2016-09 is designed to simplify several aspects of accounting for share-based payment award transactions which include &#150; the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. This guidance is effective for annual periods beginning after December 15, 2016 (year ended June 30, 2018 for the Company), including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2016, the FASB issued ASU 2016-10, &#8220;<i>Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</i>&#8221; (&#8220;ASU 2016-10&#8221;) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09, &#8220;<i>Revenue from Contracts with Customers</i>.&#8221; Specifically, ASU 2016-10 addresses an entity&#8217;s identification of its performance obligations in a contract, as well as an entity&#8217;s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as the new revenue standard, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The Company is currently evaluating the impact of ASU 2016-10 on its consolidated financial statements but has not determined the impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2016, the FASB issued ASU 2016-12, &#8220;<i>Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients</i>&#8221; (&#8220;ASU 2016-12&#8221;). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. ASU 2016-12 will have the same effective date and transition requirements as the ASU 2014-09. The Company is currently evaluating the impact of ASU 2016-12 on its consolidated financial statements but has not determined the impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In August 2016, the FASB issued ASU 2016-15, &#8220;<i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</i>&#8221; (&#8220;ASU 2016-15&#8221;). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 3 years 15 years P10Y P16Y P23Y <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">4.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Financial Instruments and Fair Value Measurement</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The carrying values of cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses in the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September 30, 2016 and June 30, 2016 due to their short-term nature. The carrying value of the capital lease obligation approximated its fair value as of September 30, 2016 and June 30, 2016 as the interest rate used to discount the lease payments approximated market.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="3"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">5.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Fixed Assets</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease. See Note&#160;8 for more details of the terms of the sublease.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The economic substance of the sublease is that the Company is financing the acquisition of the facility and equipment and, accordingly, the facility and equipment are recorded as assets and the lease is recorded as a liability. As the sublease involves real estate and equipment, the Company separated the equipment component and accounted for the facility and equipment as if each was leased separately.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Facility under capital lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Equipment under capital lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Facility improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>305</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Office equipment and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>146</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>26,508</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>26,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accumulated depreciation &#150; assets under capital lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(882)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(571)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accumulated depreciation &#150; other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(46)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(928)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(605)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>25,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Depreciation expense was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">324,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,300</font> in Fiscal 2017 and Fiscal 2016, respectively. Depreciation of the assets under the capital lease amounted to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">311,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> in Fiscal 2017 and Fiscal 2016, respectively.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Facility under capital lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>20,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Equipment under capital lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Facility improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>57</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Medical equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>305</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Office equipment and software</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>146</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>137</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>26,508</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>26,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accumulated depreciation &#150; assets under capital lease</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(882)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(571)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Accumulated depreciation &#150; other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(46)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(34)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(928)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(605)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Net fixed assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>25,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,574</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 305000 0 26508000 26179000 928000 605000 86000 49000 0 684000 321000 -185000 1347000 1271000 -149000 -1793000 -1361000 0 0 483000 0 18000 7000 0 -1775000 -1837000 0 11810000 36330000 -49000 8000 25572000 0 2023000 0 0 1000 323000 0 88000 0 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">6.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Intangible Assets</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has two categories of intangible assets &#150; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (&#8220;Fraunhofer&#8221;), pursuant to a Technology Transfer Agreement, as amended (the &#8220;TTA&#8221;). The Company designates such technology acquired from Fraunhofer as iBioLaunch technology or as iBioModulator technology. The value attributed to Patents owned or controlled by the Company is based on payments for services and fees related to the further development and protection of the Company&#8217;s patent portfolio.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the &#8220;Licensed Technology&#8221;). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#150; filing a New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (&#8220;IND&#8221;) &#150; became due on December 1, 2015. A six-month extension was automatically granted until June 1, 2016 under the license agreement. On August 11, 2016, the agreement was amended and replaced the original milestone schedule to provide that the IND filing be accomplished by June 30, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges during Fiscal 2017 and Fiscal 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Intellectual property &#150; gross carrying value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>3,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Patents &#150; gross carrying value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>2,284</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>5,384</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,365</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Intellectual property &#150; accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(1,971)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,932)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Patents &#150; accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(1,390)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,341)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(3,361)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(3,273)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Net intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,023</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,092</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Amortization expense was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">88,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">91,000</font> for Fiscal 2017 and Fiscal 2016, respectively.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 152000 182000 -334000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Intellectual property &#150; gross carrying value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>3,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Patents &#150; gross carrying value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>2,284</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>5,384</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,365</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Intellectual property &#150; accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(1,971)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(1,932)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Patents &#150; accumulated amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(1,390)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,341)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>(3,361)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>(3,273)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Net intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>2,023</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,092</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 5384000 5365000 3361000 3273000 160000 0 0 0 0 0 0 551000 0 0 1422000 0 0 -1813000 0 0 0 0 0 8000 0 0 -1805000 0 0 11374000 0 0 10000 0 0 2284000 0 0 1000 0 0 91000 0 0 P10Y P16Y P23Y <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">14.&#160;Commitments and Contingencies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Agreements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the &#8220;Settlement Agreement&#8221;). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. The significant modifications post June 30, 2013 are of follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s obligation under the TTA, prior to the Settlement Agreement, to make three $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> million payments to Fraunhofer in April 2013, November 2013, and April 2014 (the &#8220;Guaranteed Annual Payments&#8221;) was terminated and replaced with an undertaking to engage Fraunhofer to perform at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3</font> million in work requested and as directed by iBio before December 31, 2015. For the year ended June 30, 2015, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.7</font> million in research and development services were performed by Fraunhofer. As of December 31, 2015, the total engagement of Fraunhofer for work requested by iBio is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million. In addition to the foregoing, the Company sought to engage Fraunhofer for substantial additional other work, but Fraunhofer did not respond to the Company&#8217;s requests for proposals for such work.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> was terminated. Instead <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties.</font> The Company will be obligated to remit royalties to Fraunhofer only on technology license revenues that iBio actually receives and on revenues from actual sales by iBio of products derived from the technology developed under the TTA until the later of November 2023 or until such time as the aggregate royalty payments total at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font> million. All new intellectual property invented by Fraunhofer during the period of the TTA is owned by and is required to be transferred to iBio. The Company has no financial obligations to Fraunhofer with respect to the Company&#8217;s use of technologies developed independently of Fraunhofer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the &#8220;Amended Agreement&#8221;) to create a new research and development plan for the development of a recombinant Yellow Fever vaccine providing revised reporting, objectives, estimated budget, and project billing process. Under the CLA and bilateral agreement between iBio and Fraunhofer dated December 27, 2010, Fraunhofer, which has been engaged to act as the Company&#8217;s subcontractor for performance of research and development services for the new research and development plan, will bill Fiocruz directly on behalf of the Company at the rates, amounts and times provided in the Amended Agreement, and the proceeds of such billings and only the proceeds will be paid to Fraunhofer for its services so the Company&#8217;s expense is equal to its revenue and no profit is recognized for these activities under the Amended Agreement. For the year ended June 30, 2015, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.1</font> million in research and development services were performed by Fraunhofer for the Company pursuant to the amended CLA. As of December 31, 2015, the total engagement of Fraunhofer for work requested by iBio is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million. See Note 7 - Significant Vendors for additional information. In addition to the foregoing, the Company sought to engage Fraunhofer for substantial additional other work, but Fraunhofer did not respond to the Company&#8217;s requests for proposals for such work</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 14, 2014 (the &#8220;Effective Date&#8221;), the Company entered into an exclusive worldwide License Agreement (&#8220;LA&#8221;) with the University of Pittsburgh (&#8220;UP&#8221;) covering all of the U.S. and foreign patents and patent applications and related intellectual property owned by UP pertinent to the use of endostatin peptides for the treatment of fibrosis. The Company paid an initial license fee of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,000</font> and is required to pay all of UP&#8217;s patent prosecution costs that were incurred prior to, totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,627</font>, and subsequent to the Effective Date. On each anniversary date the Company is to pay license fees ranging from $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">150,000</font> for the first five years and $150,000 on each subsequent anniversary date until the first commercial sale of the licensed technology. Beginning with commercial sales of the technology or approval by the FDA or foreign equivalent, the Company will be required to pay milestone payments, royalties and a percentage of any non-royalty sublicense income to UP.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 30, 2013, the Company entered into a Project Agreement with the Medical University of South Carolina (&#8220;MUSC&#8221;) providing for the performance of research and development services by MUSC related to peptides for the treatment of fibrosis. The agreement requires the Company to make payments totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">78,000</font> through December 1, 2014 and provides the Company with certain intellectual property rights. Effective September 1, 2014, the Company and MUSC executed an Amendment to the agreement. The Amendment extended the term of the agreement to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 31, 2015</font> and increased the total payments due MUSC from the Company by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">161,754</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Lawsuits</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (&#8220;Yusibov&#8221;), Fraunhofer&#8217;s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer&#8217;s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. Briefing was completed on a motion to dismiss filed by Fraunhofer in lieu of filing an answer to the complaint. Fraunhofer also moved for a protective order in connection with certain discovery served by iBio. The Court bifurcated the action to first resolve the threshold question in the case &#150; the scope of iBio&#8217;s ownership of the technology developed or held by Fraunhofer &#151; before proceeding with the rest of the case and the parties stipulated their agreement to that approach. After considering the parties&#8217; written submissions and oral argument on this threshold issue on April 29, 2016, the Court resolved the threshold issue in favor of iBio on July 29, 2016, holding that iBio owns all proprietary rights of any kind to all plant-based technology of Fraunhofer developed or held as of December 31, 2014, including know-how, and is entitled to receive a transfer of the technology from Fraunhofer. On September 19, 2016, Fraunhofer informed the Court that it does not intend to pursue its motion for protective order at this time. iBio has sought leave of Court to supplement and amend its current complaint to add additional state law claims against Fraunhofer. Fraunhofer opposes this motion. The Company is unable to predict the further outcome of this action at this time.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 4, 2015, a putative derivative action captioned <i>Savage, Derivatively on Behalf of iBio, Inc., Plaintiff, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant</i> was filed in the Supreme Court of the State of New York, County of New York. The action alleged that the Company and its management made misstatements about the Company&#8217;s business resulting either from (i) a failure by iBio&#8217;s directors to establish a system of controls over the Company&#8217;s disclosures, or (ii) the directors&#8217; consciously ignoring &#8220;red flags&#8221; relating to disclosures, and sought to recover an unspecified amount of damages. On January 15, 2016, the defendants filed a motion to dismiss all claims against them. On March 16, 2016, the plaintiff filed a Verified Amended Complaint that added an additional named plaintiff and alleged derivative claims generally along the same lines as the original complaint, together with purported direct breach of fiduciary duty and unjust enrichment claims based on the same conduct. The Verified Amended Complaint sought to recover an unspecified amount of damages. On April 29, 2016, the defendants filed a motion to dismiss all claims against them. Plaintiffs&#8217; opposition to the motion was filed on June 6, 2016. On June 22, 2016, the plaintiffs advised the Court that the parties had reached a settlement in principle, and on July 1, 2016, the Court ordered that the defendants&#8217; pending motion to dismiss be withdrawn without prejudice. The parties entered a Stipulation of Settlement dated as of September 20, 2016. On October 11, 2016, the plaintiffs filed a motion with the Court seeking preliminary approval of the settlement. The terms of the settlement are subject to preliminary and final approval by the Court. The Company expects that the settlement will be funded by the Company&#8217;s insurance carrier.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 2700000 under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties. 122000 62000 62000 239000 200000 239000 227000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in"> <b><font style="FONT-SIZE: 10pt">13.&#160;Income Taxes</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recorded no income tax expense for the three months ended September 30, 2016 and 2015 because the estimated annual effective tax rate was zero. As of September 30, 2016, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="3"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">8.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0.8pt; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Capital Lease Obligation</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As discussed above, iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease. iBio CMO began operations at the facility on December 22, 2015 pursuant to agreements between iBio CMO and the Second Affiliate granting iBio CMO temporary rights to access the facility. These temporary agreements were superseded by the Sublease Agreement, dated January 13, 2016, between iBio CMO and the Second Affiliate (the &#8220;sublease&#8221;). The 34-year term of the sublease may be extended by iBio CMO for a ten-year period, so long as iBio CMO is not in default under the sublease. Under the sublease, iBio CMO is required to pay base rent at an annual rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,100,000</font>, paid in equal quarterly installments on the first day of each February, May, August and November. The base rent is subject to increase annually in accordance with increases in the Consumer Price Index. The base rent under the Second Affiliate&#8217;s ground lease for the property is subject to adjustment, based on an appraisal of the property, in 2030 and upon any extension of the ground lease. The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. iBio CMO is also responsible for all costs and expenses in connection with the ownership, management, operation, replacement, maintenance and repair of the property under the sublease.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO&#8217;s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Interest expense incurred under the capital lease obligation amounted to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">484,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> for Fiscal 2017 and Fiscal 2016, respectively.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Future minimum payments under the capitalized lease obligations are due as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div> Fiscal&#160;period&#160;ending&#160;on&#160;September&#160;30,:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Principal</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Interest</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="48%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>173,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,926,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>186,593</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,913,407</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>201,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,898,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>216,947</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,883,053</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>233,928</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,866,072</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,381,531</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35,468,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Total minimum lease payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,393,245</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,956,755</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,350,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Less: current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(173,048)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Long-term portion of minimum lease obligations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,220,197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">12.&#160;&#160;Related Party Transactions</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Novici Biotech, LLC</font></i></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2012, the Company entered into an agreement with Novici in which iBio&#8217;s President is a minority stockholder. See Note 7.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Agreements with Eastern Capital Limited and its Affiliates.</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As more fully discussed in Note 9, the Company entered into two share purchase agreements with Eastern and sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.622</font> per share. The Company received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,220,000</font>. In addition, Eastern agreed to exercise warrants it had previously acquired to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,784,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.53</font> per share. The Company received proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">945,000</font> from the exercise of the warrants.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Concurrently with the execution of the Purchase Agreements, iBio entered into a contract manufacturing joint venture with an affiliate of Eastern to develop and manufacture plant-made pharmaceuticals through iBio&#8217;s recently formed subsidiary, iBio CMO. The Eastern Affiliate contributed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.0</font> million in cash to iBio CMO, for a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% interest in iBio CMO. iBio retained a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 70</font>% equity interest in iBio CMO. As the majority equity holder, iBio has the right to appoint a majority of the members of the Board of Managers that manages the iBio CMO joint venture. Specified material actions by the joint venture require the consent of iBio and the Eastern Affiliate. iBio contributed to the capital of iBio CMO a royalty bearing license, which grants iBio CMO a non-exclusive license to use the iBio&#8217;s proprietary technologies, including the iBioLaunch technology and additional iBio technologies, for research purposes and an exclusive U.S. license for manufacturing purposes. iBio retains all other rights in its intellectual property, including the right for itself to commercialize products based on its proprietary technologies or to grant licenses to others to do so.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In connection with the joint venture, the Second Eastern Affiliate, which controls the subject property as sublandlord, granted iBio CMO a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 34</font>-year sublease of a Class A life sciences building in Bryan, Texas, on the campus of Texas A&amp;M University, designed and equipped for plant-made manufacture of biopharmaceuticals. Accrued expenses at September 30, 2016 and June 30, 2016 due to the Second Eastern Affiliate amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">772,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">623,000</font>, respectively. General and administrative expenses related to Second Eastern Affiliate were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">167,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> in Fiscal 2017 and Fiscal 2016, respectively. Interest expense related to the Second Eastern Affiliate was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">483,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> in Fiscal 2017 and Fiscal 2016, respectively. The terms of the sublease are described in Note 8.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A three-year standstill agreement (the &#8220;Standstill Agreement&#8221;) that took effect upon the issuance of the Eastern Shares pursuant to the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,500,000</font> Purchase Agreement restricts additional acquisitions of iBio common stock by Eastern and its controlled affiliates to limit its beneficial ownership of the Company&#8217;s outstanding shares of common stock to a maximum of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 38</font>%, absent approval by a majority of the Company&#8217;s Board of Directors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Operating Lease with Minority Stockholder</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Effective January 1, 2015, the Company is leasing office space on a month-to-month basis from an entity owned by a minority stockholder of the Company. Rent was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,200</font> per month through November 2015 and increased to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,500</font> per month effective December 2015. Rent expense totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,500</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,600</font> in Fiscal 2017 and Fiscal 2016, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Future minimum payments under the capitalized lease obligations are due as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="48%"> <div> Fiscal&#160;period&#160;ending&#160;on&#160;September&#160;30,:</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Principal</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Interest</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="48%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>173,048</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,926,952</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>186,593</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,913,407</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2019</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>201,198</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,898,802</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>216,947</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,883,053</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>233,928</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,866,072</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Thereafter</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>24,381,531</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>35,468,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,850,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Total minimum lease payments</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,393,245</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>44,956,755</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>70,350,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Less: current portion</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(173,048)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="48%"> <div>Long-term portion of minimum lease obligations</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,220,197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 623000 0 2200 2500 7500 6600 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">11.&#160;&#160;Share-Based Compensation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>259</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>329</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Stock Options</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the &#8220;Plan&#8221;) for employees, officers, directors and external service providers. The Plan, as amended on December 18, 2013, provided that the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15</font> million shares. As of September 30, 2016, there were approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.7</font> million shares of common stock reserved for future issuance under the Plan. Stock options granted under the Plan may be either incentive stock options (as defined by Section 422 of the Internal Revenue Code of 1986, as amended) or non-qualified stock options at the discretion of the Board of Directors. Vesting of service awards occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria have been satisfied. The Company uses historical data to estimate forfeiture rates.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.05pt"> <font style="FONT-SIZE: 10pt">No stock options were issued during Fiscal 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.05pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes all stock option activity during Fiscal 2017:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Term&#160;(in&#160;years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Outstanding as of July 1, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,273,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>993</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Outstanding as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,273,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Vested and, as of September 30, 2016, expected to vest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>12,233,897</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>6.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Exercisable as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,361,697</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2016, there was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.68</font> years.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>259</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>265</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>329</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.05pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table summarizes all stock option activity during Fiscal 2017:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Stock</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Term&#160;(in&#160;years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Outstanding as of July 1, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,273,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>993</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Outstanding as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,273,334</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Vested and, as of September 30, 2016, expected to vest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>12,233,897</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>6.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>433</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="41%"> <div>Exercisable as of September 30, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,361,697</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.31</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>405</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO&#8217;s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively. <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">9.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt"> Stockholders&#8217; Equity</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Preferred Stock</font></i></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1</font> million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. As of September 30, 2016 and June 30, 2016, there were no shares of preferred stock issued and outstanding.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Common Stock</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2016 and 2015, the Company was authorized to issue up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 175</font> million shares of common stock. &#160; As of September 30, 2016, the Company had reserved up to <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">15</font></font> <font style="BACKGROUND-COLOR: transparent">million shares</font></font>&#160;of common stock for incentive compensation (stock options and restricted stock). No shares are reserved for the exercise of warrants.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">No shares of common stock were issued for the period July 1, 2016 through the date of the filing of this report. Recent issuances of common stock include the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Aspire Capital &#150; 2015 Facility</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <font style="COLOR: #231f20; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">On May 15, 2015, the Company entered into a common stock purchase agreement (the &#8220;2015 Aspire Purchase Agreement&#8221;) with Aspire Capital, pursuant to which the Company has the option to require Aspire Capital to purchase up to an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.0</font> million of shares of the Company&#8217;s common stock (the &#8220;Purchase Shares&#8221;) upon and subject to the terms of the 2015 Aspire Purchase Agreement.&#160;</font> <font style="FONT-SIZE: 10pt">In consideration for entering into the purchase agreement, Aspire Capital received a commitment fee of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 450,000</font> shares <font style="COLOR: #231f20">(the &#8220;Commitment Shares&#8221;)</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">On any business day after the Commencement Date (as defined below) and over the 36-month term of the 2015 Aspire Purchase Agreement, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a &#8220;Purchase Notice&#8221;) directing Aspire Capital to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,000</font> Purchase Shares per business day; however, no sale pursuant to such a Purchase Notice may exceed five hundred thousand dollars ($<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font>) per business day, unless the Company and Aspire Capital mutually agree. The Company and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> Purchase Shares per business day. The purchase price per Purchase Share pursuant to such Purchase Notice (the &#8220;Purchase Price&#8221;) is the lower of (i) the lowest sale price for the Company&#8217;s common stock on the date of sale or (ii) the average of the three lowest closing sale prices for the Company&#8217;s common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The applicable Purchase Price will be determined prior to delivery of any Purchase Notice.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital for at least <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000</font> Purchase Shares and the closing sale price of the Company&#8217;s common stock is higher than $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.40</font>, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a &#8220;VWAP Purchase Notice&#8221;) directing Aspire Capital to purchase an amount of the Company&#8217;s common stock equal to up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% of the aggregate shares of common stock traded on the next business day (the &#8220;VWAP Purchase Date&#8221;), subject to a maximum number of shares determined by the Company (the &#8220;VWAP Purchase Share Volume Maximum&#8221;). The purchase price per Purchase Share pursuant to such VWAP Purchase Notice (the &#8220;VWAP Purchase Price&#8221;) shall be the lesser of the closing sale price of the Company&#8217;s common stock on the VWAP Purchase Date or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 97</font>% of the volume weighted average price for the Company&#8217;s common stock traded on the VWAP Purchase Date if the aggregate shares to be purchased on that date does not exceed the VWAP Purchase Share Volume Maximum, or the portion of such business day until such time as the sooner to occur of (1) the time at which the aggregate shares traded has exceeded the VWAP Purchase Share Volume Maximum, or (2) the time at which the sale price of the Company&#8217;s common stock falls below the VWAP Minimum Price Threshold (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). The VWAP Minimum Price Threshold is the greater of (i) <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the closing sale price of the Company&#8217;s common stock on the business day immediately preceding the VWAP Purchase Date or (ii) such higher price as set forth by the Company in the VWAP Purchase Notice</font><font style="FONT-SIZE: 10pt">.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">The number of Purchase Shares covered by and timing of each Purchase Notice or VWAP Purchase Notice are determined at the Company&#8217;s discretion. The aggregate number of shares that the Company can sell to Aspire Capital under the 2015 Aspire Purchase Agreement may in no case exceed <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,343,406</font> shares of our common stock (which is equal to approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 19.99</font>% of the common stock outstanding on the date of the 2015 Aspire Purchase Agreement, including the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 450,000</font> Commitment Shares issued to Aspire Capital in consideration for entering into the 2015 Aspire Purchase Agreement) (the &#8220;Exchange Cap&#8221;), unless (i) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company&#8217;s common stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">The 2015 Aspire Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. Sales under the 2015 Aspire Purchase Agreement could commence only after certain conditions were satisfied (the date on which all requisite conditions have been satisfied being referred to as the &#8220;Commencement Date&#8221;), which conditions included the delivery to Aspire Capital of a prospectus supplement covering the Commitment Shares and the Purchase Shares, approval for listing on NYSE MKT of the Purchase Shares and the Commitment Shares, the issuance of the Commitment Shares to Aspire Capital, and the receipt by Aspire Capital of a customary opinion of counsel and other certificates and closing documents. Either party had the option to terminate the 2015 Aspire Purchase Agreement in the event the Commencement Date had not occurred by July 1, 2015. The 2015 Aspire Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost or penalty.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">The Company&#8217;s net proceeds will depend on the Purchase Price, the VWAP Purchase Price and the frequency of the Company&#8217;s sales of Purchase Shares to Aspire Capital; subject to the maximum $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.0</font> million available amount. The Company&#8217;s delivery of Purchase Notices and VWAP Purchase Notices will be made subject to market conditions, in light of the Company&#8217;s capital needs from time to time. The Company expects to use proceeds from sales of Purchase Shares for general corporate purposes and working capital requirements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt"> &#160;</font></div> <font style="COLOR: #231f20; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">In connection with the 2015 Aspire Purchase Agreement, the Company also entered into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) with Aspire Capital, dated May 15, 2015. The Registration Rights Agreement provides, among other things, a requirement to register the sale of the Commitment Shares and the Purchase Shares to Aspire Capital pursuant to the Company&#8217;s existing shelf registration statement (the &#8220;Registration Statement&#8221;). The Company further agreed to keep the Registration Statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement. On May 29, 2015, the Company filed a prospectus supplement to the Company&#8217;s existing Registration Statement on Form S-3, registering $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15.0</font> million of the Company&#8217;s common stock that it may issue and sell to Aspire Capital from time to time pursuant to the 2015 Aspire Purchase Agreement, together with the 450,000 Commitment Shares issued to Aspire Capital in consideration for entering into the 2015 Aspire Purchase Agreement.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt">No shares have been sold under the 2015 Facility as of the date of the filing of this report.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: #231f20; FONT-SIZE: 10pt"> &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Eastern &#150; Share Purchase Agreements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 13, 2016, the Company entered into a share purchase agreement with Eastern pursuant to which Eastern agreed to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,500,000</font> shares of the Company&#8217;s common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.622</font> per share. The Company received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,177,000</font> and the shares were issued on January 25, 2016. In addition, Eastern agreed to exercise warrants it had previously acquired to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,784,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.53</font> per share. The Company received proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">945,000</font> from the exercise of the warrants and the shares were issued on January 25, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On January 13, 2016, the Company entered into a separate share purchase agreement with Eastern pursuant to which Eastern agreed to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,500,000</font> shares of the Company&#8217;s common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.622</font> per share, subject to the approval of the Company&#8217;s stockholders. The Company&#8217;s stockholders approved the issuance of the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,500,000</font> shares to Eastern at the Company&#8217;s annual meeting on April 7, 2016. On April 13, 2016, the Company issued the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,500,000</font> shares and received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,043,000</font>. These shares are subject to a three-year standstill agreement which will restrict additional acquisitions of the Company&#8217;s common stock by Eastern and its controlled affiliates to limit its beneficial ownership of the Company&#8217;s outstanding shares of common stock to a maximum of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 38</font>%, absent the approval by a majority of the Company&#8217;s board of directors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Warrants</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has historically financed its operations through the sale of common stock and warrants, sold together as units. No warrants were outstanding as of September 30, 2016 and June 30, 2016.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 12273334 0 12273334 12233897 9361697 1.31 1.31 1.31 1.31 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <strong><font style="FONT-SIZE: 10pt">10.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Earnings (Loss) Per Common Share</font></strong></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Basic and diluted numerator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Net loss available to iBio, Inc. stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(3,061)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,805)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Basic and diluted denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Weighted-average common shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>89,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>77,307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Per Share Amount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(0.03)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.02)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In Fiscal 2017 and Fiscal 2016, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September 30, 2016, shares issuable which could potentially dilute future earnings included approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12.3</font> million stock options. &#160; As of September 30, 2015, shares issuable which could potentially dilute future earnings included approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12.1</font> million stock options and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.0</font> million warrants.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> P5Y6M P6Y1M6D P6Y4M24D P6Y1M6D 993000 433000 6500000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Basic and diluted numerator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Net loss available to iBio, Inc. stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(3,061)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,805)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Basic and diluted denominator:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Weighted-average common shares outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>89,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>77,307</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Per Share Amount</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div>(0.03)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(0.02)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1400000 P1Y8M5D 0 1000000 1000000 175000000 71000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <b><font style="FONT-SIZE: 10pt">7.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><b><font style="FONT-SIZE: 10pt">Significant Vendors</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Fraunhofer</font></i></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Fraunhofer was the Company&#8217;s most significant vendor solely on the basis of the three-party Yellow Fever vaccine development program among Fiocruz/Bio-Manguinhos, the Company, and Fraunhofer (described in greater detail below). The accounts payable balance under this three-party agreement includes amounts due <font style="BACKGROUND-COLOR: transparent">Fraunhofer of approximately <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">122,000</font></font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">341,000</font> as of September 30, 2016 and June 30, 2016, respectively, and accrued expenses of <font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">62,000</font></font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">122,000</font> as of September 30, 2016 and June 30, 2016, respectively. See Note 14 &#150; Commitments and Contingencies.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">On January 4, 2011, the Company entered into the Collaboration and License Agreement (the &#8220;CLA&#8221;) which is a three-party agreement involving the Company, Fraunhofer and Fiocruz, a public entity, member of the Indirect Federal Public Administration and linked to the Health Ministry of Brazil, acting through its unit Bio-Manguinhos. The CLA provides for the development of a Yellow Fever vaccine to be manufactured and distributed within Latin America and Africa by Fiocruz. The CLA was supplemented by a bilateral agreement between iBio and Fraunhofer dated December 27, 2010 in which the Company engaged Fraunhofer as a contractor to provide the research and development services (both, together, the &#8220;Agreement&#8221;). The services are billed to Fiocruz at Fraunhofer&#8217;s cost, so the Company&#8217;s revenue is equivalent to expense and there is no profit.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">&#160;</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the &#8220;Amended Agreement&#8221;) which provides for revised research and development, work plans, reporting, objectives, estimated budget, and project billing process. In Fiscal 2017 and Fiscal 2016, under the Amended Agreement, the Company recognized revenue of $<font style="BACKGROUND-IMAGE: none; BACKGROUND-ATTACHMENT: scroll; BACKGROUND-REPEAT: repeat; BACKGROUND-POSITION: 0% 0%"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">62,000</font></font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,000</font>, respectively</font>, for work performed for Fiocruz pursuant to the Amended Agreement by the Company&#8217;s subcontractor, Fraunhofer, and recognized research and development expenses of the same amount due Fraunhofer for that work.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the &#8220;Settlement Agreement&#8221;). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. See Note 14 - Commitments and Contingencies for significant modifications.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov, Fraunhofer's Executive Director. See Note 14 - Lawsuits for additional information.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> &#160;&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Novici Biotech, LLC</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2012, the Company entered into an agreement with Novici Biotech, LLC (&#8220;Novici&#8221;) in which iBio&#8217;s President is a minority stockholder. Novici performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. In addition, the Company and Novici collaborate on the development of new technologies and product candidates for exclusive worldwide commercial use by the Company. The accounts payable balance includes amounts due to Novici of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">239,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font> at September 30, 2016 and June 30, 2016, respectively. Research and development expenses related to Novici were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">239,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">227,000</font> in Fiscal 2017 and Fiscal 2016, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.25in"> <strong><font style="FONT-SIZE: 10pt">15.&#160;Segment Reporting</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">In accordance with FASB ASC 280, &#8220;<i>Segment Reporting</i>,&#8221; the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, iBio, Inc. and iBio CMO. Commencing July 1, 2016, management determined that the activity of iBio CMO should be segregated as a separate segment. In addition, management determined that the activity of iBio Brazil was no longer material and will be included in the activity of iBio, Inc. As such, the segment information for the three months ended September 30, 2015 was conformed to the current presentation. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2016&#160;(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio,&#160;Inc.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio&#160;CMO</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Eliminations</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues - external customers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues &#150; intersegment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>152</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(334)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>684</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(185)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>820</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,347</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(149)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Operating loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,793)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,361)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,154)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(483)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(483)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest and other income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Consolidated net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,775)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,837)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,612)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,810</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>36,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(49)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>48,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,572</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,023</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,023</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Depreciation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Amortization of intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2015&#160;(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio,&#160;Inc.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio&#160;CMO&#160;*</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Eliminations</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues - external customers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues &#150; intersegment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Operating loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,813)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,813)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest and other income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Consolidated net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,805)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,805)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,284</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,284</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Depreciation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Amortization of intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">* iBio CMO commenced operations in December 2015<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2016&#160;(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio,&#160;Inc.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio&#160;CMO</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Eliminations</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues - external customers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>49</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>135</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues &#150; intersegment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>152</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>182</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(334)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>684</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>321</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(185)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>820</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,347</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,271</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(149)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,469</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Operating loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,793)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,361)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,154)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(483)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(483)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest and other income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Consolidated net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,775)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,837)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,612)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,810</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>36,330</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(49)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>48,091</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,572</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,580</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,023</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,023</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Depreciation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>324</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Amortization of intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> Three&#160;Months&#160;Ended&#160;September&#160;30,&#160;2015&#160;(in&#160;thousands)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio,&#160;Inc.</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>iBio&#160;CMO&#160;*</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Eliminations</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues - external customers</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Revenues &#150; intersegment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>551</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,422</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Operating loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,813)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,813)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Interest and other income</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Consolidated net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,805)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,805)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>11,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Fixed assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Intangible assets, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,284</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,284</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Depreciation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Amortization of intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>91</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">* iBio CMO commenced operations in December 2015</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> iBio CMO commenced operations in December 2015. EX-101.SCH 7 ibio-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Nature of Business link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Financial Instruments and Fair Value Measurement link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Fixed Assets link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Significant Vendors link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Capital Lease Obligation link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Earnings (Loss) Per Common Share link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Fixed Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Capital Lease Obligation (Tables) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Nature of Business (Details Textual) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Basis of Presentation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Fixed Assets (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Fixed Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Intangible Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Significant Vendors (Details Textual) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Capital Lease Obligation (Details) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Capital Lease Obligation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Earnings (Loss) Per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Earnings (Loss) Per Common Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - Share-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 145 - Disclosure - Share-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 146 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 147 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 148 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 ibio-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ibio-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ibio-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 ibio-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document And Entity Information - shares
 3 Months Ended
Sep. 30, 2016
Nov. 18, 2016
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q1  
Entity Registrant Name iBio, Inc.  
Entity Central Index Key 0001420720  
Current Fiscal Year End Date --06-30  
Entity Filer Category Smaller Reporting Company  
Trading Symbol IBIO  
Entity Common Stock, Shares Outstanding   89,109,410
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2016
Jun. 30, 2016
Current assets:    
Cash $ 20,098 $ 23,014
Accounts receivable - trade 170 484
Accounts receivable - unbilled 62 122
Work in process 0 22
Prepaid expenses and other current assets 132 264
Total Current Assets 20,462 23,906
Fixed assets, net of accumulated depreciation 25,580 25,574
Intangible assets, net of accumulated amortization 2,023 2,092
Security deposit 26 28
Total Assets 48,091 51,600
Current liabilities:    
Accounts payable (related party of $239 and $200 as of September 30, 2016 and June 30, 2016, respectively) 979 1,177
Accrued expenses (related party of $772 and $623 as of September 30, 2016 and June 30, 2016 respectively) 1,022 920
Capital lease obligation - current portion 173 170
Deferred revenue 0 24
Total Current Liabilities 2,174 2,291
Capital lease obligation - net of current portion 25,220 25,265
Total Liabilities 27,394 27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - no par value; 1,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,109,410 shares issued and outstanding as of September 30, 2016 and June 30, 2016 89 89
Additional paid-in capital 67,733 67,468
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (60,652) (57,591)
Total iBio, Inc. Stockholders’ Equity 7,141 9,937
Noncontrolling interest 13,556 14,107
Total Equity 20,697 24,044
Total Liabilities and Equity $ 48,091 $ 51,600
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2016
Jun. 30, 2016
Accounts payable, related parties $ 239 $ 200
Accrued expenses, related parties $ 772 $ 623
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 175,000,000 175,000,000
Common stock, shares issued (in shares) 89,109,410 89,109,410
Common stock, shares outstanding (in shares) 89,109,410 89,109,410
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Revenues $ 135 $ 160
Operating expenses:    
Research and development (related parties of $239 and $227), net of $36 and $0 in grant income 820 551
General and administrative (related parties of $175 and $0) 2,469 1,422
Total operating expenses 3,289 1,973
Operating loss (3,154) (1,813)
Other income (expense):    
Interest expense (related party of $483 and $0) (483) 0
Interest income 13 2
Royalty income 12 6
Total other income (458) 8
Consolidated net loss (3,612) (1,805)
Net loss attributable to noncontrolling interest 551 0
Net loss attributable to iBio, Inc. (3,061) (1,805)
Comprehensive loss:    
Net loss (3,612) (1,805)
Other comprehensive loss - foreign currency translation adjustments 0 (9)
Comprehensive loss $ (3,612) $ (1,814)
Loss per common share - basic and diluted $ (0.03) $ (0.02)
Weighted-average common shares outstanding - basic and diluted 89,109 77,307
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Operating expenses research and development, related party $ 239 $ 227
Operating expenses general and administrative, related party 175 0
Interest Expense, Related Party 483 0
Revenue from Grants $ 36 $ 0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statement of Stockholders' Equity - 3 months ended Sep. 30, 2016 - USD ($)
shares in Thousands, $ in Thousands
Total
Other Comprehensive Income (Loss) [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Balance at Jun. 30, 2016 $ 24,044 $ (29) $ 0 $ 89 $ 67,468 $ (57,591) $ 14,107
Balance (in shares) at Jun. 30, 2016     0 89,110      
Share-based compensation 265 0 $ 0 $ 0 265 0 0
Foreign currency translation adjustment 0 0 0 0 0 0 0
Net loss (3,612) 0 0 0 0 (3,061) (551)
Balance at Sep. 30, 2016 $ 20,697 $ (29) $ 0 $ 89 $ 67,733 $ (60,652) $ 13,556
Balance (in shares) at Sep. 30, 2016     0 89,110      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Net loss $ (3,612) $ (1,805)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 265 329
Amortization of intangible assets 88 91
Depreciation 324 1
Changes in operating assets and liabilities:    
Accounts receivable - trade 315 (34)
Accounts receivable - unbilled 61 (126)
Work in process 22 0
Prepaid expenses and other current assets 131 90
Security deposit 2 0
Accounts payable 53 171
Accrued expenses 102 136
Deferred revenue (24) 0
Net cash used in operating activities (2,273) (1,147)
Cash flows from investing activities:    
Additions to intangible assets (202) (18)
Purchases of fixed assets (400) 0
Net cash used in investing activities (602) (18)
Cash flows from financing activities:    
Payment of capital lease obligation (41) 0
Proceeds from exercise of warrants 0 63
Net cash (used in) provided by financing activities (41) 63
Effect of exchange rate changes 0 (8)
Net decrease in cash (2,916) (1,110)
Cash - beginning of period 23,014 9,494
Cash - end of period 20,098 8,384
Schedule of non-cash activities:    
Unpaid intangible assets included in accounts payable 184 0
Unpaid fixed assets included in accounts payable 71 0
Unpaid intangible assets included in accrued expenses 0 (3)
Supplemental cash flow information:    
Cash paid during the period for interest $ 484 $ 0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Nature of Business
 3 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations [Text Block]
1.
Nature of Business
 
iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include reduced production time, capital and operating costs for biopharmaceuticals and the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods.
 
iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:
 
iBioDefense Biologics LLC (“iBioDefense”) – iBioDefense, a wholly-owned subsidiary, is a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology. iBioDefense did not commence any business activities and was dissolved on June 10, 2016.
 
iBio Peptide Therapeutics LLC (“iBio Peptide”) – iBio Peptide, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2013. iBio Peptide did not commence any business activities and was dissolved on June 9, 2016.
 
iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”) – iBio Brazil is a subsidiary organized in Brazil in which the Company has a 99% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the current Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.
 
iBio Manufacturing LLC (“iBio Manufacturing”) – iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date.
 
iBio CMO LLC (“iBio CMO”) – iBio CMO is a Delaware limited liability company formed on December 16, 2015 to develop and manufacture plant-made pharmaceuticals. As of December 31, 2015, the Company owned 100% of iBio CMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $15 million in cash for a 30% interest in iBio CMO. The Company retained a 70% interest in iBio CMO and contributed a royalty bearing license which grants iBio CMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.
 
iBio CMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000 square foot Class A life sciences building on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Affiliate granted iBio CMO a 34-year sublease for the facility as well as certain equipment (see Note 8). Commercial operations commenced in January 2016. iBio CMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases; and (3) Commercial technology transfer services.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation
 3 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
2.
Basis of Presentation
 
Interim Financial Statements
The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2016, from which the accompanying condensed balance sheet dated June 30, 2016 was derived.
 
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.
 
Liquidity
The Company’s primary sources of liquidity are cash on hand and cash available from the sale of common stock of the Company. At this time, cash flows from operating activities represent net outflows for operating expenses and expenses for technology and product development. As of September 30, 2016, the Company had $20.1 million in cash on hand which is expected to support the Company’s activities through September 30, 2017.
 
Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of September 30, 2016, the Company’s accumulated deficit was $60.7 million, and it had cash used in operating activities of $2.3 million for the three months ended September 30, 2016. The Company has historically financed its activities through the sale of common stock and warrants. Through September 30, 2016, the Company has dedicated most of its financial resources to investing in its iBioLaunch™ and iBioModulator™ platforms, its proprietary candidates for treatment of fibrotic diseases, advancing its intellectual property, and general and administrative activities.
 
On May 15, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”) pursuant to which the Company has the option to require Aspire Capital, upon and subject to the terms of the agreement, to purchase up to $15 million of its common stock, over a three-year term. No shares have been sold under the 2015 Facility as of the date of the filing of this report. See Note 9 for a further description of the agreement.
 
Coincident with the entry into the iBio CMO joint venture, Eastern agreed to acquire 10 million shares of the Company's common stock at $0.622 per share. The closing for the sale of 3,500,000 of such shares occurred on January 25, 2016 and the sale of the remaining 6,500,000 shares occurred on April 13, 2016. In addition, on January 25, 2016, Eastern exercised warrants it previously acquired to purchase 1,784,000 shares of the Company's common stock at $0.53 per share. As of the date of the filing of this report, the Company has received $15 million for the capitalization of iBio CMO and approximately $7.2 million from Eastern for the acquisition of 10 million shares of common stock and the exercise of the warrants. See Note 9 for a further description of the transactions.
 
The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities, including sales of common stock to Aspire Capital pursuant to the common stock purchase agreement entered into on May 15, 2015, and through proceeds realized in connection with license and collaboration arrangements. The Company cannot be certain that such funding will be available on favorable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution.
 
The Company's financial statements were prepared under the assumption that the Company will continue as a going concern. If the Company is unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and the Company may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies
 3 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
3.
Summary of Significant Accounting Policies
 
The Company’s significant accounting policies are described in Note 3 of the Notes to Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2016.
 
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
 
Revenue Recognition
The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided.
 
The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “Revenue Arrangements with Multiple Deliverables,” and Staff Accounting Bulletin 104, “Revenue Recognition.” Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. In Fiscal 2017 and Fiscal 2016, the Company did not have any revenue arrangements with multiple deliverables.
 
The Company generates (or may generate in the future) contract revenue under the following types of contracts:
 
Fixed-Fee
Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.
 
Time and Materials
Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred.
 
Grant Income
Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In Fiscal 2017, grant income amounted to approximately $36,000. No grant income was recognized in Fiscal 2016.
 
Work in Process
Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. There was no work in process at September 30, 2016.
 
Fixed Assets
Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years.
 
Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5).
 
Intangible Assets
The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges in Fiscal 2017 and Fiscal 2016.
 
Recently Issued Accounting Pronouncements
In May 2014, ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”) was issued. The amendments in ASU 2014-09 affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in ASC 605, “Revenue Recognition,” and most industry-specific guidance, and creates ASC 606, “Revenue from Contracts with Customers.”
 
The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:
 
Step 1: Identify the contract(s) with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
 
ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” (“ASU 2015-14”) which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual reporting periods after December 15, 2017 (year ended June 30, 2018 for the Company) including interim periods within that reporting period.  Earlier application is permitted only as of annual reporting periods beginning after December 15, 2015, including interim reporting periods within that reporting period. The Company is currently evaluating the effects of adopting ASU 2014-09 on its consolidated financial statements but has not determined the impact as of the filing of this report.
   
Effective January 1, 2016, the Company adopted ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).  ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. An entity should recognize compensation cost in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. ASU 2014-12 became effective for interim and annual periods beginning on or after December 15, 2015. The adoption of ASU 2014-12 did not have a significant impact on the Company’s consolidated financial statements.
 
In June 2014, ASU 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”) was issued.  Before the issuance of ASU 2014-15, there was no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. This guidance is expected to reduce the diversity in the timing and content of footnote disclosures. ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards as specified in the guidance. ASU 2014-15 becomes effective for the annual period ending after December 15, 2016 (year ended June 30, 2017 for the Company) and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the effects of adopting ASU 2014-15 on its consolidated financial statements but the adoption is not expected to have a significant impact.
 
Effective January 1, 2016, the Company adopted ASU 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” (“ASU 2015-01”). ASU 2015-01 eliminates the concept of an extraordinary item from accounting principles generally accepted in the United States of America. As a result, an entity will no longer be required to segregate extraordinary items from the results of ordinary operations, to separately present an extraordinary item on its income statement, net of tax, after income from continuing operations or to disclose income taxes and earnings-per-share data applicable to an extraordinary item. However, ASU 2015-01 will still retain the presentation and disclosure guidance for items that are unusual in nature and occur infrequently. The adoption of ASU 2015-01 did not have a significant impact on the Company’s consolidated financial statements.
 
Effective July 1, 2016, the Company adopted ASU 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”). The amendments in ASU 2015-02 change the analysis that reporting entity must perform to determine whether it should consolidate certain types of legal entities. A reporting entity may apply the amendments in ASU 2015-02 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The adoption of ASU 2015-02 did not have a significant impact on the Company’s consolidated financial statements.
 
In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”).  ASU 2015-17 requires deferred tax assets and liabilities to be classified as noncurrent in the consolidated balance sheet. ASU 2015-17 becomes effective for interim and annual reporting periods beginning after December 15, 2016 (year ended June 30, 2017 for the Company). Early adoption is permitted.  A reporting entity should apply the amendment prospectively or retrospectively. The Company is currently evaluating the effects of adopting ASU 2015-17 on its consolidated financial statements but the adoption is not expected to have a significant impact as the Company continues to provide a full valuation allowance against its net deferred tax assets.
 
In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The amendments require all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. This guidance is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company), including interim periods within those fiscal years. The Company will evaluate the effects of adopting ASU 2016-01 if and when it is deemed to be applicable.
 
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) which supersedes existing guidance on accounting for leases in “Leases (Topic 840).”  The standard requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet.  A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term.  The new guidance is effective for annual reporting periods beginning after December 15, 2018 (year ended June 30, 2020 for the Company) and interim periods within those fiscal years. The amendments should be applied at the beginning of the earliest period presented using a modified retrospective approach with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the effects of adopting ASU 2016-02 on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.
 
In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 affects entities that issue share-based payment awards to their employees. ASU 2016-09 is designed to simplify several aspects of accounting for share-based payment award transactions which include – the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. This guidance is effective for annual periods beginning after December 15, 2016 (year ended June 30, 2018 for the Company), including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements.
 
In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09, “Revenue from Contracts with Customers.” Specifically, ASU 2016-10 addresses an entity’s identification of its performance obligations in a contract, as well as an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as the new revenue standard, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The Company is currently evaluating the impact of ASU 2016-10 on its consolidated financial statements but has not determined the impact as of the filing of this report.
 
In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients” (“ASU 2016-12”). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. ASU 2016-12 will have the same effective date and transition requirements as the ASU 2014-09. The Company is currently evaluating the impact of ASU 2016-12 on its consolidated financial statements but has not determined the impact as of the filing of this report.
 
In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.
 
Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Financial Instruments and Fair Value Measurement
 3 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
4.
Financial Instruments and Fair Value Measurement
 
The carrying values of cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses in the Company’s condensed consolidated balance sheets approximated their fair values as of September 30, 2016 and June 30, 2016 due to their short-term nature. The carrying value of the capital lease obligation approximated its fair value as of September 30, 2016 and June 30, 2016 as the interest rate used to discount the lease payments approximated market.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fixed Assets
 3 Months Ended
Sep. 30, 2016
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Disclosure [Text Block]
 
5.
Fixed Assets
 
iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34-year sublease. See Note 8 for more details of the terms of the sublease.
 
The economic substance of the sublease is that the Company is financing the acquisition of the facility and equipment and, accordingly, the facility and equipment are recorded as assets and the lease is recorded as a liability. As the sublease involves real estate and equipment, the Company separated the equipment component and accounted for the facility and equipment as if each was leased separately.
 
The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):
 
 
 
September 30,
 
June 30,
 
 
 
2016
 
2016
 
Facility under capital lease
 
$
20,000
 
$
20,000
 
Equipment under capital lease
 
 
6,000
 
 
6,000
 
Facility improvements
 
 
57
 
 
42
 
Medical equipment
 
 
305
 
 
-
 
Office equipment and software
 
 
146
 
 
137
 
 
 
 
26,508
 
 
26,179
 
Accumulated depreciation – assets under capital lease
 
 
(882)
 
 
(571)
 
Accumulated depreciation – other
 
 
(46)
 
 
(34)
 
 
 
 
(928)
 
 
(605)
 
Net fixed assets
 
$
25,580
 
$
25,574
 
 
Depreciation expense was approximately $324,000 and $1,300 in Fiscal 2017 and Fiscal 2016, respectively. Depreciation of the assets under the capital lease amounted to approximately $311,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets
 3 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block]
6.
Intangible Assets
 
The Company has two categories of intangible assets – intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (“Fraunhofer”), pursuant to a Technology Transfer Agreement, as amended (the “TTA”). The Company designates such technology acquired from Fraunhofer as iBioLaunch technology or as iBioModulator technology. The value attributed to Patents owned or controlled by the Company is based on payments for services and fees related to the further development and protection of the Company’s patent portfolio.
 
In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the “Licensed Technology”). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing a New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (“IND”) – became due on December 1, 2015. A six-month extension was automatically granted until June 1, 2016 under the license agreement. On August 11, 2016, the agreement was amended and replaced the original milestone schedule to provide that the IND filing be accomplished by June 30, 2017.
 
The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges during Fiscal 2017 and Fiscal 2016.
 
The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):
 
 
 
September 30,
 
June 30,
 
 
 
2016
 
2016
 
Intellectual property – gross carrying value
 
$
3,100
 
$
3,100
 
Patents – gross carrying value
 
 
2,284
 
 
2,265
 
 
 
 
5,384
 
 
5,365
 
Intellectual property – accumulated amortization
 
 
(1,971)
 
 
(1,932)
 
Patents – accumulated amortization
 
 
(1,390)
 
 
(1,341)
 
 
 
 
(3,361)
 
 
(3,273)
 
Net intangible assets
 
$
2,023
 
$
2,092
 
 
Amortization expense was approximately $88,000 and $91,000 for Fiscal 2017 and Fiscal 2016, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Vendors
 3 Months Ended
Sep. 30, 2016
Significant Vendor [Abstract]  
Significant Vendor Disclosures [Text Block]
7.
Significant Vendors
 
Fraunhofer
Fraunhofer was the Company’s most significant vendor solely on the basis of the three-party Yellow Fever vaccine development program among Fiocruz/Bio-Manguinhos, the Company, and Fraunhofer (described in greater detail below). The accounts payable balance under this three-party agreement includes amounts due Fraunhofer of approximately $122,000 and $341,000 as of September 30, 2016 and June 30, 2016, respectively, and accrued expenses of $62,000 and $122,000 as of September 30, 2016 and June 30, 2016, respectively. See Note 14 – Commitments and Contingencies.
 
On January 4, 2011, the Company entered into the Collaboration and License Agreement (the “CLA”) which is a three-party agreement involving the Company, Fraunhofer and Fiocruz, a public entity, member of the Indirect Federal Public Administration and linked to the Health Ministry of Brazil, acting through its unit Bio-Manguinhos. The CLA provides for the development of a Yellow Fever vaccine to be manufactured and distributed within Latin America and Africa by Fiocruz. The CLA was supplemented by a bilateral agreement between iBio and Fraunhofer dated December 27, 2010 in which the Company engaged Fraunhofer as a contractor to provide the research and development services (both, together, the “Agreement”). The services are billed to Fiocruz at Fraunhofer’s cost, so the Company’s revenue is equivalent to expense and there is no profit.
 
On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) which provides for revised research and development, work plans, reporting, objectives, estimated budget, and project billing process. In Fiscal 2017 and Fiscal 2016, under the Amended Agreement, the Company recognized revenue of $ 62,000 and $160,000, respectively, for work performed for Fiocruz pursuant to the Amended Agreement by the Company’s subcontractor, Fraunhofer, and recognized research and development expenses of the same amount due Fraunhofer for that work.
 
In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. See Note 14 - Commitments and Contingencies for significant modifications.
 
On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov, Fraunhofer's Executive Director. See Note 14 - Lawsuits for additional information.
  
Novici Biotech, LLC
In January 2012, the Company entered into an agreement with Novici Biotech, LLC (“Novici”) in which iBio’s President is a minority stockholder. Novici performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. In addition, the Company and Novici collaborate on the development of new technologies and product candidates for exclusive worldwide commercial use by the Company. The accounts payable balance includes amounts due to Novici of approximately $239,000 and $200,000 at September 30, 2016 and June 30, 2016, respectively. Research and development expenses related to Novici were approximately $239,000 and $227,000 in Fiscal 2017 and Fiscal 2016, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Capital Lease Obligation
 3 Months Ended
Sep. 30, 2016
Leases, Capital [Abstract]  
Leases of Lessee Disclosure [Text Block]
 
8.
Capital Lease Obligation
 
As discussed above, iBio CMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Affiliate under a 34-year sublease. iBio CMO began operations at the facility on December 22, 2015 pursuant to agreements between iBio CMO and the Second Affiliate granting iBio CMO temporary rights to access the facility. These temporary agreements were superseded by the Sublease Agreement, dated January 13, 2016, between iBio CMO and the Second Affiliate (the “sublease”). The 34-year term of the sublease may be extended by iBio CMO for a ten-year period, so long as iBio CMO is not in default under the sublease. Under the sublease, iBio CMO is required to pay base rent at an annual rate of $2,100,000, paid in equal quarterly installments on the first day of each February, May, August and November. The base rent is subject to increase annually in accordance with increases in the Consumer Price Index. The base rent under the Second Affiliate’s ground lease for the property is subject to adjustment, based on an appraisal of the property, in 2030 and upon any extension of the ground lease. The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. iBio CMO is also responsible for all costs and expenses in connection with the ownership, management, operation, replacement, maintenance and repair of the property under the sublease.
 
In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively.
 
Interest expense incurred under the capital lease obligation amounted to approximately $484,000 and $0 for Fiscal 2017 and Fiscal 2016, respectively.
 
Future minimum payments under the capitalized lease obligations are due as follows:
 
Fiscal period ending on September 30,:
 
Principal
 
Interest
 
Total
 
2017
 
$
173,048
 
$
1,926,952
 
$
2,100,000
 
2018
 
 
186,593
 
 
1,913,407
 
 
2,100,000
 
2019
 
 
201,198
 
 
1,898,802
 
 
2,100,000
 
2020
 
 
216,947
 
 
1,883,053
 
 
2,100,000
 
2021
 
 
233,928
 
 
1,866,072
 
 
2,100,000
 
Thereafter
 
 
24,381,531
 
 
35,468,469
 
 
59,850,000
 
 
 
 
 
 
 
 
 
 
 
 
Total minimum lease payments
 
 
25,393,245
 
$
44,956,755
 
$
70,350,000
 
Less: current portion
 
 
(173,048)
 
 
 
 
 
 
 
Long-term portion of minimum lease obligations
 
$
25,220,197
 
 
 
 
 
 
 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity
 3 Months Ended
Sep. 30, 2016
Stockholders Equity Note [Abstract]  
Stockholders Equity Note Disclosure [Text Block]
9.
Stockholders’ Equity
 
Preferred Stock
The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. As of September 30, 2016 and June 30, 2016, there were no shares of preferred stock issued and outstanding.
 
Common Stock
As of September 30, 2016 and 2015, the Company was authorized to issue up to 175 million shares of common stock.   As of September 30, 2016, the Company had reserved up to 15 million shares of common stock for incentive compensation (stock options and restricted stock). No shares are reserved for the exercise of warrants.
 
No shares of common stock were issued for the period July 1, 2016 through the date of the filing of this report. Recent issuances of common stock include the following:
 
Aspire Capital – 2015 Facility
 
On May 15, 2015, the Company entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire Capital, pursuant to which the Company has the option to require Aspire Capital to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock (the “Purchase Shares”) upon and subject to the terms of the 2015 Aspire Purchase Agreement.  In consideration for entering into the purchase agreement, Aspire Capital received a commitment fee of 450,000 shares (the “Commitment Shares”).
 
On any business day after the Commencement Date (as defined below) and over the 36-month term of the 2015 Aspire Purchase Agreement, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”) directing Aspire Capital to purchase up to 200,000 Purchase Shares per business day; however, no sale pursuant to such a Purchase Notice may exceed five hundred thousand dollars ($500,000) per business day, unless the Company and Aspire Capital mutually agree. The Company and Aspire Capital also may mutually agree to increase the number of shares that may be sold to as much as an additional 2,000,000 Purchase Shares per business day. The purchase price per Purchase Share pursuant to such Purchase Notice (the “Purchase Price”) is the lower of (i) the lowest sale price for the Company’s common stock on the date of sale or (ii) the average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date. The applicable Purchase Price will be determined prior to delivery of any Purchase Notice.
 
In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital for at least 150,000 Purchase Shares and the closing sale price of the Company’s common stock is higher than $0.40, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of the Company’s common stock equal to up to 35% of the aggregate shares of common stock traded on the next business day (the “VWAP Purchase Date”), subject to a maximum number of shares determined by the Company (the “VWAP Purchase Share Volume Maximum”). The purchase price per Purchase Share pursuant to such VWAP Purchase Notice (the “VWAP Purchase Price”) shall be the lesser of the closing sale price of the Company’s common stock on the VWAP Purchase Date or 97% of the volume weighted average price for the Company’s common stock traded on the VWAP Purchase Date if the aggregate shares to be purchased on that date does not exceed the VWAP Purchase Share Volume Maximum, or the portion of such business day until such time as the sooner to occur of (1) the time at which the aggregate shares traded has exceeded the VWAP Purchase Share Volume Maximum, or (2) the time at which the sale price of the Company’s common stock falls below the VWAP Minimum Price Threshold (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction). The VWAP Minimum Price Threshold is the greater of (i) 80% of the closing sale price of the Company’s common stock on the business day immediately preceding the VWAP Purchase Date or (ii) such higher price as set forth by the Company in the VWAP Purchase Notice.
 
The number of Purchase Shares covered by and timing of each Purchase Notice or VWAP Purchase Notice are determined at the Company’s discretion. The aggregate number of shares that the Company can sell to Aspire Capital under the 2015 Aspire Purchase Agreement may in no case exceed 15,343,406 shares of our common stock (which is equal to approximately 19.99% of the common stock outstanding on the date of the 2015 Aspire Purchase Agreement, including the 450,000 Commitment Shares issued to Aspire Capital in consideration for entering into the 2015 Aspire Purchase Agreement) (the “Exchange Cap”), unless (i) shareholder approval is obtained to issue more, in which case the Exchange Cap will not apply; provided that at no time shall Aspire Capital (together with its affiliates) beneficially own more than 19.99% of the Company’s common stock.
 
The 2015 Aspire Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. Sales under the 2015 Aspire Purchase Agreement could commence only after certain conditions were satisfied (the date on which all requisite conditions have been satisfied being referred to as the “Commencement Date”), which conditions included the delivery to Aspire Capital of a prospectus supplement covering the Commitment Shares and the Purchase Shares, approval for listing on NYSE MKT of the Purchase Shares and the Commitment Shares, the issuance of the Commitment Shares to Aspire Capital, and the receipt by Aspire Capital of a customary opinion of counsel and other certificates and closing documents. Either party had the option to terminate the 2015 Aspire Purchase Agreement in the event the Commencement Date had not occurred by July 1, 2015. The 2015 Aspire Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost or penalty.
 
The Company’s net proceeds will depend on the Purchase Price, the VWAP Purchase Price and the frequency of the Company’s sales of Purchase Shares to Aspire Capital; subject to the maximum $15.0 million available amount. The Company’s delivery of Purchase Notices and VWAP Purchase Notices will be made subject to market conditions, in light of the Company’s capital needs from time to time. The Company expects to use proceeds from sales of Purchase Shares for general corporate purposes and working capital requirements.
 
In connection with the 2015 Aspire Purchase Agreement, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Aspire Capital, dated May 15, 2015. The Registration Rights Agreement provides, among other things, a requirement to register the sale of the Commitment Shares and the Purchase Shares to Aspire Capital pursuant to the Company’s existing shelf registration statement (the “Registration Statement”). The Company further agreed to keep the Registration Statement effective and to indemnify Aspire Capital for certain liabilities in connection with the sale of the Securities under the terms of the Registration Rights Agreement. On May 29, 2015, the Company filed a prospectus supplement to the Company’s existing Registration Statement on Form S-3, registering $15.0 million of the Company’s common stock that it may issue and sell to Aspire Capital from time to time pursuant to the 2015 Aspire Purchase Agreement, together with the 450,000 Commitment Shares issued to Aspire Capital in consideration for entering into the 2015 Aspire Purchase Agreement.
 
No shares have been sold under the 2015 Facility as of the date of the filing of this report.
 
Eastern – Share Purchase Agreements
 
On January 13, 2016, the Company entered into a share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 3,500,000 shares of the Company’s common stock at a price of $0.622 per share. The Company received proceeds of $2,177,000 and the shares were issued on January 25, 2016. In addition, Eastern agreed to exercise warrants it had previously acquired to purchase 1,784,000 shares of the Company’s common stock at an exercise price of $0.53 per share. The Company received proceeds of approximately $945,000 from the exercise of the warrants and the shares were issued on January 25, 2016.
 
On January 13, 2016, the Company entered into a separate share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 6,500,000 shares of the Company’s common stock at a price of $0.622 per share, subject to the approval of the Company’s stockholders. The Company’s stockholders approved the issuance of the 6,500,000 shares to Eastern at the Company’s annual meeting on April 7, 2016. On April 13, 2016, the Company issued the 6,500,000 shares and received proceeds of $4,043,000. These shares are subject to a three-year standstill agreement which will restrict additional acquisitions of the Company’s common stock by Eastern and its controlled affiliates to limit its beneficial ownership of the Company’s outstanding shares of common stock to a maximum of 38%, absent the approval by a majority of the Company’s board of directors.
  
Warrants
The Company has historically financed its operations through the sale of common stock and warrants, sold together as units. No warrants were outstanding as of September 30, 2016 and June 30, 2016.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings (Loss) Per Common Share
 3 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
10.
Earnings (Loss) Per Common Share
 
Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
 
 
 
Three Months ended
 
 
 
September 30,
 
 
 
2016
 
2015
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss available to iBio, Inc. stockholders
 
$
(3,061)
 
$
(1,805)
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
89,109
 
 
77,307
 
 
 
 
 
 
 
 
 
Per Share Amount
 
$
(0.03)
 
$
(0.02)
 
  
In Fiscal 2017 and Fiscal 2016, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September 30, 2016, shares issuable which could potentially dilute future earnings included approximately 12.3 million stock options.   As of September 30, 2015, shares issuable which could potentially dilute future earnings included approximately 12.1 million stock options and 6.0 million warrants.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share-Based Compensation
 3 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
11.  Share-Based Compensation
 
The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):
 
 
 
Three Months Ended
 
 
 
September 30,
 
 
 
2016
 
2015
 
Research and development
 
$
6
 
$
5
 
General and administrative
 
 
259
 
 
324
 
Total
 
$
265
 
$
329
 
 
Stock Options
On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors and external service providers. The Plan, as amended on December 18, 2013, provided that the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 15 million shares. As of September 30, 2016, there were approximately 2.7 million shares of common stock reserved for future issuance under the Plan. Stock options granted under the Plan may be either incentive stock options (as defined by Section 422 of the Internal Revenue Code of 1986, as amended) or non-qualified stock options at the discretion of the Board of Directors. Vesting of service awards occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria have been satisfied. The Company uses historical data to estimate forfeiture rates.
 
No stock options were issued during Fiscal 2017.
 
The following table summarizes all stock option activity during Fiscal 2017:
 
 
 
 
 
 
 
Weighted-
 
 
 
 
 
 
 
Weighted-
 
average
 
 
 
 
 
 
 
average
 
Remaining
 
Aggregate
 
 
 
Stock
 
Exercise
 
Contractual
 
Intrinsic Value
 
 
 
Options
 
Price
 
Term (in years)
 
(in thousands)
 
Outstanding as of July 1, 2016
 
 
12,273,334
 
$
1.31
 
 
6.4
 
$
993
 
Granted
 
 
-
 
 
 
 
 
 
 
 
 
 
Outstanding as of September 30, 2016
 
 
12,273,334
 
$
1.31
 
 
6.1
 
$
433
 
Vested and, as of September 30, 2016, expected to vest
 
 
12,233,897
 
$
1.31
 
 
6.1
 
$
433
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable as of September 30, 2016
 
 
9,361,697
 
$
1.31
 
 
5.5
 
$
405
 
 
As of September 30, 2016, there was approximately $1.4 million of total unrecognized compensation cost related to non-vested stock options that the Company expects to recognize over a weighted-average period of 1.68 years.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions
 3 Months Ended
Sep. 30, 2016
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]
12.  Related Party Transactions
 
Novici Biotech, LLC
In January 2012, the Company entered into an agreement with Novici in which iBio’s President is a minority stockholder. See Note 7.
 
Agreements with Eastern Capital Limited and its Affiliates.
As more fully discussed in Note 9, the Company entered into two share purchase agreements with Eastern and sold 10 million shares of common stock at a price of $0.622 per share. The Company received proceeds of $6,220,000. In addition, Eastern agreed to exercise warrants it had previously acquired to purchase 1,784,000 shares of the Company’s common stock at an exercise price of $0.53 per share. The Company received proceeds of approximately $945,000 from the exercise of the warrants.
 
Concurrently with the execution of the Purchase Agreements, iBio entered into a contract manufacturing joint venture with an affiliate of Eastern to develop and manufacture plant-made pharmaceuticals through iBio’s recently formed subsidiary, iBio CMO. The Eastern Affiliate contributed $15.0 million in cash to iBio CMO, for a 30% interest in iBio CMO. iBio retained a 70% equity interest in iBio CMO. As the majority equity holder, iBio has the right to appoint a majority of the members of the Board of Managers that manages the iBio CMO joint venture. Specified material actions by the joint venture require the consent of iBio and the Eastern Affiliate. iBio contributed to the capital of iBio CMO a royalty bearing license, which grants iBio CMO a non-exclusive license to use the iBio’s proprietary technologies, including the iBioLaunch technology and additional iBio technologies, for research purposes and an exclusive U.S. license for manufacturing purposes. iBio retains all other rights in its intellectual property, including the right for itself to commercialize products based on its proprietary technologies or to grant licenses to others to do so.
 
In connection with the joint venture, the Second Eastern Affiliate, which controls the subject property as sublandlord, granted iBio CMO a 34-year sublease of a Class A life sciences building in Bryan, Texas, on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. Accrued expenses at September 30, 2016 and June 30, 2016 due to the Second Eastern Affiliate amounted to $772,000 and $623,000, respectively. General and administrative expenses related to Second Eastern Affiliate were approximately $167,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively. Interest expense related to the Second Eastern Affiliate was approximately $483,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively. The terms of the sublease are described in Note 8.
 
A three-year standstill agreement (the “Standstill Agreement”) that took effect upon the issuance of the Eastern Shares pursuant to the 6,500,000 Purchase Agreement restricts additional acquisitions of iBio common stock by Eastern and its controlled affiliates to limit its beneficial ownership of the Company’s outstanding shares of common stock to a maximum of 38%, absent approval by a majority of the Company’s Board of Directors.
 
Operating Lease with Minority Stockholder
Effective January 1, 2015, the Company is leasing office space on a month-to-month basis from an entity owned by a minority stockholder of the Company. Rent was $2,200 per month through November 2015 and increased to $2,500 per month effective December 2015. Rent expense totaled $7,500 and $6,600 in Fiscal 2017 and Fiscal 2016, respectively.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes
 3 Months Ended
Sep. 30, 2016
Income Tax Disclosure [Abstract]  
Income Tax Disclosure [Text Block]
13. Income Taxes
 
The Company recorded no income tax expense for the three months ended September 30, 2016 and 2015 because the estimated annual effective tax rate was zero. As of September 30, 2016, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies
 3 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]
14. Commitments and Contingencies
 
Agreements
In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. The significant modifications post June 30, 2013 are of follows:
 
The Company’s obligation under the TTA, prior to the Settlement Agreement, to make three $1 million payments to Fraunhofer in April 2013, November 2013, and April 2014 (the “Guaranteed Annual Payments”) was terminated and replaced with an undertaking to engage Fraunhofer to perform at least $3 million in work requested and as directed by iBio before December 31, 2015. For the year ended June 30, 2015, $2.7 million in research and development services were performed by Fraunhofer. As of December 31, 2015, the total engagement of Fraunhofer for work requested by iBio is $3.0 million. In addition to the foregoing, the Company sought to engage Fraunhofer for substantial additional other work, but Fraunhofer did not respond to the Company’s requests for proposals for such work.
 
The Company’s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $200,000 was terminated. Instead under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties. The Company will be obligated to remit royalties to Fraunhofer only on technology license revenues that iBio actually receives and on revenues from actual sales by iBio of products derived from the technology developed under the TTA until the later of November 2023 or until such time as the aggregate royalty payments total at least $4 million. All new intellectual property invented by Fraunhofer during the period of the TTA is owned by and is required to be transferred to iBio. The Company has no financial obligations to Fraunhofer with respect to the Company’s use of technologies developed independently of Fraunhofer.
 
On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) to create a new research and development plan for the development of a recombinant Yellow Fever vaccine providing revised reporting, objectives, estimated budget, and project billing process. Under the CLA and bilateral agreement between iBio and Fraunhofer dated December 27, 2010, Fraunhofer, which has been engaged to act as the Company’s subcontractor for performance of research and development services for the new research and development plan, will bill Fiocruz directly on behalf of the Company at the rates, amounts and times provided in the Amended Agreement, and the proceeds of such billings and only the proceeds will be paid to Fraunhofer for its services so the Company’s expense is equal to its revenue and no profit is recognized for these activities under the Amended Agreement. For the year ended June 30, 2015, $2.1 million in research and development services were performed by Fraunhofer for the Company pursuant to the amended CLA. As of December 31, 2015, the total engagement of Fraunhofer for work requested by iBio is $3.0 million. See Note 7 - Significant Vendors for additional information. In addition to the foregoing, the Company sought to engage Fraunhofer for substantial additional other work, but Fraunhofer did not respond to the Company’s requests for proposals for such work
 
On January 14, 2014 (the “Effective Date”), the Company entered into an exclusive worldwide License Agreement (“LA”) with the University of Pittsburgh (“UP”) covering all of the U.S. and foreign patents and patent applications and related intellectual property owned by UP pertinent to the use of endostatin peptides for the treatment of fibrosis. The Company paid an initial license fee of $20,000 and is required to pay all of UP’s patent prosecution costs that were incurred prior to, totaling $30,627, and subsequent to the Effective Date. On each anniversary date the Company is to pay license fees ranging from $25,000 to $150,000 for the first five years and $150,000 on each subsequent anniversary date until the first commercial sale of the licensed technology. Beginning with commercial sales of the technology or approval by the FDA or foreign equivalent, the Company will be required to pay milestone payments, royalties and a percentage of any non-royalty sublicense income to UP.
 
On December 30, 2013, the Company entered into a Project Agreement with the Medical University of South Carolina (“MUSC”) providing for the performance of research and development services by MUSC related to peptides for the treatment of fibrosis. The agreement requires the Company to make payments totaling $78,000 through December 1, 2014 and provides the Company with certain intellectual property rights. Effective September 1, 2014, the Company and MUSC executed an Amendment to the agreement. The Amendment extended the term of the agreement to December 31, 2015 and increased the total payments due MUSC from the Company by $161,754.
 
Lawsuits
 
On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (“Yusibov”), Fraunhofer’s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer’s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. Briefing was completed on a motion to dismiss filed by Fraunhofer in lieu of filing an answer to the complaint. Fraunhofer also moved for a protective order in connection with certain discovery served by iBio. The Court bifurcated the action to first resolve the threshold question in the case – the scope of iBio’s ownership of the technology developed or held by Fraunhofer — before proceeding with the rest of the case and the parties stipulated their agreement to that approach. After considering the parties’ written submissions and oral argument on this threshold issue on April 29, 2016, the Court resolved the threshold issue in favor of iBio on July 29, 2016, holding that iBio owns all proprietary rights of any kind to all plant-based technology of Fraunhofer developed or held as of December 31, 2014, including know-how, and is entitled to receive a transfer of the technology from Fraunhofer. On September 19, 2016, Fraunhofer informed the Court that it does not intend to pursue its motion for protective order at this time. iBio has sought leave of Court to supplement and amend its current complaint to add additional state law claims against Fraunhofer. Fraunhofer opposes this motion. The Company is unable to predict the further outcome of this action at this time.
 
On December 4, 2015, a putative derivative action captioned Savage, Derivatively on Behalf of iBio, Inc., Plaintiff, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant was filed in the Supreme Court of the State of New York, County of New York. The action alleged that the Company and its management made misstatements about the Company’s business resulting either from (i) a failure by iBio’s directors to establish a system of controls over the Company’s disclosures, or (ii) the directors’ consciously ignoring “red flags” relating to disclosures, and sought to recover an unspecified amount of damages. On January 15, 2016, the defendants filed a motion to dismiss all claims against them. On March 16, 2016, the plaintiff filed a Verified Amended Complaint that added an additional named plaintiff and alleged derivative claims generally along the same lines as the original complaint, together with purported direct breach of fiduciary duty and unjust enrichment claims based on the same conduct. The Verified Amended Complaint sought to recover an unspecified amount of damages. On April 29, 2016, the defendants filed a motion to dismiss all claims against them. Plaintiffs’ opposition to the motion was filed on June 6, 2016. On June 22, 2016, the plaintiffs advised the Court that the parties had reached a settlement in principle, and on July 1, 2016, the Court ordered that the defendants’ pending motion to dismiss be withdrawn without prejudice. The parties entered a Stipulation of Settlement dated as of September 20, 2016. On October 11, 2016, the plaintiffs filed a motion with the Court seeking preliminary approval of the settlement. The terms of the settlement are subject to preliminary and final approval by the Court. The Company expects that the settlement will be funded by the Company’s insurance carrier.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting
 3 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
15. Segment Reporting
 
In accordance with FASB ASC 280, “Segment Reporting,” the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, iBio, Inc. and iBio CMO. Commencing July 1, 2016, management determined that the activity of iBio CMO should be segregated as a separate segment. In addition, management determined that the activity of iBio Brazil was no longer material and will be included in the activity of iBio, Inc. As such, the segment information for the three months ended September 30, 2015 was conformed to the current presentation. These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.
 
Three Months Ended September 30, 2016 (in thousands)
 
iBio, Inc.
 
iBio CMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
86
 
$
49
 
$
-
 
$
135
 
Revenues – intersegment
 
 
152
 
 
182
 
 
(334)
 
 
-
 
Research and development
 
 
684
 
 
321
 
 
(185)
 
 
820
 
General and administrative
 
 
1,347
 
 
1,271
 
 
(149)
 
 
2,469
 
Operating loss
 
 
(1,793)
 
 
(1,361)
 
 
-
 
 
(3,154)
 
Interest expense
 
 
-
 
 
(483)
 
 
-
 
 
(483)
 
Interest and other income
 
 
18
 
 
7
 
 
-
 
 
25
 
Consolidated net loss
 
 
(1,775)
 
 
(1,837)
 
 
-
 
 
(3,612)
 
Total assets
 
 
11,810
 
 
36,330
 
 
(49)
 
 
48,091
 
Fixed assets, net
 
 
8
 
 
25,572
 
 
-
 
 
25,580
 
Intangible assets, net
 
 
2,023
 
 
-
 
 
-
 
 
2,023
 
Depreciation expense
 
 
1
 
 
323
 
 
-
 
 
324
 
Amortization of intangible assets
 
 
88
 
 
-
 
 
-
 
 
88
 
 
Three Months Ended September 30, 2015 (in thousands)
 
iBio, Inc.
 
iBio CMO *
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
160
 
$
-
 
$
-
 
$
160
 
Revenues – intersegment
 
 
-
 
 
-
 
 
-
 
 
-
 
Research and development
 
 
551
 
 
-
 
 
-
 
 
551
 
General and administrative
 
 
1,422
 
 
-
 
 
-
 
 
1,422
 
Operating loss
 
 
(1,813)
 
 
-
 
 
-
 
 
(1,813)
 
Interest expense
 
 
-
 
 
-
 
 
-
 
 
-
 
Interest and other income
 
 
8
 
 
-
 
 
-
 
 
8
 
Consolidated net loss
 
 
(1,805)
 
 
-
 
 
-
 
 
(1,805)
 
Total assets
 
 
11,374
 
 
-
 
 
-
 
 
11,374
 
Fixed assets, net
 
 
10
 
 
-
 
 
-
 
 
10
 
Intangible assets, net
 
 
2,284
 
 
-
 
 
-
 
 
2,284
 
Depreciation expense
 
 
1
 
 
-
 
 
-
 
 
1
 
Amortization of intangible assets
 
 
91
 
 
-
 
 
-
 
 
91
 
 
* iBio CMO commenced operations in December 2015
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition
The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided.
 
The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “Revenue Arrangements with Multiple Deliverables,” and Staff Accounting Bulletin 104, “Revenue Recognition.” Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors. In Fiscal 2017 and Fiscal 2016, the Company did not have any revenue arrangements with multiple deliverables.
 
The Company generates (or may generate in the future) contract revenue under the following types of contracts:
 
Fixed-Fee
Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.
 
Time and Materials
Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred.
 
Grant Income
Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. In Fiscal 2017, grant income amounted to approximately $36,000. No grant income was recognized in Fiscal 2016.
Inventory Work in Process, Policy [Policy Text Block]
Work in Process
Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. There was no work in process at September 30, 2016.
Property, Plant and Equipment, Policy [Policy Text Block]
Fixed Assets
Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years.
 
Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5).
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Intangible Assets
The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges in Fiscal 2017 and Fiscal 2016.
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Pronouncements
In May 2014, ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”) was issued. The amendments in ASU 2014-09 affect any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition requirements in ASC 605, “Revenue Recognition,” and most industry-specific guidance, and creates ASC 606, “Revenue from Contracts with Customers.”
 
The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:
 
Step 1: Identify the contract(s) with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
 
ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” (“ASU 2015-14”) which defers the effective date of ASU 2014-09 by one year. ASU 2014-09 is now effective for annual reporting periods after December 15, 2017 (year ended June 30, 2018 for the Company) including interim periods within that reporting period.  Earlier application is permitted only as of annual reporting periods beginning after December 15, 2015, including interim reporting periods within that reporting period. The Company is currently evaluating the effects of adopting ASU 2014-09 on its consolidated financial statements but has not determined the impact as of the filing of this report.
   
Effective January 1, 2016, the Company adopted ASU 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).  ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period is treated as a performance condition. An entity should recognize compensation cost in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. ASU 2014-12 became effective for interim and annual periods beginning on or after December 15, 2015. The adoption of ASU 2014-12 did not have a significant impact on the Company’s consolidated financial statements.
 
In June 2014, ASU 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”) was issued.  Before the issuance of ASU 2014-15, there was no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. This guidance is expected to reduce the diversity in the timing and content of footnote disclosures. ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards as specified in the guidance. ASU 2014-15 becomes effective for the annual period ending after December 15, 2016 (year ended June 30, 2017 for the Company) and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the effects of adopting ASU 2014-15 on its consolidated financial statements but the adoption is not expected to have a significant impact.
 
Effective January 1, 2016, the Company adopted ASU 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items” (“ASU 2015-01”). ASU 2015-01 eliminates the concept of an extraordinary item from accounting principles generally accepted in the United States of America. As a result, an entity will no longer be required to segregate extraordinary items from the results of ordinary operations, to separately present an extraordinary item on its income statement, net of tax, after income from continuing operations or to disclose income taxes and earnings-per-share data applicable to an extraordinary item. However, ASU 2015-01 will still retain the presentation and disclosure guidance for items that are unusual in nature and occur infrequently. The adoption of ASU 2015-01 did not have a significant impact on the Company’s consolidated financial statements.
 
Effective July 1, 2016, the Company adopted ASU 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”). The amendments in ASU 2015-02 change the analysis that reporting entity must perform to determine whether it should consolidate certain types of legal entities. A reporting entity may apply the amendments in ASU 2015-02 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The adoption of ASU 2015-02 did not have a significant impact on the Company’s consolidated financial statements.
 
In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”).  ASU 2015-17 requires deferred tax assets and liabilities to be classified as noncurrent in the consolidated balance sheet. ASU 2015-17 becomes effective for interim and annual reporting periods beginning after December 15, 2016 (year ended June 30, 2017 for the Company). Early adoption is permitted.  A reporting entity should apply the amendment prospectively or retrospectively. The Company is currently evaluating the effects of adopting ASU 2015-17 on its consolidated financial statements but the adoption is not expected to have a significant impact as the Company continues to provide a full valuation allowance against its net deferred tax assets.
 
In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The amendments require all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. This guidance is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company), including interim periods within those fiscal years. The Company will evaluate the effects of adopting ASU 2016-01 if and when it is deemed to be applicable.
 
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) which supersedes existing guidance on accounting for leases in “Leases (Topic 840).”  The standard requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet.  A lessee should recognize in the balance sheet a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term.  The new guidance is effective for annual reporting periods beginning after December 15, 2018 (year ended June 30, 2020 for the Company) and interim periods within those fiscal years. The amendments should be applied at the beginning of the earliest period presented using a modified retrospective approach with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the effects of adopting ASU 2016-02 on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.
 
In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 affects entities that issue share-based payment awards to their employees. ASU 2016-09 is designed to simplify several aspects of accounting for share-based payment award transactions which include – the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations. This guidance is effective for annual periods beginning after December 15, 2016 (year ended June 30, 2018 for the Company), including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-09 on its consolidated financial statements.
 
In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing” (“ASU 2016-10”) related to identifying performance obligations and licensing. ASU 2016-10 is meant to clarify the guidance in FASB ASU 2014-09, “Revenue from Contracts with Customers.” Specifically, ASU 2016-10 addresses an entity’s identification of its performance obligations in a contract, as well as an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. The pronouncement has the same effective date as the new revenue standard, which is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The Company is currently evaluating the impact of ASU 2016-10 on its consolidated financial statements but has not determined the impact as of the filing of this report.
 
In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients” (“ASU 2016-12”). The amendments in ASU 2016-12 affect the guidance in ASU 2014-09 by clarifying certain specific aspects of the guidance, including assessment of collectability, treatment of sales taxes and contract modifications, and providing certain technical corrections. ASU 2016-12 will have the same effective date and transition requirements as the ASU 2014-09. The Company is currently evaluating the impact of ASU 2016-12 on its consolidated financial statements but has not determined the impact as of the filing of this report.
 
In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (year ended June 30, 2019 for the Company). The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements but the adoption is not expected to have a significant impact as of the filing of this report.
 
Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fixed Assets (Tables)
 3 Months Ended
Sep. 30, 2016
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment [Table Text Block]
The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):
 
 
 
September 30,
 
June 30,
 
 
 
2016
 
2016
 
Facility under capital lease
 
$
20,000
 
$
20,000
 
Equipment under capital lease
 
 
6,000
 
 
6,000
 
Facility improvements
 
 
57
 
 
42
 
Medical equipment
 
 
305
 
 
-
 
Office equipment and software
 
 
146
 
 
137
 
 
 
 
26,508
 
 
26,179
 
Accumulated depreciation – assets under capital lease
 
 
(882)
 
 
(571)
 
Accumulated depreciation – other
 
 
(46)
 
 
(34)
 
 
 
 
(928)
 
 
(605)
 
Net fixed assets
 
$
25,580
 
$
25,574
 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets (Tables)
 3 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):
 
 
 
September 30,
 
June 30,
 
 
 
2016
 
2016
 
Intellectual property – gross carrying value
 
$
3,100
 
$
3,100
 
Patents – gross carrying value
 
 
2,284
 
 
2,265
 
 
 
 
5,384
 
 
5,365
 
Intellectual property – accumulated amortization
 
 
(1,971)
 
 
(1,932)
 
Patents – accumulated amortization
 
 
(1,390)
 
 
(1,341)
 
 
 
 
(3,361)
 
 
(3,273)
 
Net intangible assets
 
$
2,023
 
$
2,092
 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Capital Lease Obligation (Tables)
 3 Months Ended
Sep. 30, 2016
Table Text Block Supplement [Abstract]  
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]
Future minimum payments under the capitalized lease obligations are due as follows:
 
Fiscal period ending on September 30,:
 
Principal
 
Interest
 
Total
 
2017
 
$
173,048
 
$
1,926,952
 
$
2,100,000
 
2018
 
 
186,593
 
 
1,913,407
 
 
2,100,000
 
2019
 
 
201,198
 
 
1,898,802
 
 
2,100,000
 
2020
 
 
216,947
 
 
1,883,053
 
 
2,100,000
 
2021
 
 
233,928
 
 
1,866,072
 
 
2,100,000
 
Thereafter
 
 
24,381,531
 
 
35,468,469
 
 
59,850,000
 
 
 
 
 
 
 
 
 
 
 
 
Total minimum lease payments
 
 
25,393,245
 
$
44,956,755
 
$
70,350,000
 
Less: current portion
 
 
(173,048)
 
 
 
 
 
 
 
Long-term portion of minimum lease obligations
 
$
25,220,197
 
 
 
 
 
 
 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings (Loss) Per Common Share (Tables)
 3 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
 
 
 
Three Months ended
 
 
 
September 30,
 
 
 
2016
 
2015
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss available to iBio, Inc. stockholders
 
$
(3,061)
 
$
(1,805)
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
89,109
 
 
77,307
 
 
 
 
 
 
 
 
 
Per Share Amount
 
$
(0.03)
 
$
(0.02)
 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share-Based Compensation (Tables)
 3 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):
 
 
 
Three Months Ended
 
 
 
September 30,
 
 
 
2016
 
2015
 
Research and development
 
$
6
 
$
5
 
General and administrative
 
 
259
 
 
324
 
Total
 
$
265
 
$
329
 
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
The following table summarizes all stock option activity during Fiscal 2017:
 
 
 
 
 
 
 
Weighted-
 
 
 
 
 
 
 
Weighted-
 
average
 
 
 
 
 
 
 
average
 
Remaining
 
Aggregate
 
 
 
Stock
 
Exercise
 
Contractual
 
Intrinsic Value
 
 
 
Options
 
Price
 
Term (in years)
 
(in thousands)
 
Outstanding as of July 1, 2016
 
 
12,273,334
 
$
1.31
 
 
6.4
 
$
993
 
Granted
 
 
-
 
 
 
 
 
 
 
 
 
 
Outstanding as of September 30, 2016
 
 
12,273,334
 
$
1.31
 
 
6.1
 
$
433
 
Vested and, as of September 30, 2016, expected to vest
 
 
12,233,897
 
$
1.31
 
 
6.1
 
$
433
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercisable as of September 30, 2016
 
 
9,361,697
 
$
1.31
 
 
5.5
 
$
405
 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting (Tables)
 3 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.
 
Three Months Ended September 30, 2016 (in thousands)
 
iBio, Inc.
 
iBio CMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
86
 
$
49
 
$
-
 
$
135
 
Revenues – intersegment
 
 
152
 
 
182
 
 
(334)
 
 
-
 
Research and development
 
 
684
 
 
321
 
 
(185)
 
 
820
 
General and administrative
 
 
1,347
 
 
1,271
 
 
(149)
 
 
2,469
 
Operating loss
 
 
(1,793)
 
 
(1,361)
 
 
-
 
 
(3,154)
 
Interest expense
 
 
-
 
 
(483)
 
 
-
 
 
(483)
 
Interest and other income
 
 
18
 
 
7
 
 
-
 
 
25
 
Consolidated net loss
 
 
(1,775)
 
 
(1,837)
 
 
-
 
 
(3,612)
 
Total assets
 
 
11,810
 
 
36,330
 
 
(49)
 
 
48,091
 
Fixed assets, net
 
 
8
 
 
25,572
 
 
-
 
 
25,580
 
Intangible assets, net
 
 
2,023
 
 
-
 
 
-
 
 
2,023
 
Depreciation expense
 
 
1
 
 
323
 
 
-
 
 
324
 
Amortization of intangible assets
 
 
88
 
 
-
 
 
-
 
 
88
 
 
Three Months Ended September 30, 2015 (in thousands)
 
iBio, Inc.
 
iBio CMO *
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
160
 
$
-
 
$
-
 
$
160
 
Revenues – intersegment
 
 
-
 
 
-
 
 
-
 
 
-
 
Research and development
 
 
551
 
 
-
 
 
-
 
 
551
 
General and administrative
 
 
1,422
 
 
-
 
 
-
 
 
1,422
 
Operating loss
 
 
(1,813)
 
 
-
 
 
-
 
 
(1,813)
 
Interest expense
 
 
-
 
 
-
 
 
-
 
 
-
 
Interest and other income
 
 
8
 
 
-
 
 
-
 
 
8
 
Consolidated net loss
 
 
(1,805)
 
 
-
 
 
-
 
 
(1,805)
 
Total assets
 
 
11,374
 
 
-
 
 
-
 
 
11,374
 
Fixed assets, net
 
 
10
 
 
-
 
 
-
 
 
10
 
Intangible assets, net
 
 
2,284
 
 
-
 
 
-
 
 
2,284
 
Depreciation expense
 
 
1
 
 
-
 
 
-
 
 
1
 
Amortization of intangible assets
 
 
91
 
 
-
 
 
-
 
 
91
 
 
* iBio CMO commenced operations in December 2015
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Nature of Business (Details Textual)
$ in Millions
 3 Months Ended
Sep. 30, 2016
ft²
Jan. 13, 2016
USD ($)
Dec. 31, 2015
BRAZIL      
Nature of Business [Line Items]      
Equity Method Investment, Ownership Percentage 99.00%    
Second Eastern Affilate [Member]      
Nature of Business [Line Items]      
Area of Land | ft² 139,000    
iBio CMO LLC [Member] | Second Eastern Affilate [Member]      
Nature of Business [Line Items]      
Lease Term 34 years    
iBio CMO [Member]      
Nature of Business [Line Items]      
Noncontrolling Interest, Ownership Percentage by Parent     100.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   70.00%  
iBio CMO [Member] | Second Eastern Affilate [Member]      
Nature of Business [Line Items]      
Noncontrolling Interest, Amount Represented by Preferred Stock | $   $ 15  
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   30.00%  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended
May 15, 2015
Apr. 13, 2016
Jan. 25, 2016
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Basis of Presentation [Line Items]              
Accumulated deficit       $ (60,652)   $ (57,591)  
Net Cash Used in Operating Activities       (2,273) $ (1,147)    
Stock Issued During Period, Shares, New Issues   6,500,000          
Cash and Cash Equivalents, at Carrying Value, Total       $ 20,098 $ 8,384 $ 23,014 $ 9,494
Common Stock, Par or Stated Value Per Share       $ 0.001   $ 0.001  
Aspire Capital Fund Llc [Member] | Maximum [Member]              
Basis of Presentation [Line Items]              
Sale of Stock, Consideration Received on Transaction $ 15,000            
iBio CMO [Member] | Eastern [Member]              
Basis of Presentation [Line Items]              
Stock Issued During Period, Shares, New Issues     3,500,000        
Stock Issued During Period, Shares, Acquisitions     10,000,000 10,000,000      
Common Stock, Par or Stated Value Per Share       $ 0.622      
Class Of Warrants Or Rights Exercised     1,784,000        
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 0.53        
Proceeds From Capitalization Received     $ 15,000        
Stock Issued During Period, Value, Acquisitions     $ 7,200        
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Summary Of Significant Accounting Policies [Line Items]    
Revenue from Grants $ 36 $ 0
Minimum [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Property, Plant and Equipment, Estimated Useful Lives 3 years  
Maximum [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Property, Plant and Equipment, Estimated Useful Lives 15 years  
Patents [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Finite-Lived Intangible Assets, Remaining Amortization Period 10 years  
Intellectual Property [Member] | Minimum [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Finite-Lived Intangible Assets, Remaining Amortization Period 16 years  
Intellectual Property [Member] | Maximum [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Finite-Lived Intangible Assets, Remaining Amortization Period 23 years  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fixed Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Jun. 30, 2016
Sep. 30, 2015
Property, Plant and Equipment, Gross $ 26,508 $ 26,179  
Accumulated depreciation - assets under capital lease (882) (571)  
Accumulated depreciation - other (46) (34)  
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (928) (605)  
Net fixed assets 25,580 25,574 $ 10
Facility under capital lease [Member]      
Property, Plant and Equipment, Gross 20,000 20,000  
Equipment under capital lease [Member]      
Property, Plant and Equipment, Gross 6,000 6,000  
Facility improvements [Member]      
Property, Plant and Equipment, Gross 57 42  
Medical equipment [Member]      
Property, Plant and Equipment, Gross 305 0  
Office equipment and software [Member]      
Property, Plant and Equipment, Gross $ 146 $ 137  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fixed Assets (Details Textual) - USD ($)
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Depreciation, Total $ 324,000 $ 1,000
iBio CMO LLC [Member] | Second Eastern Affilate [Member]    
Lease Term 34 years  
Capital Leased Assets [Member]    
Depreciation, Total $ 311,000 $ 0
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, gross carrying value $ 5,384 $ 5,365
Finite-Lived Intangible Assets, accumulated amortization (3,361) (3,273)
Net intangible assets 2,023 2,092
Intellectual property [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, gross carrying value 3,100 3,100
Finite-Lived Intangible Assets, accumulated amortization (1,971) (1,932)
Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, gross carrying value 2,284 2,265
Finite-Lived Intangible Assets, accumulated amortization $ (1,390) $ (1,341)
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets (Details Textual) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Finite-Lived Intangible Assets [Line Items]    
Amortization of Intangible Assets $ 88 $ 91
Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 10 years  
Maximum [Member] | Intellectual Property [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 23 years  
Minimum [Member] | Intellectual Property [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 16 years  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Significant Vendors (Details Textual) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2015
Jun. 30, 2016
Significant Vendor [Line Items]        
Accounts Payable, Current $ 979,000     $ 1,177,000
Accrued Liabilities, Current 1,022,000     920,000
Research and Development Expense 820,000 $ 551,000    
Revenue, Net, Total 135,000 160,000    
Amended Agreement [Member]        
Significant Vendor [Line Items]        
Research and Development Expense     $ 2,100,000  
Revenue, Net, Total 62,000 160,000    
Fraunhofer [Member]        
Significant Vendor [Line Items]        
Accounts Payable, Current 122,000     341,000
Accrued Liabilities, Current 62,000     122,000
Novici [Member]        
Significant Vendor [Line Items]        
Accounts Payable, Current 239,000     $ 200,000
Research and Development Expense $ 239,000 $ 227,000    
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Capital Lease Obligation (Details) - USD ($)
Sep. 30, 2016
Jun. 30, 2016
2017 $ 2,100,000  
2018 2,100,000  
2019 2,100,000  
2020 2,100,000  
2021 2,100,000  
Thereafter 59,850,000  
Total minimum lease payments 70,350,000  
Less: current portion (173,000) $ (170,000)
Long-term portion of minimum lease obligations 25,220,000 $ 25,265,000
Principal [Member]    
2017 173,048  
2018 186,593  
2019 201,198  
2020 216,947  
2021 233,928  
Thereafter 24,381,531  
Total minimum lease payments 25,393,245  
Less: current portion (173,048)  
Long-term portion of minimum lease obligations 25,220,197  
Interest [Member]    
2017 1,926,952  
2018 1,913,407  
2019 1,898,802  
2020 1,883,053  
2021 1,866,072  
Thereafter 35,468,469  
Total minimum lease payments $ 44,956,755  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Capital Lease Obligation (Details Textual) - USD ($)
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Capital Leases, Income Statement, Interest Expense $ 484,000 $ 0
Sub Lease Expiration Period 34 years  
Operating Leases, Rent Expense $ 2,100,000  
Capital Lease Obligation Description The base rent under the sublease will be increased by any increase in the base rent under the ground lease as a result of such adjustments. In addition to the base rent, iBio CMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $16,000 and $0 in Fiscal 2017 and Fiscal 2016, respectively.  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended
Apr. 07, 2016
Jan. 13, 2016
May 15, 2015
Apr. 13, 2016
Jan. 25, 2016
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2016
May 29, 2015
Stockholders' Equity [Line Items]                  
Preferred Stock, Shares Authorized           1,000,000   1,000,000  
Common Stock, Shares Authorized           175,000,000 175,000,000 175,000,000  
Proceeds from Warrant Exercises           $ 0 $ 63,000    
Stock Issued During Period, Shares, New Issues       6,500,000          
Stock Issued During Period, Value, New Issues       $ 4,043,000          
Registration Common Stock                 $ 15,000,000
Common Stock, Par or Stated Value Per Share           $ 0.001   $ 0.001  
Stockholders [Member]                  
Stockholders' Equity [Line Items]                  
Stock Issued During Period, Shares, Other 6,500,000                
Eastern Share Purchase Agreements [Member]                  
Stockholders' Equity [Line Items]                  
Proceeds from Warrant Exercises         $ 945,000        
Stock Issued During Period, Value, New Issues         $ 2,177,000        
Stock Issued During Period, Shares, Other   6,500,000              
Class of Warrant or Right, Exercise Price of Warrants or Rights         $ 0.53        
Stock Issued During Period, Shares, Acquisitions   3,500,000              
Common Stock, Par or Stated Value Per Share   $ 0.622              
Class Of Warrants Or Rights Exercised         1,784,000        
Maximum Common Stock Percentage   38.00%              
Eastern Share Purchase Agreements [Member] | Stockholders [Member]                  
Stockholders' Equity [Line Items]                  
Common Stock, Par or Stated Value Per Share   $ 0.622              
Aspire Capital Fund, LLC 2014 [Member]                  
Stockholders' Equity [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized           15,000,000      
Aggregate Common Stock Purchased     $ 15,000,000            
Percentage Of Aggregate Shares Of Company           35.00%      
Percentage Of Closing Price Of Common Stock           80.00%      
Percentage Of Volume Weighted Average Price           97.00%      
Stock Issued During Period, Shares, Other           150,000      
Share Price           $ 0.40      
Aspire Capital Fund, LLC 2015 [Member]                  
Stockholders' Equity [Line Items]                  
Commitment Shares Issued During Period     450,000            
Maximum Amount Available For Purchase Of Shares           $ 15,000,000      
Aspire Capital Fund, LLC 2015 [Member] | Aspirre Purchase Agreement 2015 [Member]                  
Stockholders' Equity [Line Items]                  
Percentage Of Common Stock Outstanding           19.99%      
Commitment Shares Issued During Period           450,000      
Stock Issued During Period, Shares, Other           15,343,406      
Aspire Capital Fund Llc [Member]                  
Stockholders' Equity [Line Items]                  
Stock Issued During Period, Value, New Issues     $ 500,000            
Stock Issued During Period, Shares, Other     200,000            
Additional Purchase Of Shares     2,000,000            
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Basic and diluted numerator:    
Net loss available to iBio, Inc. stockholders $ (3,061) $ (1,805)
Basic and diluted denominator:    
Weighted-average common shares outstanding 89,109 77,307
Per Share Amount $ (0.03) $ (0.02)
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Earnings (Loss) Per Common Share (Details Textual) - shares
shares in Millions
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Warrant [Member]    
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]    
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants   6.0
Employee Stock Option [Member]    
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]    
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12.3 12.1
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated Share-based Compensation Expense $ 265 $ 329
Research and Development Expense [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated Share-based Compensation Expense 6 5
General and Administrative Expense [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Allocated Share-based Compensation Expense $ 259 $ 324
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share-Based Compensation (Details 1) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2016
Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock Options, Outstanding at beginning of the period 12,273,334  
Stock Options, Granted 0  
Stock Options, Outstanding at end of the period 12,273,334 12,273,334
Stock Options, Vested and, as of September 30, 2016, expected to vest 12,233,897  
Stock Options, Exercisable as of September 30, 2016 9,361,697  
Weighted-average Exercise Price, Outstanding at beginning of the period $ 1.31  
Weighted-average Exercise Price, Outstanding at end of the period 1.31 $ 1.31
Weighted-average Exercise Price, Vested and, as of September 30, 2016, expected to vest 1.31  
Weighted-average Exercise Price, Exercisable as of September 30, 2016 $ 1.31  
Weighted-average Remaining Contractual Term (in years), Outstanding 6 years 1 month 6 days 6 years 4 months 24 days
Weighted-average Remaining Contractual Term (in years), Vested and, as of September 30, 2016, expected to vest 6 years 1 month 6 days  
Weighted-average Remaining Contractual Term (in years), Exercisable as of September 30, 2016 5 years 6 months  
Aggregate Intrinsic Value ,Outstanding $ 433 $ 993
Aggregate Intrinsic Value, Vested and, as of September 30, 2016, expected to vest 433  
Aggregate Intrinsic Value, Exercisable as of September 30, 2016 $ 405  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share-Based Compensation (Details Textual)
shares in Millions, $ in Millions
 3 Months Ended
Sep. 30, 2016
USD ($)
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares) 2.7
Employee Stock Option [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares) 15.0
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars) | $ $ 1.4
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 1 year 8 months 5 days
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended
Apr. 13, 2016
Dec. 31, 2015
Nov. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2016
Related Party Transaction [Line Items]            
Accounts Payable, Related Parties, Current       $ 239,000   $ 200,000
Operating Leases, Rent Expense       $ 2,100,000    
Stock Issued During Period, Shares, New Issues 6,500,000          
Common Stock, Par or Stated Value Per Share       $ 0.001   $ 0.001
Stock Issued During Period, Value, New Issues $ 4,043,000          
Proceeds from Warrant Exercises       $ 0 $ 63,000  
Eastern Two Share Purchase Agreements [Member]            
Related Party Transaction [Line Items]            
Stock Issued During Period, Shares, New Issues       10,000,000    
Common Stock, Par or Stated Value Per Share       $ 0.622    
Class Of Warrants Or Rights Exercised       1,784,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 0.53    
Stock Issued During Period, Value, New Issues       $ 6,220,000    
Proceeds from Warrant Exercises       $ 945,000    
Eastern Capital Limited and its Affiliates [Member] | Retained Interest [Member]            
Related Party Transaction [Line Items]            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       70.00%    
Eastern Capital Limited and its Affiliates [Member] | iBio CMO LLC [Member]            
Related Party Transaction [Line Items]            
Related Party Transaction, Due from (to) Related Party, Total       $ 15,000,000    
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       30.00%    
Second Eastern Affilate [Member]            
Related Party Transaction [Line Items]            
Accounts Payable, Related Parties, Current       $ 772,000   $ 623,000
Interest Expense, Debt       483,000 0  
Other General And Administrative Expense       $ 167,000 0  
Second Eastern Affilate [Member] | iBio CMO LLC [Member]            
Related Party Transaction [Line Items]            
Lease Term       34 years    
Stockholders [Member] | Standstill Agreements [Member]            
Related Party Transaction [Line Items]            
Stock Issued During Period, Shares, New Issues       6,500,000    
Director [Member] | Standstill Agreements [Member] | Maximum [Member]            
Related Party Transaction [Line Items]            
Equity Method Investment, Ownership Percentage       38.00%    
Related Party [Member]            
Related Party Transaction [Line Items]            
Operating Leases, Rent Expense   $ 2,500 $ 2,200 $ 7,500 $ 6,600  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 14, 2014
Dec. 31, 2015
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2015
Sep. 01, 2014
Apr. 30, 2014
Dec. 30, 2013
Nov. 30, 2013
Apr. 30, 2013
Commitments and Contingencies [Line Items]                    
Research and Development Expense, Total     $ 820,000 $ 551,000            
Royalty Guarantees, Commitments, Amount     $ 200,000              
Long Term Purchase Commitment Expire Date     Dec. 31, 2015              
Commitments [Member]                    
Commitments and Contingencies [Line Items]                    
Research Services Agreements Value Fulfilling Commitment   $ 3,000,000                
Research and Development Expense, Total     $ 2,700,000              
License Costs $ 30,627                  
Initial license fee 20,000                  
Contractual Obligation, Due in Next Twelve Months               $ 78,000    
Contractual Obligation, Due in Second Year           $ 161,754        
Settlement Agreement [Member]                    
Commitments and Contingencies [Line Items]                    
Prepaid Expense             $ 1,000,000   $ 1,000,000 $ 1,000,000
Amended Agreement [Member]                    
Commitments and Contingencies [Line Items]                    
Research and Development Expense, Total         $ 2,100,000          
Minimum [Member] | Commitments [Member]                    
Commitments and Contingencies [Line Items]                    
License Costs 25,000                  
Maximum [Member] | Commitments [Member]                    
Commitments and Contingencies [Line Items]                    
License Costs $ 150,000                  
Fraunhofer [Member]                    
Commitments and Contingencies [Line Items]                    
Royalty Guarantees, Commitments, Amount   $ 3,000,000 $ 4,000,000              
Other Commitments, Description     under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties.              
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2016
Segment Reporting Information [Line Items]      
Revenues - external customers $ 135 $ 160  
Revenues - intersegment 0 0  
Research and development 820 551  
General and administrative 2,469 1,422  
Operating loss (3,154) (1,813)  
Interest expense (483) 0  
Interest and other income 25 8  
Consolidated net loss (3,612) (1,805)  
Total assets 48,091 11,374 $ 51,600
Fixed assets, net 25,580 10 25,574
Intangible assets, net 2,023 2,284 $ 2,092
Depreciation expense 324 1  
Amortization of intangible assets 88 91  
Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Revenues - external customers 49    
Revenues - intersegment 182    
Research and development 321    
General and administrative 1,271    
Operating loss (1,361)    
Interest expense (483)    
Interest and other income 7    
Consolidated net loss (1,837)    
Total assets 36,330    
Fixed assets, net 25,572    
Intangible assets, net 0    
Depreciation expense 323    
Amortization of intangible assets 0    
Intersegment Eliminations [Member]      
Segment Reporting Information [Line Items]      
Revenues - external customers 0 0  
Revenues - intersegment (334) 0  
Research and development (185) 0  
General and administrative (149) 0  
Operating loss 0 0  
Interest expense 0 0  
Interest and other income 0 0  
Consolidated net loss 0 0  
Total assets (49) 0  
Fixed assets, net 0 0  
Intangible assets, net 0 0  
Depreciation expense 0 0  
Amortization of intangible assets 0 0  
iBio, Inc. [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Revenues - external customers 86 160  
Revenues - intersegment 152 0  
Research and development 684 551  
General and administrative 1,347 1,422  
Operating loss (1,793) (1,813)  
Interest expense 0 0  
Interest and other income 18 8  
Consolidated net loss (1,775) (1,805)  
Total assets 11,810 11,374  
Fixed assets, net 8 10  
Intangible assets, net 2,023 2,284  
Depreciation expense 1 1  
Amortization of intangible assets $ 88 91  
iBio CMO [Member] | Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Revenues - external customers [1]   0  
Revenues - intersegment [1]   0  
Research and development [1]   0  
General and administrative [1]   0  
Operating loss [1]   0  
Interest expense [1]   0  
Interest and other income [1]   0  
Consolidated net loss [1]   0  
Total assets [1]   0  
Fixed assets, net [1]   0  
Intangible assets, net [1]   0  
Depreciation expense [1]   0  
Amortization of intangible assets [1]   $ 0  
[1] iBio CMO commenced operations in December 2015.
EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 130 203 1 true 48 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.ibioinc.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.ibioinc.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.ibioinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.ibioinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.ibioinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 106 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.ibioinc.com/role/CondensedConsolidatedStatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity Statements 6 false false R7.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.ibioinc.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 108 - Disclosure - Nature of Business Sheet http://www.ibioinc.com/role/NatureOfBusiness Nature of Business Notes 8 false false R9.htm 109 - Disclosure - Basis of Presentation Sheet http://www.ibioinc.com/role/BasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 110 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.ibioinc.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 111 - Disclosure - Financial Instruments and Fair Value Measurement Sheet http://www.ibioinc.com/role/FinancialInstrumentsAndFairValueMeasurement Financial Instruments and Fair Value Measurement Notes 11 false false R12.htm 112 - Disclosure - Fixed Assets Sheet http://www.ibioinc.com/role/FixedAssets Fixed Assets Notes 12 false false R13.htm 113 - Disclosure - Intangible Assets Sheet http://www.ibioinc.com/role/IntangibleAssets Intangible Assets Notes 13 false false R14.htm 114 - Disclosure - Significant Vendors Sheet http://www.ibioinc.com/role/SignificantVendors Significant Vendors Notes 14 false false R15.htm 115 - Disclosure - Capital Lease Obligation Sheet http://www.ibioinc.com/role/CapitalLeaseObligation Capital Lease Obligation Notes 15 false false R16.htm 116 - Disclosure - Stockholders' Equity Sheet http://www.ibioinc.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 117 - Disclosure - Earnings (Loss) Per Common Share Sheet http://www.ibioinc.com/role/EarningsLossPerCommonShare Earnings (Loss) Per Common Share Notes 17 false false R18.htm 118 - Disclosure - Share-Based Compensation Sheet http://www.ibioinc.com/role/SharebasedCompensation Share-Based Compensation Notes 18 false false R19.htm 119 - Disclosure - Related Party Transactions Sheet http://www.ibioinc.com/role/RelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 120 - Disclosure - Income Taxes Sheet http://www.ibioinc.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 121 - Disclosure - Commitments and Contingencies Sheet http://www.ibioinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 122 - Disclosure - Segment Reporting Sheet http://www.ibioinc.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 123 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.ibioinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.ibioinc.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 124 - Disclosure - Fixed Assets (Tables) Sheet http://www.ibioinc.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://www.ibioinc.com/role/FixedAssets 24 false false R25.htm 125 - Disclosure - Intangible Assets (Tables) Sheet http://www.ibioinc.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.ibioinc.com/role/IntangibleAssets 25 false false R26.htm 126 - Disclosure - Capital Lease Obligation (Tables) Sheet http://www.ibioinc.com/role/CapitalLeaseObligationTables Capital Lease Obligation (Tables) Tables http://www.ibioinc.com/role/CapitalLeaseObligation 26 false false R27.htm 127 - Disclosure - Earnings (Loss) Per Common Share (Tables) Sheet http://www.ibioinc.com/role/EarningsLossPerCommonShareTables Earnings (Loss) Per Common Share (Tables) Tables http://www.ibioinc.com/role/EarningsLossPerCommonShare 27 false false R28.htm 128 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.ibioinc.com/role/SharebasedCompensationTables Share-Based Compensation (Tables) Tables http://www.ibioinc.com/role/SharebasedCompensation 28 false false R29.htm 129 - Disclosure - Segment Reporting (Tables) Sheet http://www.ibioinc.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.ibioinc.com/role/SegmentReporting 29 false false R30.htm 130 - Disclosure - Nature of Business (Details Textual) Sheet http://www.ibioinc.com/role/NatureOfBusinessDetailsTextual Nature of Business (Details Textual) Details http://www.ibioinc.com/role/NatureOfBusiness 30 false false R31.htm 131 - Disclosure - Basis of Presentation (Details Textual) Sheet http://www.ibioinc.com/role/BasisOfPresentationDetailsTextual Basis of Presentation (Details Textual) Details http://www.ibioinc.com/role/BasisOfPresentation 31 false false R32.htm 132 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.ibioinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.ibioinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies 32 false false R33.htm 133 - Disclosure - Fixed Assets (Details) Sheet http://www.ibioinc.com/role/FixedAssetsDetails Fixed Assets (Details) Details http://www.ibioinc.com/role/FixedAssetsTables 33 false false R34.htm 134 - Disclosure - Fixed Assets (Details Textual) Sheet http://www.ibioinc.com/role/FixedAssetsDetailsTextual Fixed Assets (Details Textual) Details http://www.ibioinc.com/role/FixedAssetsTables 34 false false R35.htm 135 - Disclosure - Intangible Assets (Details) Sheet http://www.ibioinc.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://www.ibioinc.com/role/IntangibleAssetsTables 35 false false R36.htm 136 - Disclosure - Intangible Assets (Details Textual) Sheet http://www.ibioinc.com/role/IntangibleAssetsDetailsTextual Intangible Assets (Details Textual) Details http://www.ibioinc.com/role/IntangibleAssetsTables 36 false false R37.htm 137 - Disclosure - Significant Vendors (Details Textual) Sheet http://www.ibioinc.com/role/SignificantVendorsDetailsTextual Significant Vendors (Details Textual) Details http://www.ibioinc.com/role/SignificantVendors 37 false false R38.htm 138 - Disclosure - Capital Lease Obligation (Details) Sheet http://www.ibioinc.com/role/CapitalLeaseObligationDetails Capital Lease Obligation (Details) Details http://www.ibioinc.com/role/CapitalLeaseObligationTables 38 false false R39.htm 139 - Disclosure - Capital Lease Obligation (Details Textual) Sheet http://www.ibioinc.com/role/CapitalLeaseObligationDetailsTextual Capital Lease Obligation (Details Textual) Details http://www.ibioinc.com/role/CapitalLeaseObligationTables 39 false false R40.htm 140 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.ibioinc.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.ibioinc.com/role/StockholdersEquity 40 false false R41.htm 141 - Disclosure - Earnings (Loss) Per Common Share (Details) Sheet http://www.ibioinc.com/role/EarningsLossPerCommonShareDetails Earnings (Loss) Per Common Share (Details) Details http://www.ibioinc.com/role/EarningsLossPerCommonShareTables 41 false false R42.htm 142 - Disclosure - Earnings (Loss) Per Common Share (Details Textual) Sheet http://www.ibioinc.com/role/EarningsLossPerCommonShareDetailsTextual Earnings (Loss) Per Common Share (Details Textual) Details http://www.ibioinc.com/role/EarningsLossPerCommonShareTables 42 false false R43.htm 143 - Disclosure - Share-Based Compensation (Details) Sheet http://www.ibioinc.com/role/SharebasedCompensationDetails Share-Based Compensation (Details) Details http://www.ibioinc.com/role/SharebasedCompensationTables 43 false false R44.htm 144 - Disclosure - Share-Based Compensation (Details 1) Sheet http://www.ibioinc.com/role/SharebasedCompensationDetails1 Share-Based Compensation (Details 1) Details http://www.ibioinc.com/role/SharebasedCompensationTables 44 false false R45.htm 145 - Disclosure - Share-Based Compensation (Details Textual) Sheet http://www.ibioinc.com/role/SharebasedCompensationDetailsTextual Share-Based Compensation (Details Textual) Details http://www.ibioinc.com/role/SharebasedCompensationTables 45 false false R46.htm 146 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.ibioinc.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.ibioinc.com/role/RelatedPartyTransactions 46 false false R47.htm 147 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.ibioinc.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.ibioinc.com/role/CommitmentsAndContingencies 47 false false R48.htm 148 - Disclosure - Segment Reporting (Details) Sheet http://www.ibioinc.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.ibioinc.com/role/SegmentReportingTables 48 false false All Reports Book All Reports ibio-20160930.xml ibio-20160930.xsd ibio-20160930_cal.xml ibio-20160930_def.xml ibio-20160930_lab.xml ibio-20160930_pre.xml true true ZIP 66 0001144204-16-135413-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-135413-xbrl.zip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

MA(]M2%)!VL7F&HH@,'T?<_%7<6XTVBMK-&UG%-,XLOY K3(BS&MYP9P#\L-" M+\8R*+\)Q<6:4E/6>J V"S5C(+LS4_XF)29K(YB6BIHRI0M2\XNJ-]NEO@]C M:KFX4[M7:':/]]L)Q66$X!? 6:,V&E;@&D-Z1,;4'QDY8*^!M^>XF)4C[KLH M"G/4NXQF0\0)_O?%^.;1DQ>$%/Y]JL]#NGT\PDU@8->,_@&'6M'HJJ*G;TQ? M"3&J<'+&R@7/-"C06*_![&IE:Z"?!9L'<..F7RAI# M/M:K1-J*/^(T'B4QAC,,IGR<4-/N+Q\-?*;E6B_^/#H9.S^(_;%2 DV>$Y M]?M=/Z1+T-,;G;JI7.5*"5Z];4WP"IT_R8EQ!+K0,,T#2$QITK>:]*VM3-_J M-.E;JZ9OG0K%I\J])H-K2PQUIRK\V/O:F1I27QFQPDICY&P#;F4HL4L0'OH" MLVKN67,;8S-@RH(+BO_BVALL8XE\*)$W)A;U9!\(\:CY1*A!!L]!1@M:?;[_ M!_.A VH>!W;RIAZ_$MU B@LCR1:F6QYO7HR+.AY"[= MCD?6!MB%H/"(S")F L/ZU)F OY 5])0^#!-\'@YO-'<*0'$X)\7$=#R(.\;7 M2K=S:@0#&CKH+;N8J!X8X6BPWBJ43P;IB!QU,C[,QV>.)"!#$TYA;-[4@:L3= M#[XX>C]SEUT@Q:LLQ^3AQ)^[-JQ!?0+\RN0=S ID+\Z\QWBOI(1 M"AQU$E\N2I;*BMD,&?E8R0QX5)\H]>E!;OV7Q#3GEFRPSPYC?*>KG?B8! ^6 MB\<@G! 2&8P2VHM8N@$EX1.QUQ\W6HL,-XJ4T%:([,JHW,32B9X'S<7:4M2J M:*-%3J202H*G8>9(IG:)%LMFI&+2=9E<%+="_&SP$QP/U%!U'X%+)0_!I><$ MXA("F)&Z.=L?<7V/I\FX<:9@-(7^/!@QZ>(* MXJ!FQOLKJH(F[&;$9A]8HA@]MOU"RT5E/<)"1G:7ESB@]*Q%$,D+93H^W(U! M$C%[39R2K]S&4R.367'40*"';![Q'U!%&#]/V%B$4*3IL#]06<81.B4ZJ.;" MB#O;.S#UV*5M.^N&=&+5?&O8:1^8Q?>&@NY,G3MA;/' Q=!\AO9!GA6A9C1, M G_^.$FC>+C] FI'/8I!D3E21D!=&]1N%")*F MX9+1]4-Q+CQH\ 0F=! KW\MF-OS;N1R%QDE7. MKJ^N;T^,?^^8YM@<(P=D2-!ME$$ZY#EWC#LJ2Z\]XXOU8D"653K7*I78I)R/ M&>^C8UBB.1'S[5F7'YG"!'F[^ZEL-/TA+>Y#WQO.0?K2);/3JUDTBY4F^B** MDEAWWYC/>,"%>BR_0]4D9HA0H4+H41'&E81]'TL)!4KS&?RYD30G+AU4TNX; M/N0D6TS^LI^4RVY.#)MG0;"$ M8C>^/49#DII+$#KC=]_'(E0X#S"-PB;A*'!FD9+@+6F[X5/>&$V98)_Y$ :Q MY3G%]"HO"E[8Z<90I"^XHVL_6B!VZ6D](._N$<';6W:&_A@EM M'=5[7+%OMP[/#/(3 !9F<8Q8:TQIK @CHM[$E?U^NYU.\Z'+A',J&05I1MQX M]95LDSZ/18I0JH"/!82GE@/#:.J%=I -;0:40VJBN#*;%B+.LJ1B/PN+F >) M' ,AC#,P8*F;^^3X\Q#O'7A4717H]69>[1\>]?+1W#"?]KNY;#JL+MK35FQ M1@0"V)M1@^(4\2X#:N\%-0G6FE%#](C0K:X5LL.#3@YHX.8)]A-P6O', MEKH/?;D<3/DI+%66'0RQS;'OLHC25D.VVW5U\4;5LNJ\0B8E.H7C.8_&C^>8 M2RE+])0<0Y:ZK(:Z]J53.^/#1](11J5PC>#L+$B/9IFPH;P6W>+7K%)LOMPCW*VS_:?PVS;^:>"91$B5R0V$6S* M,N8N;Y!QD M24CR=+PY8?U4'GU^0TT9V:/6E'ZU1Y7\W+-XNQSD.\YKSQ/J',HL!! $*=[> M9T:" @]PG.<;KD\/50!'@\ND)[(O=9%8&9Y%-S3R3PSK9Y4]J?JVB6N][!M0 MN0I)S^CX8JV&1 [>)6X=E"86L,X'K2M00:\FM8CCH_% @2#D#T5&^ $+CL'O M",R_[%+D@EQ6J3:"N%XM54*P^ [E5 ?+1&/T,]$DY-UD%V@\ M6C((O-,]UB>B5UB])HCS>I:63-].SGI9!N+S.;GW5Z7L83&" M+H^*1;UYH L'AP,A\OF1K 6K#V:F#FT;%X!G$-8.I47X&@5<:D M).$L7GQE4/.(6CQZ=UV@LL$/"U"TPLC;$@#9DBL!ET?#"E-":@.NXDB9!(05 M1G240%C0T'QQ,/,(>;1.,)<;]9E'T4HJ!\=OMMOF4N,W5X,[A\2]2LJH;KB7 M._2]"GHI;L9?LNSRT.51LH(ZJ@^ZI8Y]KX(>J@!BM3.UPKGO55!"J\%9.&UH M^1FOW5X%O;38E.+<2:^*+?UR'\?(+WBZ)$QY5CX.?W.BB?J3Q8MR>V5^4\+3 M6Q' S>#;5_!-#$[JE?A?G<[A>O%](MZLQ$?K#A(()%9<%J0B MHA9-H^IJZKP".)D$OR,N7"=^9AEA0\\>:OE@ZSL@_78Q;LP9*668FN#?"FH5 M<$(_-;&F@!,V2:A+WN^(_WY%GD@-R-&Q[!WI89*"Q5>'LV@W"H:3)W9C 1#O MXNCZ4!9GWOBN U.&5N@/T6_Z0S3](9;I+,#^:<"_][+O#)J^$J6WB-VFK\2J M?27NYE,LU(+B#.6"/!:2AI"2RY!Z.YI-5"^WV_G+=*V"1LUX4%L2\ UEHV0P MS^E!-+F-B-$5^4Y?68&YG]FL0M29KU!3OCW)%[O.()4K5&O-]=1(\(W=S%]0 MP" #<9>;F;"<$YDTD5,V#K8BE!9!&A*F62X:GY\9Y?S"X#DS M>MYK&LR 'L\XPB(3Y9:%* +7TGNK.>9RFDEU=Y<(( M[+C?J\6^E_B.1-,2C';Q"610>T]!8T7SQM"-)I@WIVP,/!=BADL,&20-RD(Y M-8<,7O]D!9!.S3,#TSL(.8G$=<@3R[-FO3Y"GV49Q6E,(R<8S:<0%AQA?1G# M1K0C&6&&"LSYHH^+3$65>@=U'N7=*#5K!/(B ID'K:AF'OG4#-CQEAYQ!V3$ MYD\LX&<(8J8>/:'AW,)NR.0)*GE&+*57RW%E,S1 9-+S^40"ELPO:B]8FO^8 M$$@*Q#PKS/HBD-/FX.G=ERFT5#:)GN]8)L#/]PN* _JN ^.Z$]"S 7[WP!S:: _[C"I!:P)Y-8Q6]#46SF!':+M: 5O"":G3G3AWD M>DQJ6/8*S,.6[]%3MZEJ(\;[CCP;EC00(MRWQSKQR&W&VD5);R,VA MDAO/(/]"-3/T2H()$" ^0"2$L1C=5T>OXIS6B%IS*J2G% M-GYYH"XP=%U_)"TFP858-"]V*-Y8-$S^13^BK(_;*+98VZO08#83;[4LGPE9 M=!LX&R229"+&$<1"5IS.?(\US0.CT8^X989G!,^&S7-E89T(1+;%,&#S5 WZ MI46A"?PP%#42[(UQ/7*\(9C&G0>?Z/LFLXKWTRGBT-D?CL<#3!,0-E5<.JB] M<%^<;:T\%,J0H9,=/(.U(!#K)SPYVAI'[)PK:.,NN01FSO+91M!4&U*LL<3O M$YM2!+U3\!7QWXDN"F*V&RH&IA+9WELIAIT*AK45AFW4QH9-%M80 AL[XIB' M^!,10V&53#^GE4KL+;"AJ.A;O3&H:MCX1DH9_ MO@V8E"'P#9G*8B9N"^Q=P4FZH!E1-QJ&8_,G184[ZQV!=@TOF52DRP&GCOI6 M;L.REZB2B+V*-_=4ZBRI.H"F%-2J>9FQ3C4Z8!D^ "2QB?D@IB_D*D&T4S4 M5MP AX\\0=WE1"Z17?=#6;/'+3/-!^#J+,/^WYK0YCOHSU?YZ,*BN'U?+&CB M:KD94>!"M26,_G'G8>QOH+,\EM6O_/P8!6A(GL<+;]Q_:M:U?,KX*V='1+JQ[.G6^BR5/80#O)8X3]7QVD XMP6:RR ME95$A])7>8Q_.YZ[8P=G.+&+MX"PT4I*^!G5$_KBHG3V199QRY\?&&P7^.KT M'2,8ET3/"X,*WJB,PI'#SI*S8$7,(NG?[/,Y9?S]S);@O7/6U\.B.TBU)3DP MOOHZ+,^LN8?8 D>%>]"$W+=9Q&Q!R/TW/_@#>.8&NC*$NWH%*K"8,2QR(ILL M1L-:.&*U.!Y_IF4A-C)A_>WCMD:QWD?1(^/:&-.61CD:%0$[B)YO/"=@H3_, MZ'*YN^?RC9L#\OU;<#C1,36&>"6^HR>3H2!N]0/"+NMM.!5X%+&1]3C1.'=& M]9G#[[_/E;]0KUONB#\83_N$2";T5VC!3#UC2J*);[.NBWA9P(.E\ M"308# M7.@X1LM@@T D]G]C%]?0J18Z]SC4&Z>''?*!MFAF:'4[TQ=,N^S^_ QVTA##?ELC1-NFA M2R\"Z0C>V$XK(^W*60Q.X8.I!()";*"GZ01J4A4J+'6B%SU[021Z%E;_ M+-1(+'J$(63V\FS-=&#<6!$1+C)?A-BBC3#+34/!(S238LAF)J*A4YWS'E1X M=?*..="C%U2-UOGZ3J)!)E/-B<#>DT.>^:6L%00X\.D)&XWPCE+I#4D(\ G2"P&"$PI^-%<,\2MG 3\N($Z.ZB+XPOW@0T0^^'NN[%?$HALNB MD?)*XH(G%_*&M I@,E'S][G].)77U_+7\7QJ&'80LJ CCO.1:8X\HLB2.Z ] M%XME@"FFC$/0S2.I&>->LY)EQT3>..@X'QB7$G#H=@?)32]L1IT62"4_T%,2 M+EJ2<&)IG&,GMU'5NMP!(WB-KE)+!)&=PMOJ'=:$M7I>:U,@6VJ&;H%JO24C M@MWS>,<$M8@EH(;FG J679ZT>D$$!),-+SI[Z)=;0\*HC2.$AKIC,L2EU;)L@KOQ)Y[7QP DA5C (1 M!_4L-CP-6;_31'9(@>FB-]2<>?Y7ISQSH7R MW'-YM$O<'0?2^$N'$RH..WK8P6'#9@(Q=PD+' M))%6ITU"X;"Q:68AK[[ #UT6S2!BGBV3"M!.- 4,MB>V1A.HX&#+Z\393U,! M^J^^)/*TPHC,-I":U?!T=EDKI;YAGAB7,-0#LEXYYZ X^BG\F<]IEERW6UF1 MB%TG@1W5(SA-&4L?E,@9UU\"^1W$M'MBG,O,]40G?I:DNX-(]4Y$#G<.3C+U MY>/9!/'M!3)P7/Y:6 MNA6E7GU@7%B0Z::V27="C!C-0*I$>/%\J8S!%,/>H.Z$>SC"G>FWP/N*/=[8 M!JYD^AH_W?O4.@(#^N<37B5&J0&ETY)*YU0F).UB7"S+*0-X=*<,S2&;L.S5 MB4I^4?*K;MC#B[S1.-"^0 H]5]V\["T[-'[*J?X_DHX9#S3^O.SFQH<&M]F! M>*R^T7*3*::NF.I6+QNF7U/,D&J$%2YB60-J"AR)@Y7QWC& ;1CL1S]7-\GW M^(B\LCGG#_,(JQV!Z94*'E@#0GS@F\N@8?: NZV1KLM0;<;'Z&VAB>/N]N,"ECL_P&6KS M;E@-*F5C< J-&T4?WT.0.*(0@6-T2HPA\Z3$[2F\[Y:P 5$$^EZ!SV6P/I,+ M!*+,CBKS#K+V5WDV#O0S+U8S("(&L-)^(33$W%G6 0%=0$ '9E6DT0DD.MR% M%+=!X#5C\(2G3:JKRE1.*G3SG6JU?0&[,N-6GUC!$S.\X?(#4AAQP,>#&+<1 MI2Q(CJVB+$I,3PLVA;[XVG*@ BR7$H4 M^X5E?@6@&K!BFD]FR0 VA1EEQ0?")C!S\!_(&)QT9B_:\2R_[)W93]Z^>$K2 M9QIA3I<'+3V7 @,!,SB3D!&7OM+)6YP)?U8B&5]GI5=5UN)M->(/#T=C644/_APCI!@RP4H1P_@#7)A%L@.U3XL8T(VF:6?$K"R9Z82:9+YIB0(DU.[6^'WF0FJ5T M1^)7+VI06Y5^6-3 J&5#66"(=_],2E#Q)@0PM@CE8^(S%U'(F]<)BJ43K(8W M#,/S1GXPPV%^'#B*#V]QSFHK^>P^&;M6!'_LP)G>,4F$A=RQ2]1>/1Z@,F:N[&O6S4UY8O]4VL_43JW.+E9'1,BY^1('E M!_20P.N!J;]Y\Q 8_)(^$ZI*J=-O=4 IW5&N@,X>P(RI-VHJD,J,"Q=$6&QHF$;) :(1^*Y@/OL3:Q1"859.%;9:'/IP6O1I+38%XG]D?5CGTM. M_@R"P;4$6LSQ#%RF%[EF(N(']!6B9Y\5@)$=MNA/6M@R#\*#EHB=<=\N$] # MX^_^,R3T[6N[S/(9(OC_ >$S8XE 60ZG5)1EK(K9D$FBSHZ<<[:GKZ&<,P]8 M&3$VZZ*?C6&K4$3G^@$(4^,'O'5!/'.\?(D^TB(\;PS#$,)\YL.?XX"U$C(0$6S,1T5C4MIJ&&M+(V.YH9^/D09Q ML;39_:A#(UD@PO#5?V)>2=D]X&&A57>/JI:+DT,,'YQ:+JJ[NPF!$#FOJH_; MN,FFD?C;!82*>5@U' [/QFZI+1:D=D%>NV!VAZNW /!\C_M(2AI"S+T/',\0 M\#Q0*9;C)V:$ Q>_F%O$>RSV!Y482H; 2"5]27&1# H'V>)C14\3Z;@93Q/V M6NLCPP,2H1ISL;#H0FGA#)W]GI$!K$>J6N#6@@("1FP&OS4VU"O&4KD7&QM/ M&8)ND.N^QN'42[K)P3P53[WF31)CI_6(.JUH62D)RJPE$[' )9CRT)K2(326 M2O&'5[%\JBPE!RD7]3ZIZE$J8J<5;F(X'MQG2 /P :K/$$XLNE9J:%BN>ES4 ME"BQ4>YRHDF +?QTDM3URN:$U7XZI=#I8HRM9ZK4C M<:74XUO)RI+EFOJ^.MD-;%60F51E'>@$?\:0L>XW,)P('MM/FIQED7!)J9 MHK@5Y>9(?N[3<.Q&77\B3P$E?1Q3B#CBO4^$!&,7N?G192C%I?@21RR.BEDO?.!A>3Q M\#U5_8Q%L1/JORK@M17PM#J@V/J^Q^IO=AL5>RU0J$68#1JGRBCUM2D/AHD[ M)^0!4]&#(D,^Z*8_6RB=EN-D2195<8EI+XE6%3]%H@-&_"R3G!;56%#A[H]; MT)L:$8D3<5 L@(4"S\#+YUS\HF7@L@)?_(D0+&P1B =),CI46[.EW!+.U]' M>=*NT\Z^NEM0S"DZ4\E.F;%6D#S/*14&(I@/RN)BG/;Y@$\8RU7&\GPP.)8)74W#K MXY$1%].9Z[\0DI4BJA18+Z)HCG4O3/E"YE_JEBHBH8UUXA)5)J%A;!YZ@'!H M0_VU:-H -_.K/7YA2CT9=% I5\_DX=(U6NZB:KU.*)(P^4 KQ0-F;HJX>L/C MB1=7;*Y *@#(\0$_A5=&,X)G2&4?&.UX1@_P"Q+Z*9-9,[4/"0:D4'#K M"=)X+\N_ G-=K"<\H7VA;XKB$_LR0:ZR6-VO-::QDI"F_/0>2YO>G^CG#6T* M!7].N&,)P?_5"@+_V;C#7BZ:J0N'Y09>@-WI+J@S9#NR55!%R5\ULP,>%1UQ MDA(\49K)!3TF_O)$#1GJ5JQ6]2VJ1<42C:5)J$TNW&?%2>++T,+T8)D?)H<1 M396I:ERJL)L_%:B(C"8>;^Q'3_F(VY4JPAB@1,\R5^1YW*S.:'S#Q:%"GM7D MRX(>\Y;+ET:6?-3*MPO%24ZQR)WJ/9V!]_0)O2EETQXK*V M[J&OT)8T\P_X-RN??O #FP2_[+7W!%S/CAU-3LQV^R\?#7RFY5HO_CPZP4[L M'_>HR>6Z(3V(E++X._A[!@D&[&_Y_D#^RY:0J?\,XG_",O#7WS[,P]:C93-8=-K_B%!U\F/9-X[BO9.VDH>&!I%#4BK*1XKR[0/RC MQ/UDJ!) W'' TUK(+3.$ML^K"52'+U!M+ M:(;!MFJ&10393BB%O!;"NZD7"N:38N(;Y#?-+)XZ2WX* ME8G!$ _"6L2 \&XR,'B8^D!L7@YU746DB$V@5X8&*V,%,@8'QS4@<2]H[JC+ ML:;HY<>]2UD/7%Z/*EOJR@%K+X0/6>/Y^AN8/UA-*& M*ETBYC8E6J-3GSNP6]3JHOR!CT-B>A6G?* Y M>==*64#\[)UL5W'J@].J!M4@ JC=QV;^[DP)<2=B ;!:+0A/XH6@NP-\83UV)-P2[C.7!)Q+B MK2?+<9G85FN?,-@XQY@@!#;#*$YG%^-H]!?NB[,-&D2RL,]K8N 9%FL!6!Y? ME.Y>.MJX2RYY@@@<%1!_0)8G)8X?I ;K)D>QZ/#KQ:ELL@_NO95BV*E@6%MA MV$9M;-AD8:TNP+6!=LA0H2P^D94S.!#OY[12B3V6N"&]+/"6XG_]W>G?P8Y6 M'FUNX/C.UB=2>;#YEFW -V0JBYFX+;!WX_P\!"3 M"E7I.'S^*B5LW+3&0H1<4^ +NQ2J_,!#%_ M(5,-Q'&D4'=BO\ MQ\I'%Q9E5:K\MB,C4KI31S@2"(GKF[#D+*O^A3'QYU [CYIHYL[#V-] 9QG. M%(NS\?,3IZQ 75YJOF#FH4Q!J!Q.S=J,6YL"6&!E/OG\"E.1"<*D<=@,/_5@ M:NX9][ 5W(HPD0/.M__8OG7M^AF3.EGKC:J'L\JDNG@VYA8>9T2::2N;L4=YL.I:_R&/]V/'?'E.]9W"H2W3HM-02.ZHGU9.9=I5]D#VGY\P.# M[0)?'?(9M*XA%NNQ&7LU(<&:%>P*1L^^Z\]XM(W%+)+^S3Y/W>7O9[:$S,<( M_!^B"?%_U'G9VQWLM]MMC1<.C*^^#@LT4%6VP/%2(S'?0MB_-+"?O FX]&#B MJQ^\_.8'?UQZ-RR;A?UHB4N P^828$.7 +!?P,5\Q[;4@*N*ABB]<*3WMZ.I"@Z^$DA<<,OBV]@L3V9$-=68J^1F)LSLF8.7&SPQA/ 5CR/!DW%L<9S< T S7@%'S&=8R5X MAF4T2Y:12\GF#R$WY@UJK'G^E+JL&5QTH)4\8C ,0\K)QA7\_C&-1CCQGSU1 M4:;E*W$T^*4B)%!'S\"9XF9S;#%/VY[+,3?2YO8Q[NN,5/\L%TJ,MZHW=:36N( MNPL.1;6I0%!(M(AW9U#2\]@@*<_F?7]#T;N+JU 7UQE[, =Z#(IJ^#I? MW^GJK\]HKA"0)X<\\ZMU*P@PH5^VH6/MZI,;CFQ ?^X$&,Z!*!0TVC @>A"A M7E(Z)J%,@DGEM:[":H& 7=:"29#J-02 M5P%.8<[!FU'2"RO;I+:FAU IG5#K_OD/5G9O!^UM5=;;YLK6D!3+BZ@N>35I MG/ZD;^V.JO.X$I_/5?OJ']3:1*1THIG>%DJ=:)9?2-^+>T9A1I/H50M1.=% M"9I?H)+RD_F3\9TFB%Q^;V\\^M C U/=>":MG_<64:$J?TM%J>=[<5T&%_B\ M[E3)+@A(W(6#&CC8C@ FR"#(\?BMG\C!XP&4I(K+E_@5HMMB_-'/O(T3T(:- M8A'-&[FR$>G$<>-EK<(>R7H&*8Y+I!BF>,F!9@-@=-1 M0[5)/0 PJ+UMS=8$0M[8]6P5+V'D8ZTYG^"4[%9AB($F5OX47"5)U28SAW?- M4$\=[^YC9YQ>.+'RH&.001A#O)C;#ELK$):- /'#UT6 MQ*&&%VM./9:-N%/ T!/JBYFU!I\KK!)G/TV%N- \SN0+(S+;0/)>P].98-]1 MZAMFW$1,< Z*(^B$C0(I+L_8K;Q9Q*Z3P*Z@29>*_ YBVCTQSF5M@Y0JK*TC M2^/>0:1Z)R++/P@/3(?Y"8M/?E:%.E2:AF.,6N>09'MN M4MZ9L%4-?7 )PM&$V'-75NG6U+VZ7ZD-J39V311(\SE"2FMHWDQ%&2^K]28J M'"D%Y3W2+XUMX"5:G;$Z0DH-*/"75#JG,F&!H9YF+Z,I/ [Q"96NU+*!ESI< MFO4O$Q#)$2I9HZ"%84!0Z5)Z(G6PP/B[;%_GB:,B""+)<2 MQ7YAF7@!J :LJ;\DA:< M1CB>9:$\EI@BF+XNREN<"7]61!M?E:575=;BS5_BU(M"MI/;B$&31/V%:,8O M&JJHW>2 ZU5& /[ F:[LZ_B%./U,>1&4;?"L;GC'@2I_8/?T-J(YLR33^AQW'3+898W-A)PXQ2> 8! MV1A!.=Y,Z4+!BE7"^0-&5-4%#D7Y8]L*H94/A:,AF2[+@# P ?)0=LGB[U>Q%%/+F M]2MCJ0JKX?WP@F4M ;7-+6FK4'SH?U"E8?4M;WLK8]>*X->ZF.)F6W.P2)3. MDMC0F=\*Q1UG!?UT3+-'!F/.@BK>03O7,QQ8=L[G[\\:5X6R4%];/G#TP]3=O'@*#7])G0E4I M=?JM#BBE.SXI"9@Q]49-!5*9<<%GF0J.1M4S0W&F+XW++1"%2L[M5;Z(!ZC* M&SRQ)HA ;5EJST[Y(-G8157D%^NN ?EC]'N"9.9RZ9OGP%^(.I[0X91 'B,% MA54U0O\_]?(.?2"J]5S?>Z0R*-$\.B2/ 7D$/98&,)2- V5;04@,$(] #J+H MQ(]ODJ-XA6.5C3:7'KQ:44J+?5'/$%D_]KGDY,\@&%Q+H,4L5^9Z4=; MB@#^.$)A[HT!\>0N%$Z%1/H>HG1K@6Y$W! MHV*6-K.CV%K)D#*79M,Y&Z$)P9/L;G".C&0HC!T/!Q&=AU@SV'C<\C!C+>LE MN[E^ OJJ SP?7GB*.7N<5VW11UJ\83D+0PCSF<_;RYGIR2+8G?!;Q'' Q2_F%O$>B_U!;;YT2F"DDKZDN$@&A8-L\;&BIXETW-P8$:W3 M$ ](A&K,Q<*"#J71./1^?$8&L!ZI:H%;"PH(&+$9_-;84*\82^5>;-D\XASW M-0ZG7M)-#N:I>.HU;Z,9.ZU'U&E%RTI)4&9-NX@%+H&89*3TD(VE4OSA52R? M*DO)0CZCB$+,30S'@_L,:0 ^0&4;PHFUYDI]#LM5CPNF$N4[REU. M- FP43X3S.*DE!C[J;7GC8F4.EJA%U[KQRHQ6;A^"7\JG*2@6*S>0 M&&*$I*F YI DA726\;PSYU7Q9^GK&>QP?160"8Q$?8J=37#_0';&Z_+>L[ZB.X--70#)_R#I9(I*61P^4A<*?7X5K)J M;+FFOJ].=HMC%60F55F/0L&?,62L/Q+4/<%C^TGS4D9&XBN]0(:)I?.>IE+F M4AISQN6/>)LX9@42RL!NT4EW-G^@#G]?BH=4Y$/%.!$2:O'>4%$@ZOB& M><@H+GOQ)A#B \2U^,N##*OS4[ PRMS6UHP1?%,>QJ4CMM.G2#3^B)]EDM.B&@NJY_UQ"[J7(R)Q(@Z*!;!0V#A)'SNA%%H,@D-8_/07X1#&^JO1=,&N)E?[?$+4^K)H(.J#NE.:+3<1=5ZG5 D8?*Q M:XH'S-P4%LX!%IL28OA/\ M'6R;+#J>L1'@)79O;H;>HH&X=-9_#9;O@E/%%\B:;PS?#=ZV8VHF\3.$$J^L=IG#0[-E3."B,9"XLUL:W:T2$B#V3W*JGE%?$DZI#ZF]1M^XXX$6-KA!A<^R[0#LY;R\-HZ^ M(NW@#!94-UI*NWLJ$9^)ZV(B7.;;B3;G$G.>6=: 6(<5GP/Q6$]HB].9Y,[% M%-XQ"F(JML!*XK$U1C]':R?-4L"A(SY(3*PR\!U^04(_93)KIO8AP8 4"FX] M01KO9?E78*Z+]80GM"_T35%\8E\FR%46J_MK& 6_I)"F_/0>2YO>G^CG#6T* M!7].N&,)P?_5"@+_V;C#7BZ:J0N'Y09>@)WO+J@S9#NR55!%R5\ULP,>%1UQ MDA(\49K)!3TF_O)$#1GJ5JQ6]2VJ1<42C:5)J,VVW&?%2>++T,+T8)D?)L=5 M396Y>URJL)L_%:B(C"8>;QI(3_F(VY4JPAB@1,\R5^1YW*S.:'S#Q:%"GM7D MRX(>\Y;+ET:6?-3*MPO%24ZQR)WJ/9V!]_0)O2Q0*R0@QL/?O<(T1LJX=#["U1H\!,9 MB;0"HD3#\/LXP<,I="=U@#9W1W(@PY-Y[%&S+S% M%[OKH$>7BWN1Z@KY'/MQ2>7(PC&2QG-<_!??3F7FBNG9'[%0D&%(E'+*L@4B M3&;/^J)59*Y04Q%_%S' 1MI]_!+7$]D^"7EG53?N604,Q:[F ]$5D0G"?=Q] MC\^EKURQ&5W M.I,NVEBT\KR-"]%"^1NVH[W"?O$5NI)^_^)XSG0^_8(">!["*K>@,X8_G##1 MLM3<^[7+)'B%?NA9 &T &^M'56PZ>[]2154G.I\W?OUQFS_,T9[2<@W28!+)18C=FE) M:BS"\ST@U> =DZKZ@>I34G6Z:R"5Y03_@(2@N,PZ7*7S\F!;.R^'SI_DQ#B" M.)!AF@?4&(A?S]0:7^#J\NM%Z^\7EY__#E":_;_HZU 7PW4> F<_I$YS"YO( MZSWD33 Q%!590?49L>YC_[0%,#?#\_/+KY];I]?W]]=?T([Y:(@/KRX^W?./ M?KL\O_\[A+FZ%%7YP"U#0OO1_?4-?K('>6!H!T7^;"^A;%>%HM-7GZ@.AH&& MQ"][G5[9WF<8=HE]2O)6QE9UU,Y&#U7MP%Z&P?20;3JM1,WE=G$3-,NSH"N3 M,#N+&?.-(4,1!9*:GKP,P3\H!RJV%IOH\OK[&FO3,$(1R=B/QZ%@D.0)MF0? M(B(SR['E;%-ES(@H=V$I9LKO9]8+&[X*65RC40"Q)OE[I[#<*\LITG+*0G5D MJLUS'.*\V9"[XND1A0B-&DX9X @GF2<13J@R;D$HDU^3L4A$>G8(EO:H$Z64 M2SH=. ?'1OX\&_X;KO?CS&LPP^7*F M+5-K"L4JOG@ULZUST%_.;!/V4O?557]=^FRM!NC!D4KF[3-!J2GD>X]52=K/ M$+SZ&]9HC%8AY6OSY&+D+)[16I&PZS4Z&P-3!W8; 71.'=\X^W(-]SM@.XDZ M@C%5)2YO;W8:O*!>)C^L4$VS$C?[1)@/<<^;.YA62MES#/<_:*QA@:)5Z]@[ MH]O3Z-O"B\)P_H!&X $%@LT Y][)9^*"&NSWI"/C/?DN7"P$!"ZJ\+9)7U/O'",* M7&U9<\L @RLMW^/X)&ITB_ )X1Z-8#F)Q0XB_5%<1=NDG[VB_*Y-7&F8PRF+ M1P%Q[V,^I3XJ=5)"3.RB6__H!SR%-_!A])CN?7,>RYQ@SDJ E8'4/[&$SCGU M0.SPYV;LT *H&#HNBND.;G]M/F2*.O _[AOP]8XARL!_?W9]=36\N:- 0M:> M-0O)1^/Z'Q>WGZZN?SLQGJC8I= L[E16]R0%IM+M[X)YC;CGA@4W>O;$^/?V_A_J2/VT:"HWU^> M#:_$4G2?(W_*'_R-P]AKMZ7/-.C_13/Z,[BJW"/95N3,&G![GC@1:0$SD!// M?PZL&3\**^.[''Z'*GX406!\"AT5'IT4LC*N&&/=;>\WF[IUF]I;8%,A*MSL M9])S;R3Q5B.WKD.;,# XQ(89Z_A=D=5PA]!L\@YN\B*R^UUO\NKBVB7C:!DJ MG [/_NOS[?6WK^>4%*,1(>/QIB3X)Q'L8,$_[9)X"4YX70I,'=L&=VJM$F![ MT!4;KGJ/&<(G7^2GJ?$?2Q !V]ED4R%QQ=,3U\I;3YEVFC2=]C[]^^A!KO^$STFC.QFT;$&/]O4T:$S$W:)BMB:1+LIL2L=\=+S(25T%V?;%PC M#3*$W^ U95_#W:_N+^XV=Y>I]H:[MU.SOU)XP%&ZK#3VWG:C^X8T^AIID"'S M^H<[M]<-:^^J.E\C#3)8N]?9N;U^^[I\LU[Z%V)C:R^9TMA8=]N-[AO2XYOU MS+OM_LYM=L/;NZK(-^N7MW9NJ]^^'M^L3WX]'CLCHI=E&*$_CIZMH+FSST1W ML0R=+>2)NK7^8@39%2>HS"XP>\MD-S7G8_O/Q^L29%?.1YEM87:; -CV61>; MC1+LL$_Q5D7ER@Q08X+@SDK2UR-B5M[48+_?/FH.V'L\8&_55'D](F8?,//P MN#E@6V?,;#94,LPKO%=F^_'2^RW*7-Q&6W@;T=T&\Z:B;-T)PSW!B>;\6SVXW8R'90 M)$MN]@:O)C:;P[!3R1J[?QA*C8ANKSD,VV=#;#8DL<-^QEN5BSL=@'@-L;E= M(8KCSE'CFKW+L_063)#M"G,,VOWF+&W(1-%'(ICMK4D[SC);OI)(:U7"K=V:(Q.[.OMCJV47GZC49'ZB)\U.4J8_NB_$?=3)> MM].3S6LD;:!(JM95S/UN<@U*JT]."#76G;9YR(;/RK\'^T9 PAD91,6']"T,"UUD_F?EV:&K3 P] MVM:)H:L.L=EF^=Y,(-H=O=Y,(&HF$%7Q*;8)N;@=;'(S@6@+;ILWF9*PD 1O)A#M;D9@,X&HF4#4G(FM MN?Q]@V>BF4"THT;$9M/3F@E$KR\QM[O6;D>R7A8R")H9+3N ;M/IN)E ]*8T M>S.!:*NX8AO1?4,:O9E U+#V&U7GS02B=Z_+-^NE-Q.(=@S=-Z3'-^N9-Q.( MMA[=-Z3(-^N7-Q.(MD^/-Q.(MM+*V^U6'&O5^MO2MKR90-2;$9F,CS02B=^?9[49L M9#LHTDP@>D^'86OC&-M!D68"T:[8$,T$HM=GA=V^BGX3]RL[0;!F E%SEK:% M7CMXEIH)1%MDHC03B-Z('?N.YJ0T$XC6F1723"!ZOR>KF4"TSG209@)1@6&3 MF$#TUD9V+#ZHXS,;Y* .Z1B&UUX\G.,[KZ65O_B";\;<<]A*W^[.]PR;C!S*9>$O>ZWNWJ_==I_R2P5,$>Z5L1RL!\O# M=C&6FT,P9\;*H5D,8&?0;Q^]RD8DX.R4P6D>'J\ IW++J0Y)HO]V"?R#OF X M]8/(^1,_SWWY I3O%F-TW-'I7A>$&\0\;R][Q9@/$D=_79C?62X);\D3\>8$ M7+T* XJ^7SXX_J4W4H7"740A0R$P#QV/A.$=><2602 .OE]36"A8WJ/X5/WI MF>^A9D>X+^E;P@P1TB^FUM% (U8"J3IP7AV%03$*O>-UHW )O;I#!OZ%ZTP= M#^%=&)'#RN*\!(E;$A(K&$TH?Y[3AUP?.?2"3ZO;4DX\*CFW1SUM'PMQK)\@ MJ^-79I)TS-?$KR8>/BHQ25KF47]Y-#\3C^Z""R+9IA Z801[\D2VF[./2JP@ ML]L[U&A2@N8ZJ+(ZDB4FE-DY-%\;R;IXO,2V:ID)E;,@JG(O*)OZ4W*5,F6W MA[-+;*T6-9N[&BDR<*L+_=6Q*;&%6F9W8&X*F[IXM<0X6@P9!(J$6VY)'%6W MHQ((U8'OZN"7&$*](_U(K0&'NIBOQ.19' DJ0J\A&YBQZ);RWW&)#60>9>Z? MCEN-%%@=H1(#YG"S^-3$G<'J;@H1VE%9%>' MO=34..H>K@?VNOBMQ+RH!/J0E586!=)?@:]*C S3/ *[20VZ(1I+(+1C:\N7'+5)#K]=FIQ&RH>&.0$1=;F@BKXH0WC(4W M#/W^86?S>-7#HKUVB8&P)%H4.LM[A'G>C*?I(Q<_1NX<;CD_^[[][+CN=O%N MKUUVD]3NI*SW4AQKI\OJ:)98$J^-8%U\76)TK(BF>M^TG29CKUUBM.CQ$!6A ME9%='?82LZ2;.(JU0E\7!U:/912!K]Y@7H^3O+JMO%=B^!PEKK +<5P#159' ML'I\9./(U<2_9O44E<50K' @^PI"_>]GK _-%;2AL=D[5TF^Z9D%-D^[\L$4 MJH&NF,3XW E'KA_. R+3K:KL7 +*SMZO/)5-Y)9]&=Y^OOQZ8K1GD2$SY%F^ MG'&/67=?R;-Q"UEW^^R#?>..!,[8T#+CQ.O.KBZ&MR R06/2=KI;ZB0"5N5KLOMYR:H9_ U?Y^'D3-^D7RT&#%C86<,X^J7 M96A;D'9;@Y3"S.7+K^<7("+;!\CD&:2,J5^&>"*96,-81;$&V+/@S-N],K#O M)\0X\Z8 M<56+7?9G]"74=#HP+C,?H0HO=,((5["HTQ>1T<3S7?_Q9=_XP_.?6Q/_>=^@ M)LC_S]ZW-K=M*PU_/S/G/V#\MI-DAM;1Q?(E.>V,XCBM^SBQ)W;;Z:<.1$(2 M6HK4X<6.^^O?W06O$F7)"B5!,IYY']%X@5 V:R&<(HGHQ^2WY@"-2HB"H\63X M$0_&W!9Q1%V XE"H%_ W*EK#^&3BPF_TRCP0I8=N(FK9?APQ&3+/CQA:7&H] M%JB/(.*PW!QVF@$F ),C2YFAF8$,X@&H?C :$&.>#S^#E+!M-,_I"5P6G]"2 M%1"C&%Y2OZ43W0.F C#X@L<2 (S;8!0%L"IXYH.PR7IB[6:SPP:!/V8? QY[ M(W\ 7_YZVP-H[09LBAT1_D>!'P]'3 ).SP7:EC3Y)Q_0 3@-V'OI%^![K6CG MM-UNOLN'S;YLO7MCL4D1QA$$<$,E.DQ0QC$UF-E!48:X4::V3 M=V'"QFP")OP ["&_0E?6+-V6ES;]#F(]$'+NA!8RE*\+(]T3V=3P!U@S$4 D4$MD #:R(V)Z[0KTXD$$8I6A5 MRC)9>> _YER@Y?))7%T'%!]B^3$AH!A#\2(&.!!PW)CCL22%<@_-EB M2](FG:(H:?KP_&C,@[]ASAZ*DX#@E40E8]"%]%0BJJHF**\.9#7(NG 0N^XC M#8!/9YH\D65<&0"'8PZ$.Q&3" D8'H;M"97.$JR"GF"M@%G!/F':*NNT+&(T M15D>..>%+2I80 -8,XS)20Q\".(AZ^6J5?$=SO?Q0P\%/$X [$\=B6 K%9TD MS#)O646="7*Q2/;%A?2%#9J0.4"^?D&-*S"Z@'T6RJ^'8Q S(^!P(-&0%HC; M'4<@OLC6 :P.0)%WV2PS@JC&.D\*_416G-=BUQWKQ$*0:^-GJ>;5U M!2%44-;*-H-]PNW#Q\#>'()IXA:P'-HC >I4)+2%C R/\HB>!TRDN._#)#;N MKRO#D6(U6G:G2>LX6;_.>NF> Z(_3BV268=!;9D$FQ1,?MAH-*I1/"948/N! M@Y21APD9F+&N_"?E"LRK1?US"-L-LD%$(]])S"$2DFIPH!HY)ED$!CM(""#2 M>Q1UJ97%@;>32=".ND>+#L0#R&R'+"#AL4?! V5)*3._VKV1X=QQR&0$3@&* M;7?4<&6[,Q#W4CR$!);-@^ 1852V82(69]%'2(779:#8:"0\@;/B-1&T'L%N M',$K@GR??A*R9[8,['@<1JBP\!>\GQB)\L0 1JP4$!G!R7QC_DB^2A^-1Q0) MN$4P(?K@#7:!JZ7P^/3" D$&1,C^BIUA8IXG&TQO)^W10YHG#!6G(M_R3/X! MCO\"=)/X<61(5 4?/-1"/!RQ@>L_A*F]FBR7=@ _!P)U- Z5$$M?QS57QJ2S;WKLBTI=>)K E^#5"5"B90>#H>@\$" MS!T2?:I@B++>ANKZ:9EOR>(JE+LM";+* ,IK=/I'?AS"J^&;MWJC:(-;J=[# ML@:C3"W9Y-O4>D+!RN1>"'?CQ?S:3BL*6,\F.&M_G[UP?GUUU;NYA5790(%\ M$HIW[/JWBR\?KZY_?\ONP5:E&A3//:]8_I!BE1I-:CM6J?.PAN)+)S77C-0) MN#HJP3R,9"0.D1C$6\]_"/BD7-)D=7A7@Z]4U0< 1,*'U0&7MV> O06_C3R8 M'&JPY\VF:K>I1\_85'3+S'Y.GVX92:PU<.MBVN>5T-195J.38C9Y!S?Y.;+[ M16_R_M=?KY#@UD#7F>=TH[5:FZM3*EA M">UKD.XA2RPJ,&I80D_;8HU%TBMLB_103E-K0L00;?NU:,4A"XN96^WCKN$0[6R-S<8Q=M@UV5=AJ5/X8F=EJ5:1 MCJ[5V9XQ8OA+&X_?\-=ZPB; 7]LS973D+TU,FR7*IZWF MID_>GF6Z8#.-F2(-QJ!]AASI %I&,5=.%F9?)6(OS7)MG;<-82Q4/+[]3_."\G$I+M1;4+2Y6QP46&Y PD;3+ MI6*46%'U*Q4-=!_9=Y5CI3SP:FK%KZQ75$C_U0RATYRGIU8SN>:6H08+A=4Z MR5EK=A*LR?=$+3FL6HM5>;%-N?NXH++J%9BV+NZH]-6%=B]I"JZ?6@D9KK:YJCK@1\+\=FD5-TTXW M"$U=C9P6-%,[['2.E@8J9;K;I'+O]>"CA+'%%4B;&?:[0V;]EA9()[JV0'IV M.4VMS!!3$U,G2\W4Q#0U,4TEMOTMGVAJ8N[AIIJ:F-LYD-()#T82K\"T>I=+ M-#4Q7\ FFYJ8&N0/:)LK8&IBZGOE;!<3!?;PL-+4Q'RA+&%J8IJ:F/ME6YB: MF)KGL.YV1OAS#(J=K:)C:F(:#M');=UW#C$U,7?3UC U,;=/"KM]DWTOKFON MDEMG:F(:_MJU"YR[Q%^F)N9NFC*F)N;.&<$Z@JN#7;/CU^)-3^9'M!!=#%0*Q0*;,$R=1Z%M3P7%_YSJWS MT()*GYN$?,.,=*()Y#6QU +CXIG%6K^(4/# 'O4\YP.\X?H36E]2)UM36EYD MM'3+:O])&->#D,V2>&>!(;1%7-1#])T%IM&J /XD/$ ]E@?O.; V&4:X$?=" M;_KO++*'P&(J,< ",->%E0TSP?(&TS;P41,C+&]0/1/(#/] R_Y87,VXD?J0 M_P(C[K!UVBH[2A6PU0G^ANE\L26W";AKHN?%QMDS@*%%B5!S\Z6SV(*; U!= M\&Z88!>8:VN&MQY"/5K>Q%H2"!#,U]%(!(J<-:75HP6&UVE)SE:#5C,"-DN\ M1PMLK8U"7Q,I+V\H+0?23> /9*2QQ7"TP&H"BZ%9#G/G(-4 [(8I=G&,JWXH M:Z+,Y4V;^4M7 ? G3A&V0H$+[)Q6JW-2/A-28*P(W(8I;GF#9G6H:J*PY6V1 MZJ7>)%?,;USNH5B\^%\L*<(P$UG?.LUU%Y@LK>:TR)L+6:U8V"QQ=IG3MN7@7$M>-DPX2\? M*MH.1FIBA.7-G57 _" F 8Q7<92OC77;76 UE0]#B@#5 NR&J7KY@%&]D-9$ MK?/K M>2#.3W[Z-12#V+V2@WE1E7(KU:3F0Q&P)Q*KWC]^XG_YP;G+PRIHVP<_WK2: M?RR3HY4O'4_XBT[Q?:YK-5J M-*6WQB:]"UOT]M/'?GV-/REJ.&VWF^\*+V8HSGYNO7O38+]Z MCE C1NEL^*'J17;/ ^G'REP)N"KQZ/ M1"!8(%S!0^%8-!7:+P G@#/V'3F0PFDP;'8= IKAH\UA0O6+G0P_\1WAAZ-07M*^M5B%KSUY$ IBCYWG( M8S?)+$7.90\\+/(1#AJ(B$,^%,6%PI=@?X%, M&2//(GM&]>*M4XTW0-"#'_P-*_Y?+,)T_0"1(\''QL_]1R;?2Y_U!:Q.L _" M5BCLM(CUNPWV,9&$CX(' )H#+Q6%0]>J%Y)VXV0N+$&2XTA0.'F6(X,![Z4- MLY 3%"MH,MWH<%Z)'=G8%2J(O(CH &U=S0H/%K80E0(4[A,<2?#FC>ST:Q$ M08.!EL,;9,2W"8OBM@U]H+RRP@O]>#B*JJD100GC?@C&>"0!YG1(5#-XVDUP M6JP?1\6W'.DPSX]P$R8^X#^9OTJZ)"@*:28L3NR'X/@F\\+VX?B-%Z-$=D\E MP-8& DSX*7$[5JXP@5#LVDUFU.<49;. MR"# F=RI5MXK3AQ7FVYH&:(<0JKF*'.D[^!OK2Z)RG"*'T?<=1%5183Z'@DK MFTS*UO=O\'5\#&2SD!/ *$R,?C-*FN)@@\ ?LQ O#N$;P&!.;,/3Z@]X/(ZD M*_\A;01OH8RZ@CF!\6"I^.D3/.?R" 6[L$>>[_I#92)'PBLLJ/G,%;D@@KT0 MIQ62Y AAR@]%/@TX@$IPR, !; 01?%&6!*Q GXP.4_HBI4WAY*2IJ"\9KX13 M]Y$A#>>0J76A84Q70^"-$6AA$MW*NH8W",![H1Q6W\N?)<@2(URA/!7[1=2G M:*&G%:EDTR>*"O>E:&K!)]@F^H3W%0E;!0NFW<'=4L^0T,2[UZBZB<6&8(TA M0F:94*FQ]5@91W/44@]V"2^%R\JB]-)#]VE:&S,G#E(*S9DGQ0VH5/_!4^_@ MCDBE5,!J(1( DB"G$<9)OL$=:91H9P2X\GPV -'@V7+*A2K3#-EQJ-=@Z4_I MM3@D-ZA$S?GN2MC="1I(7H0D6+0>C++;DK*[]I2QVFJ3J7=DL8_2MX/X'ZNX M_T1AR-+BJ[!C92:#&DN]_90BKGHS3@2%!-"#J/+Z\44[$,BF7!5-F&>_@C_A M92&'X@\H?E$V^>,^TG'$_A#H@K./\$S [KEM2]0A@7\O\307Q98$UQ]=%#Q4 M0*O0[_\%9(VRS6)@E,DQR=%^[ Q%I)PD>!T?87WD9Q@$/H,M'1:#%@@[/@J/ MH*Q""9.%*_HB>A"@.)1 +0=:')HLL[C;)[0-S2+V+?8PDH 3Y-<^CJ,,5N)J MD+NIR*OB1S!BTQB)K\S:Q/0'CB=.7>PPI$A?N#U6HHSP?Q(:2KPHI6_Z C3\ M()5A6=PIHH\!H '0KRPCI6-4*0VUE([1$(2=T4XI/))(23;E:HL M]['\6*H[)UPZ4_(.@9:PC@P+X7R9)Y*<^"8W@H!Q@L(NA-VR&X+H<7? $H_4'Q6\#.E1VP:[9M7:_3\]O0\!Z\T M>&2HY"L#?A>#@5*$[ .(XZ*B+A.9H.1_%,FH@4 ?8:Y4B._!#KO. \AK=I6X M%'G0_G5AIJM>.82(YB7.\*L'HP2AC,@\O)%1%/;C8#@JO?SK3>EE&UP",I31 M#4NTRZ^-VT;J>PK %\CX*#MM4W\S/IFX64A?12U5,X=J(SVSMG^]09$&ID/! M\DGL7F1E8"_X#1Z91("'7']&:.>DTFD@^X$?RK!LD),BXBA;)3%HZI8-A%A# ML& V5E#A1Z _GN U1SLQ>X)%P$^()J%*ET+F)]^1)+_T[)C*U1 VOTM>06N.D%9 [PS^ MT&#O!>#50]229)AZ-0LP%4((J#PG:"O" M,TGDY>.''E-&+TD )&KX59W/5$10IJD>-#?H,@I )9$#JQ!2H5."-!*$>A;] M$!C-\[W#-.( V$G)1:J[7##TKS?K=W6-ND-UEQN+R2'M4TJ,W20N7JZO,J7T M23B@)]PIY73KQ_#[.0]\D&>\I* ^_7I[7E)1N?N9\M>SW3 @:APV4U)T8+:\ MBLF=T83.2SYC=F!9#I+5+J=/3BO$VBA FS7?KE9BG22.]SV!6.98E EXGBB] M.I$Y8PK5*'*/8RMA.FJR$G*-M@!SY0 S@*R*2J TNK5,\7/I&@;YT4(QC9*1$8'6A8_(;\)#'X@7E8(.>B M-/YU[L_? MEQ17\EW9\\M?+]G_%R0HR9"F()\?6*"M!*5XC,%LBI0E. ;C2)E+J'=4K5C0 M85(,6)]D$]B2+",(:'43E88(K)!#\630/Z'Q2.^"L&ZT!D44A8 MVX#.JDKI=F=+;78:[LLWO6H+0=N1UY&AIX@/6G26PSB##N44/6N79I< ]GD MOY!YSL-"JB!B"D9-PU0)*A,XR\$_H&88/5:&"AD:>*#@A0\B2ZVR4RPTRN"' M8*OX]R([5P[\*-'Q5((8AP9Z\(3:NI*Q "NB:,$CV55Y'#!UPY&U^G(0!S9/ M4Q\3"HC\Q(T!R\EW[Y5[B.E=X/# KAS)285CDY^> ;0CX4XC,IVD]2[-4$KBVYGW1.%U6%XZ.*TMBYFK$V80 M67*2]+)4+%4R7,BE)_\*"*W!>D3A@.10.B(_HU1#%2!C#X&,\,0&GV4,FPHB-: M"CW/[AZO#&2#-0K6FKIPR/[V_(?#D?]@I0$90)*,W/1LGX[A@?#3\]T*HB&; MKLBP92&8(:'$D$F0/D>Q0DW$'!]+FOO4^4,H!%"L7I"T2?@]"?F669$.=W!G M0<,V%);Q$"L)4KN"WQ-#)-/Y0">329)-20XVRD.:A.)(5$XSE8RX"XY3C&&' MI !!]S$;'AF'E9*KF 1 M97_+[T&S6S!2^K ZBWV?G<4B4UKLTK,;%KLAUI*#@<7N&P B3!VQ]PWV?_S1 M8CV@^3A@?X!3C4=:462Q7SBBXZ[!?I:N:[&?7.%Y9)<.8:P1J/4)^S\8)P9S M"G__Q1\!3 WVR?X_\:B$VZUX' /SLX]N/,15#H#A.87:THR#=&V??4QA<_-G M%K!!E9"3J]S8&=AT7C.62@8S[]P<==9WC:?-C\;LD6I(P,II:)!*34^JB M%46RCWOID>.8.X*ADDLOAH(XZ*.)..^PK)]<'$5-%KM1(2F,I/=K^09V>\"E M&X-.3^R4T@!.8G93;!KT.T@J&8[@I? QA"4@5&07^RZHG'L1S%V)DUT8 [R# M&'\M86[*LTAG*.IT5/LVWKX 2@+"]DG_%WP(C*D-7#XL)HFKJ%62_%V:CNS1 M[,P23\;OR4T!R8O)1LHNSO,E$TN5%%IVG-4M6@=.1D.9?3UKD:+^GE(2\.Z8 MADWP,>*VUME^GW;YF;BK43/ M9 :4CM:3(7.IXB'P%2V!%/(2K,MR7IMS9K!9&<5152.HB*0F'6G7+YI;/4%D8D3\ =OUJU5 MFYLN.0V9 M@:!Z;:OUR2FS8F('96S8-U,R9;N7 M9,FO#]"W\?PLTXU_S2Y&9.E)5 UA# ./PN3J0NXA)DE:QV2@H9P E\GFF%>+ MK^;7O_B,!/+PO,CEVV59,3966J)8E&8.*"HQ?S-/SG M/Y [EL81,.;G@0& 3K:Z5P>3JR;H#"Q"NYPUVL<#5+PQJ:Y]C/%PSI5_"[J' MPCTZ4DG.6,+*(+J86"SDXF6 NX<*YQFX!=O*"MSH2R\]I.:HTO#\+T M3<44N>42@NB3=(X4^HM)^.G3;,S1*L^S]=-KP#BW"G###^I]%>FV\.(W';\" MG15I5*5#H=7.8S_*9#Y]X0A/6!F%MO#\V,N*""59"_7>+[-: M%<6"+'4#4;$23 W_$P >\: ?O!]PA]3.)X? *A_2X90_04?*'T4_P"VVV"?* M&(F'>):,FYJ6;5%[E$,JP^+Q6WIA(0&=YD6Z!).4W# Z"$P?"O.,:"^,QX#J MFT#"0Y> ]J_3\^3[,TU:I0.X8>##DTP12W95)RO34EHL=U#N*0+/#L=QVR:3 M@,LP/XM,W\<4/R#\3E,=M$_H\4=%C&%RD(K/%Q"I:I02P"A5DVR4K(1"#F78*%$OY>&J.^$AUBM6_$.='<+DGFWB_X=5&;F4 MNY"FO5J%1!HKEX]66D=0?3_FE'^H'')59)#+8!K+5:RX6^I[-ZV.BA(%&<$] M*?SW1 ^)($+I0_0F%.R6]8LB7G%'6E"6@8])8Z)TRR4-5!(8 < M#[ P5:#R;Y.J+6ATE/6NE1?N./D^'5R)M^_H(JZZ]#HH3F6QX^^GOLKT6?92 M2UV;;6>#6*P[_ZWVU&OJLJUZ[>B)R9KEUQ+)KM[#;SKSW\V?S>;,7FZPG_T' MK*(#VS=0[(U1L](>)>?!9&]E^IW4^^GLQ;XDU_DL)X>2\$WNXZ,L*:X54S1< M99GP FJ;5G*Y=\&J*,F*\M5+Z\.$%+HKL=2DK0)&@3:\)_4XW1I0*4WJ*KP? MNPX;8:XS5>^9J!,C1*J,* T(:!\#A8X2N6D1P=)Z,$TN.UOW_,+B:+H4P2C]=((WW5#QJ[Y2E#3WSE1=M*+662HJ(ACB7DCH4FJIC5-ETJ. MXTUG3.7<5&GV'34&V6SGBR26C(=#KZ]_?LGM)KL-S3AK2B;-CD?;D:^'W+*C[,)*1.,0QQ5O/ M?PCX)%M3&N?]?Y31T62M_%2$4-"[NOP)0+(IVS4ETKL_K@ (#TLVN%,A6E6G MCLKC$6*GR?H= X#O+L][5^G0L#F1/TX>_#V!Y*39S"+O1Z??ET+']+<2.CE% M*"LG_ZQ2?///OI?_G9V%YE]UFM;;)2/D]: %:.'Z2X;V5=%T5$!3:Q9+4PRS M&+;=)I06H !9"]8/TJ4]@XX;E4@.9&-V>K]W.K7?S$;O^4;?8=#CQ>YR\41Q M>6N@'CP4.S+]/]L68C#X!N04$S,JR'$N[JIL W1,5B )5PRB[2%B+!W'%6N6 M!?J ^ZW[7H&-[U9 AWX56-A*L'A*,UZTAXSS5G4M$XZ5O/H=.>HQ#"%88KU M,85UUCZVSKKMG:,3PQ:&+=;&%N5DB%VBDS6RA3:&]H#^;QU>R!Q+>FM&P\J0 M[J9T7-_&U@WN^N3@&G%0I?]/CZWN66?G-MS0MZ'O)>W;5L*@2M U6U;KS,1O-0?7T/?* MINKIV:EUVC2A6,W!-12^JZ:JCA2NC:FZZ:AJVW@LFH.[1X)NPSYYZ]@Z.S(Q M)\W!-?2]NJEZVK&:77-NH#FXAL)WU535D<*U,54W'55MMXS'HC>X>R3H-NR3 M=SK66=M$534'U]#WZJ;J\;'5/#%15 ^[\[G"_#=GX>0O?'NCZS.:X#X552IJ4C_P M0O_88M]=-\Q>N;0 MY8]^'+T=R*_">;=4 UQELF=_.>E?_RG^&>1_IBO^[W_B\'#(^>3M%9JZX?4 MH\I"?)"A[?IA'(@[\35Z[_KVWS_^^U___A=C_TU?^")<'@GGA@?1XUW O9#; M9")7O,ILWXO@PQ\9:>- MKO18J]5H2F_1\!4MGZ?H?WKYU *[3.#M8@?L?KJ1BSI$M]J- D%G?R5;QVCO M6''SB#I*C:2SN>IN*5WN*(WX?,>>TQU[:22PI_IDKPV\YX BEP7ELW\O; M2S\2]LAB5U?GLR#)2I"6:=.>][7? A(6+?#28[]P+^;!(P-YT;:HP?NY/YYP M[Y'1#6V@:.E%/N,>X\- ",P< U$?C5B"-UC!PTC:(R8!@XHJ3MNMDWH.!="5(O;!B[ZHY1C/Z[X5L[ >" M#6+7?60.:-D8-#62O"+*LRQM)U,=1&:PHQXF;[XS%^@?S&> 0\. FD+?"G M[^I<2;-QW&Z7%S,1@5I(@]T5$!@(6\A[P. D\&TAG+#VM1Q3W*/9+".GP4#2 MH76'"MG*]P7WRV&PF>*K"&P)6_C U#=L($R8B.."Q7WTH]#( ]N_R^6@7H^ MV_(ZU\Y:ULGITW@8_"4U#UHOJ;+":5(! M ,,XXEZX_H1D=#X.L(T+='$XY@[\"50]YK: 5=K<#6&1@1\/*RP>I'4";@ > M.:PSC/M@ 4DPKQ( SC]=*^Y(%Y"I4 6,[,>H8&MEB%:W,4=3P';:/!PA%M+5 M6;AT0&VM8JU3GO][W#_8QS#"%>1XH;\"$7'IH9%1[QI.IM<@0)B#,5J]E%Y( ME#CF?RF3-7E8&:W)7@*)TD,4@$(<@E CRN/Y>PE%C\6X+X),@K_W>>#@AT_< MXT/\(1IQHF+XI 9-EU(F9C"7)\*6 RF05F'A$JRRQ,MD_4=ZLTS]@2"=1;\ MA85HCH"]!C0!G@JZ*9YONL/)88C MI ?C8-@F>_&*QQY,FSWV2)"FVA]63RLICX)4#V0 ,";H-PG?@@[0>^A*DV7 M^FOCMI&M%]\I2Y[TQ1(MPS N8 Q6%RA:"8G6Z#^@_EP!;\.B$$(11(_3$"GR MPKG@%>$.$$VH[E&/@1S^!Q6\[\0VC-?G:+OZ:O!Y&&,P$@Q!FY*"$N(WM$+Z MRP'#UC?NV/9\SL1SN/_SZQ7SW@VR"4 MR%B."&%'$@<6!>-D A^0M0K*OF@#P(A]Z4^I?] .MAW$\*;X.E'< \+[5DPB MDO*@[2P,IAS3++_$GLB_<6*12M)Y>\?XV(^]1.36:@>2$AV''X:X[2( FG A;FHNH!-/?C:51>IN9+@K@BWIXDLP?@DS6B[NATE@PT M0QV:X9BCE)EEF2S"F [("AN,GT(LZ-3XB)N(R*%W)42B'2+80W@?[*<\^/P: M]RHU#MO-=[?Y0YG#F/W<>O=&&=>1[__-Q&" *C">)(I#AF',/3N+!J1L]1RDRUJL-CJ]N<#515.+](MF"'HX%7L&$I&!5*9?JGYG@I# 3^0#'^ MB#9A8A"XJ *SV"U"YV)DEQ[I@VP>2#0MF?\ 8CH8VQ0(- M]H6.], >J%4WMZWVM&S#"+%:=QI!^^S?*Z,9T:#$E&<'@OS8NNW?-@K<>0L2 MV=Y\$':^I 0YJ7$5836-NN-S)[/KJM\JMXZGYWB6L?2T0-G1[)QG)-M,Y^G< MVB/AQ*ZX'GR,T5/\I'+;26[=).55/OI!#B@R@=@)7E/X1OM=+$&AD0K!S\ MP]#?[Y+ M+Q^OKG]_R^[!7(;!EA(NS[RN\S"2D3@D-?W6\Q\"/LG6M.1MX-7;(:R6H7JR MX 9/H@MRB@!5*7TG_RS(Y,\_^U[^=Q8+R[_J-*VWLZIB8:[KZFC1,W%YMPFE M!2A UH+U@W1ISZ#C)@#K34Z ;,Q.[_=.IV%'L]%[OM%4/_#%[K(V;8ZV5EZT MNF%G:VNW"G6\XJTCN%N\D+LC3>#JO&V;E,79.2HQ3&&88GU,89VUCZVSKFD- MJCFXABTV6IG!]!/5V-#>;)T -<1W!U*FBP[0HUS]/_I\=6]ZRS M";K-US8&XK=:9B=]J#JZA[Y5-U=.S4^NT:4*QFH-K*'Q7354=*5P; M4W734=6V\5@T!W>/!-V&??+6L75V9&).FH-KZ'MU4Q6OCG?-N8'FX!H*WU53 M54<*U\94W714M=TR'HO>X.Z1H-NP3][I6&=M$U75'%Q#WZN;JL?'5O/$1%4U M!]=0^*Z:JCI2N#:FZF:CJG_9'5 M.6U9W<[6_#K#)H9-M&>33MS;IGEFG71,LKMT"U]P? MK;*_=]C_?J'AAAKOTVK0(5>K2[0[3!V&&0PS&&8PS&"8P3##2[.8-QRQQMIU M+*WFJ\KUIC5]C3NE-[A[=&2WX?ASU^J<=:SV47?G]GR;@;4.J!O'QP9 NQY9 M6[;TTC,1L7[^6 \_'!U99]UCZZ1K^,'PPT[QPV;TQ4G3ZI@(LZ;V\F8CS%H/[5%2IJ,UU M<"UW Q\FS+;#X!IV,.SPLJWHS4:=KWQO>(A]I5,+&OMMEH/0A9YQQNG:FZ#$ M%LJG[T_,HM8*ZUVKW6Y:K3-3)4-S<'4ZY=$#7BUM"T/.AIP-.6_,5,Y[5;/9 M=])A$45:=]?^]A;9TTVW>[;MQ_ 6O(W/%=IW2Q&>)V'K4EOM7GCM-8_3=MI_ MW@KXU;G@(9CG7F\PD#C )^I4&X\P5 Y6[R8!F@5BL'"/Y. 2JN=PDXPO>/Q5\JP&H]"1:8C@7( M*I>]"FSM FSM/SNM-<'6?AJV[CI@JVY>7S]LG2=A.UDO;&4FJQVVHZ?ER?&S M8?L@0]OU0Q"\UX-S?XS/4,0A6<>Y'T;A[8@'XCT,YJ0".9.]R^SP% C=@Q\3 MO9LM-&5WJL MU6HTI;=H^$*C>?5O$DU9&-/+#W'991.B/8GR><(H\+UAJB\'@-QTVJG5TBNP MRH+=D/=5Q_TZI UCQ3TE%8QC9OJX/%W)@J@!H62177[^<(&[V42\OF,5*#M@ MW)5#[X>#O^(PDH/'@V7!G[*92I#5#$JMRZYZ)B685U,K>66](IIY-6-WYD23 M07XW$FS@NZ[_ "::LNE8&(_'/ #2#EDT0JDUGO@>\C#&&T.BE#Y1BEV@%"82 M(0>@JK<\!S_C4Q[%6E X #PGW$ZF#\1@8I6LM?TGA^'W'/"-V_7OCW+4EHV MIT:DI=Y#)VF4D92J_%&K=&-E'"&&?K_\#W7X Y]O+K^_2V[EZ&$P99R)+XA^*]3#_'CNCU9G8"K M(RSQ,)*1.$1B$&\]_R'@$WV:W+<[Q2;WW8K2-H$0.<2?0"B,POSS!V> >S&\_9R3X"+KMUI% MUF]7]?@Z-C2P?S1P]#P:6.4:T'[0@";96.O+VJZ2_U]$*'A@CQCW'.:(>^'Z M$PQL;.OL4< MSM&'2>*NUVSX27@BX"Y9#=S![.TPPC.0>[$MTM Q:6F/RI4NL!U,N=*E[(AV MUY3SW4_^T/:^L%;\L;#J=?O(\,=F3(N4+JXN/JJ4(UWZK%29&U2IS!B=NEP% MV\6HA397P;0*;+2/C2_W,MEJWVY8:A4@Z;2W9N?KR%9/7-ZI*Q^4AIZ;K6@2 M?&M)\)7+KO\VPA3YZTE^A;\$@M0!F&6RE;-EZ[C :X_UXB&\!)Z Q=K-YJE% M.(0K[P6[ M<;G'7N,KB@9/V^WF._PR^]AZ]X8-_(")\<3U'P7>2? ' VF+ /YR9"#LR ]" MB@R*KWC'BKL,./<>GF"3P+^7#CS98)BRC>-:C,/#8X$YA,SWV =A4P(2:YTB M4*V.E;Z%D/"H!.*8/[)AP %/OJ(U%OEL$@?V",M(A$2%L)#_P'+'_&_!^ ,/ M',K9QMM8@;15,C<^%D_P70">#X>!&/((GA[CI31\NDY)E9RP9Y0UEJZ+F>>4 MD@Z(Z='ZLD0LUFD2'HYI

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